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Abstract 
The compartmentalisation of cAMP/PKA signalling pathway within 
specific regions of the cell plays a critical role to achieve the specificity of 
response. Adenylyl cyclases (AC) are localised at discrete regions of the plasma 
membrane and phosphodiesterases (PDEs), the only enzymes that degrade 
cAMP, have been shown to be pivotal in generating spatially restricted pools of 
cAMP, therefore underpinning spatial control of this second messenger signal. 
In addition, A-kinase anchoring proteins (AKAPs) are of key importance as 
they anchor PKA in proximity of its specific targets, thus favouring target 
selective phosphorylation. Such organisation leads to local activation of PKA 
subsets through the generation of confined intracellular gradients of cAMP.  
Interestingly it has been shown that AKAP450 localises to the 
centrosome, the major microtubule-organising centre, where it functions as a 
‘multi-scaffolding’ protein by simultaneously associating PKA with PDE4D3 as 
well as other kinases and phosphatases. Beside this a large body of evidence 
suggests that the centrosome is essential for the regulation of the cell cycle 
progression by acting as a scaffold protein for a network of signalling pathways 
which in turn trigger cellular division.  
In the past few years the development of FRET-based sensors has 
allowed the study of cAMP dynamics with high spatial-temporal resolution. By 
using this approach it is now possible to monitor real-time fluctuations of 
cAMP and PKA activity in distinct subcellular compartments and to investigate 
their physiological role. 
The aim of the research presented in this dissertation is to exploit FRET-
based sensor to investigate the signalling of cAMP at the centrosome and to 
define the role of PDE4D3 anchored to AKAP450 in shaping a cAMP pool in 
such specific compartment. The centrosomal AKAP450/PKA/PDE4D3 
macromolecular complex may play a role in the control of cell cycle 
progression.  
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To this purpose a CHO clone stably expressing the FRET sensor based on 
PKA was generated. As expected fluorescence microscopy analysis of this clone 
indicated that the sensor anchors to endogenous centrosomal AKAPs. Further 
real-time imaging of basal cAMP provided evidence that the centrosome is a 
domain with lower cAMP concentration as compared to the bulk cytosol and 
that PDE4D3 activity is required to maintain a low cAMP level in the 
centrosomal area.  
Interestingly the same cells challenged with the cAMP raising agent 
forskolin show a larger FRET change at the centrosome as compared to the 
bulk cytosol. 
By using the unimolecular FRET EPAC-based sensor for cAMP, targeted 
to the centrosome, it was possible to exclude that the level of cAMP generated 
at the centrosome by forskolin was higher than the level of cAMP generated in 
the cytosol. Thus, it has been hypothesised that anchoring of PKA to AKAP450 
lowers the activation constant of the enzyme leading to a higher FRET change 
at the centrosome as compare to the bulk cytosol. This hypothesis has been 
confirmed by expressing in the cytosol the fragment of AKAP450 that anchors 
PKA and by showing that binding of PKA to the cytosolic fragment also results 
in increased sensitivity of the enzyme to cAMP. Eventually analysis of PKA 
activity, by using a FRET-based A-kinase activity reporter (AKAR), indicated 
that anchoring of PKA to the cytosolic fragment of AKAP450 accounts also for 
an increased PKA activity.  
The molecular mechanism involved in the increased sensitivity of PKA-
bound to AKAP450 was also investigated. Interestingly anchoring of PKA to 
AKAP450 increases the auto-phosphorylation of PKA. Generation of a non-
phosphorylatable version of PKA-RII subunit (mutRII) and further generation 
of a CHO clone stably expressing the mutPKA FRET based sensor strongly 
indicates that the high sensitivity of PKA bound to AKAP450 is mediated by the 
auto-phosphorylation site and more specifically the binding of PKA to 
AKAP450 seems to favour the auto-phosphorylation of PKA.  
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Finally the role of AKAP450/PKA/PDE4D3 macromolecular complex in 
the regulation of cell cycle progression was analysed. Displacement of 
endogenous PDE4D3 from the centrosome by over-expression of a catalytically 
dead version of PDE4D3 (dnPDE4D3), results not only in the abolishment of 
difference in cAMP concentration between centrosome and cytosol, but also in 
an altered cell cycle progression, suggesting that PDE4D3 plays a key role in 
the regulation of the cell cycle.  
In conclusion this study provided evidence for a novel mechanism by 
which anchoring of PKA to AKAPs modulate the activation constant of the 
enzyme, thereby providing a mean to regulate enzyme activity locally. 
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 1 
1 Introduction 
1.1 The “second messenger concept” and the 
“signal transduction”: a cascade of Nobel 
Prizes 
In biology “signal transduction” is the process that converts the binding 
of a specific ligand to a cell-surface receptor into a specific physiological 
response, by perturbing the concentration of an intracellular molecule. The 
ligand is usually a hormone, a neurotransmitter or another signal substance 
that acts as the “first messenger” whereas the intermediate molecule, which 
triggers a cascade of phosphorylation and de-phosphorylation, is the “second 
messenger” (Robison et al., 1968) (Sutherland, 1972). 
The most studied second messengers are cyclic nucleotides such as 3’, 5’ 
cyclic adenosine monophosphate (cAMP) and 3’, 5’ cyclic guanosine 
monophosphate (cGMP); Phosphatidylinositol derivatives, such as 
Phosphatidylinositol-trisphosphate (PIP3), Diacylglycerol (DAG) and Inositol-
triphosphate (IP3), controlling the release of intracellular calcium stores; and 
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Ca2+. Among these, cAMP was the first second messenger to be discovered and 
its signalling pathway has been the most characterised signal transduction 
cascade (Figure 1-1) (Sutherland, 1972). 
 
 
Figure 1-1 Schematic representation of the “signal transduction” and “second 
messenger” concept. Adapted from (Sutherland, 1972). 
The concept of a second messenger was elucidated by Earl W. 
Sutherland with the discovery of 3’,5’ cyclic adenosine monophosphate (cAMP) 
as a molecule with an intermediary role in many hormonal functions 
(Sutherland and Robison, 1966). In 1958 Earl W. Sutherland was investigating 
the glycogenolytic action of epinephrine and glucagon in extracts of dog liver 
when he found that epinephrine regulates this reaction by activating a 
phosphorylase which in turn catalyses the glycogen degradation and the 
consequent glucose formation. He also observed that the availability of active 
phosphorylase was mediated by a heat stable factor. Further chemical analysis 
characterised such a factor as an adenine ribonucleotide the formation of 
which involves the cyclisation of ATP: now better known as 3’,5’ cyclic 
adenosine monophosphate (cAMP). 
The discovery of cAMP as intermediate molecule in the degradation of 
glycogen to glucose raised the question of how hormones can stimulate its 
production. Sutherland demonstrated that this reaction involved another 
unknown enzyme which activity required Mg2+ ions and adenosine 
triphosphate (ATP). This enzyme was named adenylyl cyclase. Based on this 
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evidence, Sutherland proposed a “model of signal transduction” in which 
binding of epinephrine to a specific receptor on the plasma membrane of the 
cell stimulates adenylyl cyclase leading to cAMP production. cAMP then exerts 
its effect by activating phosphorylase (Rall and Sutherland, 1958). 
Further characterisation of cAMP revealed that it was present not only 
in liver, but also in heart, skeletal muscle and brain and led to the extension of 
the signal transduction model to many other hormones. According to 
Sutherland, hormones do not enter the cell but bind to plasma membrane 
receptors causing the formation of an intermediary molecule or “second 
messenger”, which in turn can transduce many cellular processes by the 
activation of additional signalling cascades. This model met a lot of criticism 
from the scientific society of that time; however it was then confirmed for 
many hormones exerting their effect via cAMP.  
In 1971 Sutherland won the Nobel Prize for “his discovery concerning 
the mechanism of the action of the hormones”. 
Approximately at the same time as Sutherland isolated cAMP and 
formulated the second messenger concept, Edwin G. Krebs and Edmond H. 
Fisher were interested in dissecting the molecular mechanism by which cAMP 
promotes phosphorylase activation via phosphorylase kinase. It was Donal A. 
Walsh, a postdoctoral fellow in Krebs’ laboratory, who first discovered the 
cAMP-dependent protein kinase (PKA) from rabbit skeletal muscle extracts, 
highlighting for the first time the existence of a protein kinase cascade in which 
a kinase can phosphorylate and activate another kinase (Walsh et al., 1968). 
This discovery also promoted further work on the protein phosphorylation 
process in general that led to Krebs and Fisher winning the Nobel Prize in 1992 
for “their discoveries concerning reversible protein phosphorylation as a 
biological regulatory mechanism”. 
Later on, it was shown that PKA is composed of a regulatory subunit to 
which the cAMP binds and a catalytic subunit inhibited by binding to the 
regulatory subunit. Binding of cAMP to PKA promotes the release of the active 
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catalytic subunit and the activation of the cAMP/PKA signalling cascade (Gill 
and Garren, 1971) (Brostrom et al., 1971). 
In the process of elucidation of the hormones/cAMP pathway of signal 
transduction there was still a missing link between the binding of the hormone 
to the receptor and the activation of adenylyl cyclase with the consequent 
cAMP production. 
Gilman and co-workers provided evidence to illustrate the adenylyl 
cyclase activation. First, they noted that the adenylyl cyclase activity required a 
regulatory protein containing two functional components (now known to be  
and  subunits of the G-protein, see below). Then, they discovered that such a 
regulatory protein is a guanine nucleotide-binding protein, capable to activate 
the adenylyl cyclase. This protein was named G-protein. Finally, they 
illustrated the mechanism of adenylyl cyclase activation. Schematically, when a 
hormone activates a specific receptor it triggers the exchange of GTP for GDP 
in the G-protein, causing a conformational change, which in turn induces the 
dissociation of the G subunit bearing the GTP from the G subunits. The free 
G-GTP subunit will then binds and activates the adenylyl cyclase. Hydrolysis 
of the G subunit-bound-GTP in GDP finally promotes the re-association of the 
G-protein  and  subunits (Ross and Gilman, 1977b) (Ross and Gilman, 
1977a).  
The importance of the G-proteins family discovery, as an essential linker 
between hundreds different receptors and effectors proteins, awarded Gilman 
the Nobel Prize in 1994 “for this discovery of G-proteins and the role of these 
proteins in signal transduction in cells”. 
1.2 cAMP signalling pathway 
cAMP is a small hydrophilic freely diffusible nucleotide responsible for 
numerous effects and biological functions in a wide variety of systems: from 
memory formation to cardiac frequency and strength of contraction, lipid 
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metabolism, differentiation and gene transcription, cell growth and tumour 
genesis (Francis and Corbin, 1994).  
cAMP is generated upon ligand binding to G protein-coupled receptors 
(GPCR) that induce the release of the Gs subunit and the consequent activation 
of the adenylyl cyclases, that in turn catalyses the cyclisation of ATP in 3’,5’-
cAMP and inorganic pyrophosphate (PPi) (Rall and Sutherland, 1962).  
The intracellular level of cAMP depends on the balance between 
synthesis and degradation, thereby results from the activities of adenylyl 
cyclases (AC), the only enzymes that can generate cAMP and the 
phosphodiesterase (PDE), the only proteins capable of degrading cAMP into 5-
AMP.  
Activation of the cAMP major effector, protein kinase A (PKA), leads to 
the phosphorylation of a myriad of intracellular targets (membrane receptors, 
nuclear transcription factors, cytosolic proteins) all of which are responsible 
for the generation of a specific cellular event. 
PKA can bind to A Kinase anchoring proteins (AKAP), which contribute 
to the specificity as well as the versatility of the cAMP-PKA pathway by 
tethering PKA to discrete subcellular compartments in close proximity to its 
substrates. 
Since cAMP exerts primary metabolic functions it is clear that a great 
variety of disorders, such as cardiac hypertrophy, bronchial asthma, diabetes, 
affective disorders as well as growth of tumours, may be related to alteration 
of cAMP and its pathway. It is therefore of fundamental importance to study 
the mechanisms that regulate its formation, functions and 
compartmentalisation. 
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1.3 cAMP production and degradation  
1.3.1 Adenylyl cyclase 
The adenylyl cyclases (AC) are enzymes that catalyse the cyclisation of 
adenosine triphosphate (ATP) to generate cAMP and inorganic pyrophosphate 
(PPi). Since 1989, when the first AC (AC1) was purified, nine other isoforms 
were isolated in mammals. Nowadays it is possible to identify two basic 
subfamilies of ACs: the trans-membrane adenylyl cyclases family (tmACs) and 
a soluble adenylyl cyclase (sAC) (Willoughby and Cooper, 2006) (Kamenetsky 
et al., 2006). 
The first family of ACs to be discovered was the tmACs. This family is 
encoded by nine distinct genes (type I through type IX) and represents the 
more widely studied source of cAMP. Membrane-bound AC isoforms are large 
proteins of approximate 120–140 kDa that share a common secondary 
structure comprising of an intracellular N-terminus, that retains the regulatory 
properties of ACs, and two membrane spanning domain (including six trans-
membrane helices each) separated by two large cytoplasmatic loop domains: 
C1 and C2. C1 and C2 domains are the most conserved regions between AC 
isoforms and their interaction forms the catalytic core of the enzyme. C1 and 
C2 dimerisation constitutes, in fact, the ATP-binding site. Within these motifs 
two aspartic acid residues coordinate two catalytic metal ions. These mediate 
the attachment of the ATP, promoting the cyclisation of the cAMP and the 
release of PPi (Figure 1-2) (Cooper, 2003). 
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TM1 TM2
C1
C2catalytic core
 
Figure 1-2 Schematic representation of adenylyl cyclase. TM1 and TM2 are the trans-
membrane domains; C1 and C2 are the cytosolic loops that form the catalytic core. 
Adapted from (Willoughby and Cooper, 2007). 
In spite of this conserved secondary structure, these enzymes are 
characterised by a different tissue distribution, as well as a different and 
specific regulation (Table 1). 
The major tmACs regulators are GTP-bound G protein subunits (Gαs, Gαi 
and Gβ) each of which exerts a type-specific effect on the different ACs 
isoforms. All the sub-cloned ACs, with exception for sAC, are activated by Gαs. 
Gαi inhibits almost all the isoforms with exception for AC2, AC4 and AC7. Gβ 
can either activate or inhibit ACs. Thus AC2, AC4 and AC7 are stimulated, AC1 
and AC8 are inhibited and AC3, AC5, AC6 and AC9 are insensitive to Gβ (Table 
1).  
Activators of ACs promote the interaction between the two cytosolic 
domains (C1 and C2) and stimulate catalysis (Tesmer et al., 1997). Accordingly, 
Gαs helps the catalytic core to bend over the substrate, whereas the Gαi 
maintains the catalytic domain in an open conformation (Willoughby and 
Cooper, 2006), thus preventing the formation of the catalytic site and 
inhibiting the binding of ATP. 
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AC1 AC2 AC3 AC4 AC5 AC6 AC7 AC8 AC9
Gαs + + + + + + + + +
Gαi - - - - - -
G - + + +
Ca2+ + + - - + -
PKC + + +
()
-
()
+
()
-
PKA - -
 
Table 1 Adenylyl cyclase regulation system. 
The second major regulator of ACs activity is calcium. Ca2+ affects ACs 
activity mostly in a calmodulin (CaM)-dependent manner. The mechanism of 
action proposed indicates that the catalytic core is sterically hindered by the 
regulatory domains within the enzyme, which contain a CaM binding site. 
Increase of intracellular Ca2+ and CaM activation induces a conformational 
change that removes such inhibition, exposing the catalytic site and favouring 
the ATP binding (Hoeflich and Ikura, 2002). Although AC1, AC3 and AC8 are 
stimulated by Ca2+/CaM, supra-micro-molecular concentrations of Ca2+ exert 
an inhibitory effect on all the ACs isoforms. Only AC5 and AC6 are inhibited by 
physiological changes of Ca2+ levels (Willoughby and Cooper, 2006). 
AC activity can also be modulated by PKC and PKA. For instance PKC 
activation stimulates the Gαi- and Ca2+-insensitive ACs: AC2, AC4 and AC7 
(Cooper, 2003) (Schallmach et al., 2006) (Tabakoff et al., 2001). In addition, 
specific isoforms of PKC can also regulate AC5 (Kawabe et al., 1996) (Kawabe 
et al., 1994) and AC6 (Cheung et al., 2005). PKA-mediated phosphorylation 
inhibits the activity of AC5 and AC6 (Beazely and Watts, 2006) (Hanoune and 
Defer, 2001). 
A modest positive effect on ACs modulation has also been shown for 
receptor tyrosine kinase (Tan et al., 2001). 
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Finally, all the tmACs, with exception for AC9, are stimulated by the 
plant diterpene forskolin which, as an ACs activator, promotes the C1 and C2 
association, resulting in formation of an active catalytic site (Zhang et al., 
1997). 
A second independent source of cAMP in mammalian cells is the more 
recently discovered, soluble AC (sAC) (Buck et al., 1999). Despite its name, sAC 
is not only a soluble protein distributed throughout the cell but it also locates 
in distinct subcellular compartment such as the nucleus, mitochondria, 
microtubules and centrioles (Zippin et al., 2003). sAC is uniquely regulated by 
calcium (Jaiswal and Conti, 2003) and by bicarbonate in a pH-independent 
manner (Chen et al., 2000); in addition it is insensitive to heterotrimeric G 
protein regulation (Gαs, Gαi and Gβγ) and forskolin (Zippin et al., 2003). 
Physiological processes demonstrated to be regulated by sAC include sperm 
activation (Hess et al., 2005) and TNF activation of granulocytes (Han et al., 
2005) (Kamenetsky et al., 2006). 
A mechanism of co-localisation/compartmentalisation has been 
proposed for ACs in order to explain the preserved specificity of ACs activation 
and the generation of a pool of cAMP close to the appropriate downstream 
targets. According to this evidence of ACs compartmentalisation part of this co-
localisation rest on a residence in lipid raft and an additional part involves 
scaffolding proteins such AKAP (Willoughby and Cooper, 2007). 
1.3.2 Phosphodiesterases 
In 1962, when the concept of second messenger and cAMP/PKA signal 
transduction pathway were being elucidated, Sutherland and colleagues 
noticed that cAMP could quantitatively be converted into adenosine 5’-
monophosphate when incubated with a purified enzyme from the heart. This 
specific enzyme, capable of inactivating adenosine 3’, 5’-monophosphate, 
turned out to be a phosphodiesterase, an enzyme that was found to be 
particularly abundant in brain and heart extracts (Butcher and Sutherland, 
1962). 
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Phosphodiesterase (PDEs) enzymes are a family of related 
phosphohydrolases that selectively catalyse the hydrolysis of the 3’ cyclic 
phosphate bonds of adenosine and/or guanosine 3’, 5 cyclic monophosphate 
(Figure 1-3). 
 
PDE
 
Figure 1-3 Structural formula of cAMP. Arrow points at the bond hydrolysed by PDE. 
Adapted from (Bender and Beavo, 2006). 
PDEs represent the only cyclic nucleotide-degrading enzymes and, as 
such, they are critical regulators of cAMP intracellular homeostasis (Conti, 
2000) (Houslay and Adams, 2003). As PDEs are localised to subcellular 
compartments and recruited into multi-protein signalling complexes, they 
work together to establish local gradients of cyclic nucleotides. This 
contributes to the spatial and temporal specificity of cyclic nucleotide 
signalling by regulating the availability of cAMP to its effectors. For these 
reasons, PDEs have recently become the focus of studies as potential drugs 
targets for several diseases including asthma, chronic obstructive pulmonary 
disease (COPD), heart failure, neurological disorders, erectile dysfunction, as 
well as cancer therapy (Bender and Beavo, 2006) (Houslay et al., 2005) (Savai 
et al., 2010). 
In mammals, PDE enzymes are subdivided into eleven distinct families 
based on primary amino acid sequence, kinetics of action, mode of regulation, 
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and pharmacological properties (Beavo, 1995) (Beavo and Brunton, 2002) 
(Figure 1-4). PDEs differ also in their substrate specificity, mechanism of action 
and subcellular location. Of the eleven PDE families only three selectively 
hydrolyse cAMP (PDEs 4, 7 and 8), three families are selective for cGMP (PDEs 
5, 6, and 9), whereas five families hydrolyse both cyclic nucleotides with 
varying efficiency (PDEs 1, 2, 3, 10 and 11) (Conti and Beavo, 2007).  
The different mammalian PDEs share as common structural 
determinants a catalytic domain, encompassing a region of 270 amino acids, 
and a regulatory domain, placed between the amino terminus and the catalytic 
domain. 
Catalytic domain 
The functional structure of the catalytic domain, which constitutes the 
core of the PDE, is highly conserved in all PDEs, despite the fact that sequence 
of any catalytic domain family exhibits only 25 to 35% amino acid sequence 
identity with any other. This domain is composed of sixteen alpha helices 
forming three sub-domains that define a deep pocket where the substrates 
(cAMP or cGMP) or inhibitors bind. The catalytic core includes two consensus 
metal binding motifs indispensable for the structure and the catalytic function 
of PDEs (Francis et al., 2001). Within these motifs the two metal ions, a Zn2+ 
and an Mg2+, are coordinated by residues located on each of the three different 
domains and these residues form part of the signature recognition sequence 
for cyclic nucleotides PDEs. Several additional amino acids conserved only 
within a family are probably involved in defining substrate specificity and 
family-specific sensitivity to different inhibitors. Based on a number of 
structural studies, an interesting mechanism has recently been proposed to 
describe the specificity of substrate recognition. In each of the PDEs for which 
a crystal structure has been solved there seems to be a glutamine present, 
which stabilises the binding of the purine ring in the binding pocket (Zhang et 
al., 2004). For appropriate binding of cAMP and cGMP the glutamine residue 
must be able to rotate freely. For PDEs that can degrade both cyclic nucleotides 
this rotation is possible, whereas for PDEs that selectively degrade cAMP the 
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glutamine residue is constrained by neighbouring residues into a specific 
orientation for cAMP. Vice versa, for PDEs that selectively degrade cGMP the 
glutamine residue is constrained into the orientation that favours cGMP 
binding (Zhang et al., 2004). 
Regulatory domain 
While the catalytic domain is conserved in almost all the PDEs, the N and 
C termini always differ markedly. These differences have been hypothesised to 
confer specificity of expression, specific physiological functions or different 
ligand affinity. Of the several domains mapped to the N terminus, three are 
present in multiple PDE families. These include domains for ligand binding, 
oligomerisation, kinase recognition/phosphorylation, and regions that auto-
inhibit the catalytic domain. Docking domains are also present at the N 
terminus as well as in other regions of the PDE protein (Houslay and Adams, 
2003) (Sonnenburg et al., 1995) (Figure 1-4). 
Five of the eleven PDE families (PDE2, PDE5, PDE6, PDE10 and PDE11) 
contain two tandem N-terminal regulatory GAF domains (GAFA and GAFB) 
(mammalian cAMP and cGMP-specific and -regulated PDE, Anabaena adenylyl 
cyclase, and E. coli FhlA transcription factor), involved in dimerisation and 
cGMP binding (Martinez et al., 2002) (Aravind and Ponting, 1997). UCR1 and 
UCR2 domains (upstream conserved region) are conserved in the entire four 
genes composing the PDE4 family. Functionally, the UCR2 conserved domain 
corresponds to an auto-inhibitory domain that negatively regulates PDE 
catalytic activity (Jin et al., 1992), while regulatory phosphorylation sites have 
been mapped in the UCR1 (Sette and Conti, 1996). Although PDE4 isoforms 
lack GAF domains they appear to exist as oligomeric structures of identical 
subunits and the dimerisation domain is thought to overlap with the UCR 
modules (Richter and Conti, 2004) (see section 1.3.2.1). Besides, PDE1 contains 
two N-terminal Ca2+/calmodulin (CaM) binding site; whereas a PAS domain 
(period, arylhydrocarbon receptor nuclear translocator, and single minded), 
involved in ligand binding and protein-protein interaction, is contained only 
within PDE8. No data are available on the oligomerisation state of PDE3, PDE7 
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and PDE9 although hydrodynamic data suggest that they too exist as dimers 
(Scapin et al., 2004) (Huai et al., 2004). 
Another conserved domain of the N-terminal region is the 
phosphorylation site. PDE1A, PDE1B and PDE1C can be phosphorylated by 
PKA and CaM-kinase (CaMKII) and in vitro analysis shows that PKA-mediated 
phosphorylation decreases the binding and calmodulin-induced activation 
(Sharma and Wang, 1985) (Florio et al., 1994). PDE2A apparently can be 
phosphorylated and inhibited by tyrosine kinase (Bentley et al., 2001). PDE3A 
and PDE3B can be phosphorylated by PKA and PKB, and the PKB-mediated 
phosphorylation of PDE3B increase the catalytic activity of the enzyme 
(Zmuda-Trzebiatowska et al., 2006). Similarly, PKA phosphorylation of PDE3A 
and PDE3B potentiates PDEs activity leading to a decrease in cAMP levels (Rich 
et al., 2007). In a similar manner, PKA can phosphorylate also long form 
isoforms of PDE4 (see section 1.3.2.1). PDE5, upon binding of cGMP, undergoes 
a conformational change that promotes PKG-mediated phosphorylation 
(Bessay et al., 2007). There are no known regulatory domains on the N-
terminus of PDE7 although a consensus for PKA phosphorylation has been 
mapped in this region (Bender and Beavo, 2006). PKA phosphorylation of 
PDE10A2 appears to regulate the subcellular distribution between the Golgi 
apparatus and the cytosol. It is probable that all these different domains 
regulate PDE catalysis by a common mechanism. The binding of the agonists to 
the specific site on the N-terminal region produces a change in conformation of 
the PDE so that the negative constraint to the catalysis exerted by the 
inhibitory domain is no longer present. 
Some PDEs also contain an auto-inhibitory domain. For instance, PDE6, 
the primary regulator of cGMP in rods and cones photoreceptors of retina, 
exists as a dimer of  and β subunits and an N-terminus inhibitory  subunit. In 
the dark PDE6 is inactive and cGMP level is on the micro-molar (M) range. 
Only photo-excitation and the consequent activation of the GPCR lead to the 
displacement of the  subunit from the active site of PDE6 thus activating the 
enzyme (Cote, 2004). 
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Finally, several targeting sequences have been identified in the N-
terminal domain. The three splice variants of PDE2A differ on the first 27 
amino acid sequence and these differences seem most likely to account for 
specific subcellular localisation (Bender and Beavo, 2006). N-terminus domain 
of PDE3 includes a six-hydrophobic-helices trans-membrane domain, whereas 
PDE4 and PDE7 include an anchoring domain that enables interaction with 
AKAPs. PDE9A1 is localised to the nucleus by a pat7 nuclear localisation 
sequence (Wang et al., 2003) despite the presence of an N-terminal 
myristoylation domain in its primary sequence. 
Several properties of the C-terminal domain have also been described 
for PDEs, including phosphorylation or prenylation sites; however, there is no 
unifying concept regarding the function of the PDE C terminus (Conti and 
Beavo, 2007). 
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Figure 1-4 Schematic representation of PDEs families. Adapted from (Conti and Beavo, 
2007). 
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1.3.2.1  PDE4 
PDE4 is one of the most studied PDEs families and one of the most 
highly conserved over evolution being found in Drosophila melanogaster and 
Caenorhabditis elegans. PDE4 is expressed in a plethora of tissues and cells 
type and plays a role in a large number of physiological processes.  
The mammalian PDE4 family is encoded by four genes, PDE4A, PDE4B, 
PDE4C and PDE4D, which give rise to more than twenty distinct PDE4 isoforms 
by alternative mRNA splicing of the regulatory domain (Figure 1-5). It is 
important to notice that despite the overwhelming number of isoforms can be 
associated to a redundancy of functions; it implies unique importance for each 
individual isoforms. 
 
NTR UCR2UCR1 catalytic region
LTR1 LTR2
PDE4A: 6 isoforms
PDE4B: 5 isoforms
PDE4C: 3 isoforms
PDE4D: 11 isoforms
long
short
super-short
UCR2 catalytic region
LTR2
NTR
catalytic regionNTR
NTR catalytic regionLTR2
dead-short
 
Figure 1-5 Schematic representation of PDE4 subfamily. Adapted from (McCahill et al., 
2008) 
Each PDE4 isoform has a modular structure consisting of an isoform 
specific N-terminal region (NTR), two regions termed “upstream conserved 
region” (UCR1 and UCR2), a highly conserved catalytic region domain and a 
subfamily-specific C-terminal region (CTR) (Bolger et al., 1993). 
The catalytic domain is conserved between the eleven PDE families and 
as such it has been described previously (see section 1.3.2), whereas the C-
terminal domain is of unknown functions (Houslay, 1998). 
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Regulatory domain 
PDE4 isoforms are subject to different regulatory mechanisms, such as 
phosphorylation (Houslay et al., 2007), ubiquitinilation (Li et al., 2009) and 
interaction with other proteins (Bolger et al., 2003a). Regulation is also exerted 
at the transcriptional level (Vicini and Conti, 1997) (Mayr and Montminy, 
2001). 
The unique N-terminal region confers specificity to each isoform and 
promotes the interaction with different binding partners thus favouring 
targeting to distinct intracellular regions. Different combinations of the UCR1 
and UCR2 or the complete absence of them lead to a categorisation of PDE4 as: 
long forms that contain both UCR1 and UCR2, short forms that lack UCR1, 
super short forms that not only lack UCR1 but also include a N-terminal 
truncated UCR2 and “dead short” forms which are both N- and C-terminal 
truncated and therefore are catalytically inactive (Figure 1-5).  
UCR1 and UCR2 domains have a central role in the regulation of PDE4 
activity mediated by PKA and ERK phosphorylation. Interaction between UCR1 
and UCR2 occurs via electrostatic interaction between the hydrophobic C-
terminal of UCR1 and the hydrophilic N-terminal of UCR2 (Houslay, 2001). 
Truncation studies revealed that UCR2 exerts a constitutive inhibitory effect on 
PDE activity that can be released by PKA phosphorylation of UCR1 leading to 
the disruption of UCR1 and UCR2 interaction (Beard et al., 2000). Deletion of 
UCR2, in fact, results in an increased catalytic activity (Jin et al., 1992) (Lim et 
al., 1999). However only the long form of PDE4 can be phosphorylated by PKA 
on the RRESF motif, located at the N-terminal of the UCR1 module (Sette and 
Conti, 1996). Phosphorylation at this site causes an increase of the catalytic 
activity of the enzyme promoting a feedback loop mechanism that resets the 
cAMP concentration to the basal level. In addition the isoform PDE4D3 has a 
second site for PKA phosphorylation which lies within the NTR domain. It has 
been proposed that phosphorylation at this site can enhance the affinity of 
PDE4D3 binding to mAKAP (Dodge-Kafka et al., 2006) or promote the release 
of the specific PDE4D3 isoform from the nuclear-like protein 1 (NDEL1) 
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complex (Collins et al., 2008). Thus PKA phosphorylation of PDE4 leads to a 
dynamic redistribution of PDE4s to different complexes therefore redirecting 
modulation of cAMP gradients from one specific microdomain to another. 
PDE4B, PDE4C and PDE4D can also be regulated by ERK 
phosphorylation in a single ERK consensus motif, PXSP, within the third 
subdomain of the catalytic unit (Hoffmann et al., 1999, MacKenzie et al., 2000, 
Houslay and Adams, 2003, Baillie et al., 2001, Hill et al., 2006). Conversely to 
PKA, ERK leads to an inhibition of long form PDE4 activity. However this 
inhibition can be overcome by PKA phosphorylation of the UCR1 by a novel 
feedback loop mechanism in which the inhibition induced by ERK 
phosphorylation causes a local increase of cAMP levels, which activates PKA 
that, in turn, phosphorylates UCR1 to activate the PDE and abolish ERK 
inhibition (Hoffmann et al., 1999). 
Additionally, cAMP can also modulate PDE4 via modulation of 
transcription of PDE4 genes (Vicini and Conti, 1997, Seybold et al., 1998). This 
effect is mediated by cAMP response elements (CREs) in the promoter region 
of PDE genes (D'Sa et al., 2002) (Le Jeune et al., 2002). Activation of PKA 
results in the phosphorylation of the transcription factor CRE binding protein 
(CREB), that in turn can bind to the CRE region and promote PDE4 specific 
gene transcription (Mayr and Montminy, 2001). 
Targeting and compartmentalisation of PDE4. 
PDE4 can be strategically targeted to distinct subcellular compartments 
through association with other proteins. These protein-protein interactions are 
mediated mainly, but not exclusively, by the unique N-terminal region of PDE4 
isoforms (Houslay and Adams, 2003) (Huston et al., 2006). Thus PDE4A1 
associates with the plasma membrane and the Golgi apparatus (Shakur et al., 
1993); PDE4A4, PDE4A5 and PDE4D4 interact with members of SRC tyrosyl 
kinase family (Beard et al., 1999) (O'Connell et al., 1996); PDE4A5 with the 
immunophilin XAP2 (Bolger et al., 2003b) and PDE4D5 with receptor for 
activated protein kinase C (RACK1) (Yarwood et al., 1999) and β-arrestin 
(Perry et al., 2002); PDE4B1 interacts with disrupted in schizophrenia 1 
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(DISC1) (Millar et al., 2007) and PDE4D3 is sequestered directly to the cardiac 
ryanodin receptor (RyR2) (Terrenoire et al., 2009) and interact with a variety 
of AKAPs such as myomegalin (Verde et al., 2001), mAKAP (Dodge et al., 2001), 
AKAP18 (Stefan et al., 2006) and AKAP450 (Witczak et al., 1999). These and 
many other evidence of PDE4 sequestration are available in literature 
(McCahill et al., 2008, Houslay, 2010) and all of them underpin the role of PDEs 
in defining compartmentalisation of cAMP signalling. 
Despite the fact that PDEs can bind different proteins, they seem to be 
subject to a “scaffold fidelity” rule. Studies on several PDE4 partnerships 
indicate that a given PDE4 probably binds to no more than one scaffold at a 
time, highlighting once again the non redundancy of different PDE isoforms 
(Houslay, 2010). 
The wide diversity of PDEs, conserved between species, suggests that 
different isoforms can play specific roles. This contributes to the spatial and 
temporal specificity of cyclic nucleotide signalling by regulating the availability 
of cAMP to its effectors. 
1.4 cAMP effectors 
1.4.1  PKA 
PKA is a hetero-tetramer (Figure 1-6, C)) composed of two catalytic (C) 
subunits (Figure 1-6, B)) bound non-covalently to a dimer of regulatory (R) 
subunits (Figure 1-6, A)). The C subunit isoforms (C, C and C) have identical 
kinetic and biochemical properties (Buechler and Taylor, 1990) (Taylor et al., 
1990). In contrast, the two classes of R subunits (type I: isoforms RI, RI, and 
type II: isoforms RII, RII) and their corresponding holoenzymes (PKA type I 
and PKA type II) show different functional and biochemical properties. In 
particular PKA type-I is more immediately dissociated by cAMP then PKA type-
II (showing a Kact of 50-100 nM and 100-200 nM, respectively) (Dostmann et 
al., 1990) (Cummings et al., 1996). In addition, R subunits are also differentially 
expressed. RII expression is tissue-specific and it is predominantly associated 
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with cellular structures and organelles due to anchoring to A-Kinase Anchoring 
Proteins (AKAP) (Tasken and Aandahl, 2004) (Theurkauf and Vallee, 1982) 
(Lohmann et al., 1984) (Sarkar et al., 1984), whereas RI appears to be 
expressed in most tissues and to be predominantly cytoplasmic. However 
Dual-AKAPs and selective RI AKAPs have also been identified (Huang et al., 
1997b) (Angelo and Rubin, 1998). Binding to AKAP contributes to the 
specificity as well as to the efficiency of the cAMP-PKA pathway by targeting 
PKA to discrete subcellular compartments in close proximity to its specific 
substrates (Theurkauf and Vallee, 1982) (Lohmann et al., 1984). All these 
features underline the fact that the role of PKA type I and PKA type II in the 
cells is non redundant, but coordinated to perform a specific biological 
function. 
Regulatory subunit 
Each R subunit comprises a dimerisation/docking domain (D/D 
domain), a hinge region, essential for interacting with the C subunit; and two 
highly conserved cAMP binding domains organised in tandem (Taylor, 1989) 
(Figure 1-6). The N terminal D/D domain consists of an anti-parallel four helix 
motif forming a four helix bundle. This region provides the domain for the 
dimerisation of the two R subunits and the docking surface for high affinity 
binding to AKAPs (Newlon et al., 1999) (Newlon et al., 2001). Specifically the 
D/D of RII subunits can be divided into two regions: the first 23 amino acids 
involved in AKAP binding and the region from amino acid 24 to amino acid 44 
which covers the majority of the contacts between the two dimerising 
subunits. Deletion of the 1-5 sequence in RII abolishes the binding to AKAPs 
without interfering with the dimerisation (Hausken et al., 1994) (Hausken et 
al., 1996). The RI subunit dimerises in the same way of RII subunit forming a 
helix-turn-helix motif, however the dimerisation motif of RI is shifted forward 
and involves the sequence from amino acid 16 to amino acid 61. In addition, 
the RI helix bundle has a Y-like shape as opposed to the X-like shape of the 
corresponding RII motif (Leon et al., 1997) (Banky et al., 1998) (Banky et al., 
2000). 
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The primary function of the regulatory subunit of PKA is to bind to and 
to inactivate the catalytic subunit in the absence of cAMP (Taylor et al., 1990, 
Taylor et al., 2008). The hinge region holds this function. It corresponds to the 
peptide inhibitory site (IS domain) and it represents the region of interaction 
between the regulatory and catalytic subunits. Despite the fact that they share 
this common function, the hinge domains differ in RI and RII. In the RII subunit 
the hinge region contains an auto-phosphorylation site (serine 114) included 
in an amino acid sequence similar to the consensus sequence found in the 
substrates for the catalytic subunit (Taylor et al., 1990). Conversely in the RI 
subunit the serine is replaced by an alanine or a glycine, thus resulting in a 
pseudo-phosphorylation site (Takio et al., 1984). The auto-phosphorylation of 
the RII subunit occurs as an intra-molecular event that does not require 
subunit dissociation (Taylor et al., 1990). In addition, auto-phosphorylation of 
the regulatory subunit reduces the affinity of the regulatory for the catalytic 
subunit and therefore lowers the activation threshold of PKA (Taylor et al., 
1990) (Taylor et al., 2008). 
PKA activation and consequent release of the two catalytic subunits 
occurs only when four cAMP molecules are bound to the regulatory dimer. 
Each regulatory subunit consists of two cAMP binding domains (DomainA and 
DomainB) (Figure 1-6). In the inactive conformation only the domainB is 
available for cAMP. The engagement of this site induces a conformational 
change that enhances the cAMP binding to the domainA. Once activated, the 
catalytic subunit can phosphorylate serine and threonine residues on specific 
substrate proteins as well as the regulatory subunit itself (Kim et al., 2006) 
(Figure 1-6). 
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Figure 1-6 Schematic representation of A) the regulatory and B) the catalytic subunit of 
PKA. Star in the regulatory subunit A) indicates the pseudo-phosphorylation or the 
auto-phosphorylation site of R type I and type II respectively. C) Schematic 
representation of the quaternary structure of PKA. 
1.4.2  EPAC 
Epac proteins were identified in 1998, when evidence hinted towards 
the existence of PKA-independent mechanisms of cAMP action (de Rooij et al., 
1998). In the same period screening for brain proteins containing a cAMP 
binding domain led to the discovery of Epac proteins (Kawasaki et al., 1998).  
Epac is a guanine nucleotide exchange factors (GEFs) for Rap1 and Rap2 
(de Rooij et al., 2000). Rap is a small G protein of the Ras family and it cycles 
from the inactive guanosine diphosphate (GDP) bound state and the active 
guanosine triphosphate (GTP) bound state. In this reaction Epac catalyses the 
exchange of the GDP for the GTP whereas the GTPase-activating proteins 
(GAPs) account for the GTP hydrolysis. 
Epac represents an important intracellular effector for cAMP and 
appears to account for many of its effects from insulin secretion in pancreatic 
beta cells to cardiac contraction through regulation of calcium channels in 
cardiomyocytes and permeability of vascular epithelium (Bos et al., 2003). 
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Most of these processes are also regulated by cAMP/PKA pathway highlighting 
the cross-talk between these two cAMP pathways. 
There are two isoforms of Epac produced by two different genes: Epac1 
and Epac2. Each of these consists of an N-terminal regulatory and a C-terminal 
catalytic region (Figure 1-7). The N-terminal region contains a DEP 
(Dishevelled, Egl-10, and Pleckstrin) domain responsible for anchoring to the 
membrane, and one (Epac1) or two (Epac2) cyclic nucleotide binding domains 
(CBD) homologous to those found in the R subunit of PKA. The function of the 
extra CBD in Epac2 is not clear since it binds cAMP with low affinity and does 
not seems to be required for Epac2 regulation by cAMP. 
The C-terminal catalytic portion of Epac lodges the CDC25-homology 
domain (CDC25-HD) characteristic of the exchange factors for Ras family 
GTPase (GEF domain); and a regulatory domain named Ras exchange motif 
(REM). An additional Ras-association domain (RA) lies between REM and 
CDC25-HD domains (de Rooij et al., 1998) (de Rooij et al., 2000) (Figure 1-7). 
The regulatory domain functions as an auto-inhibitory domain that affects GEF 
activity by steric hindrance. Such inhibition can be relieved only by cAMP. 
Crystal structure of active and inactive Epac2 (Rehmann et al., 2008) 
(Rehmann et al., 2006) revealed that when cAMP is low Epac is folded in an 
inactive conformation in which the regulatory domain inhibits the Rap 
association to the catalytic site preventing Rap binding to the CDC25-HD 
domain (Bos et al., 2003). The increase in cAMP concentration and the 
occupation of the Epac cAMP-binding domain induces the unfolding of the 
protein, leading to an open conformation and the exposure of the catalytic 
domain for the binding of Rap GTPase (Figure 1-7).  
 
Chapter 1 Introduction 
23 
 
CDC25-HDREMCBDCBD DEP RA
CDC25-HDREMCBDDEP RAEpac1
Epac2
regulatory catalytic (GEF)
cAMP
REM
CBD
DEP
CDC25 
HD
RA
REM
CDC25 
HD
RA
Rap
A)
B)
 
Figure 1-7 A) Schematic representation of Epac1 and Epac 2 and B) its activation 
mechanism. 
Epac proteins are ubiquitously expressed inside the cells and like PKA 
the multiple cellular functions of Epac are regulated by its spatial localisation. 
Both Epac1 and Epac2 contain sequence mediating binding to the plasma 
membrane. Epac1 is targeted to the plasma membrane by the DEP domain 
whereas Epac2 binds via the RA domain, although it has been shown that 
Epac2 contains an additional membrane targeting sequence at the N-terminal 
region. In addition, localisation to several other subcellular sites has been 
described for Epac1. Epac1 can be localised to the nucleus, the nuclear pore 
complex (Qiao et al., 2002), the centrosome (Wang et al., 2006) as well as 
microtubules (Sehrawat et al., 2008) and mitochondria (Wang et al., 2006). The 
specific localisation may link Epac to unique cellular processes. 
1.4.3  Cyclic nucleotide-Gated Channels (CNG) 
Cyclic nucleotide gate channels are ion channels activated by cAMP and 
cGMP. They have been originally identified in photoreceptors and olfactory 
neurons where they play a crucial role in sensory transduction. Although they 
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have been successively identified in many other tissues such as kidney, 
endocrine tissue and sperm cells (Kaupp and Seifert, 2002) (Khan et al., 2010) 
(Bonigk et al., 2009). 
The primary functions of the channels are to transduce changes in 
nucleotides levels into changes of membrane potential and calcium 
concentration. All the CNG channels characterised so far allow Na+ and K+ to 
flow, but they do not discriminate between them. Also Ca2+ can flow through 
the channels even if it acts as a voltage dependent blocker of monovalent 
cation permeability (Dzeja et al., 1999). 
Structurally CNG channels belong to the super-family of pore-loop cation 
channels (Yu et al., 2005) and they share a common structure with hyper-
polarisation-activated cyclic nucleotide (HCN) channels and Eag-like K+ 
channels. The family of mammalian CNG channels comprises 6 members (4 
subunits A and 2 subunits B) sharing homology of sequence and membrane 
topology (Figure 1-8). Each member comprises a six trans-membrane domain 
(S1-S6), a loop (P) between S5 and S6, a PKA/PKG homologous cyclic 
nucleotide binding domain (CBD) connected allosterically to the channel gate 
by a C-linker domain and two cytosolic domains at the N and C terminus 
(Figure 1-8). CNG channels are tetramers with the four subunits aligned 
around the centrally located pore. In turn the pore is assembled by overlapping 
of the P-loop and the S6 segment of the four subunits (Higgins et al., 2002). 
Although subunits A1, A2 and A3 can be functional expressed as homomers, 
FRET studies strongly suggest that native CNG channels are mainly hetero-
tetramers. (Zheng et al., 2002) (Zheng and Zagotta, 2004).  
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Figure 1-8 Schematic representation of a CNG channel member. Adapted from (Biel and 
Michalakis, 2009).  
The mechanism of CNG channels activation comprises two steps: the 
ligand binding to the CBD and the consequent opening of the channel pore. The 
binding of the cyclic nucleotide to the channel, in its closed conformation, leads 
to an allosteric conformational change in which the C-linker domains of the 
four channel subunits assemble and give rise to a tetrameric gating ring 
(Taraska and Zagotta, 2007). 
Despite the fact that the CNG channels are strictly ligand-gated, exposure 
to the cyclic nucleotide does not desensitise or inactivate the channels. 
However, they are regulated by a feedback CaM-mediated mechanism (Bradley 
et al., 2005, Biel and Michalakis, 2009). 
1.5 cAMP compartmentalisation 
The cAMP/PKA pathway is responsible for a large number of 
physiological effects and an enormous amount of extracellular signals are 
converted in appropriate responses via a mechanism that involves 
concentration changes of the same intracellular molecule, cAMP. In addition, 
cAMP is a long range-acting second messenger (Kasai and Petersen, 1994) that, 
after generation, can potentially diffuse and rapidly fill the entire cell, causing 
the non-selective activation of all the PKA subsets present in the cell. This 
scenario has raised the question of how specificity is maintained in the 
cAMP/PKA pathway. 
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In recent years it has become clear that the concentration gradient of 
cAMP cannot be the only code used by the cells to transduce information, and 
that specificity of response is gained with a spatial and temporal patterning of 
signalling molecules (Kasai and Petersen, 1994) (Hunter, 2000). 
The hypothesis of cAMP/PKA compartmentalisation was proposed more 
than 40 years ago by Brunton and co-workers when they observed that 
prostaglandin E1 (PGE1) and isoproterenol, a -adrenergic receptor (-AR) 
agonist, caused the activation of different pools of PKA in cardiomyocytes. 
Although both ligands act on hormone-responsive G protein-coupled receptors 
to cause consequent AC activation and cAMP elevation, PGE1 prevalently 
activates PKA present in the soluble fraction of cardiac myocytes cells lysates, 
whereas isoproterenol activates PKA present in the particulate fraction of 
these lysates. Moreover, only isoproterenol shows a positive inotropic effect, 
whereas the PGE1-mediated response in the soluble fraction has no effect on 
contractility (Brunton et al., 1979) (Steinberg and Brunton, 2001). Based on 
these observations, it was postulated that differences in the heart response to 
isoproterenol and to PGE1 are consequence of activation of cAMP signalling 
transduction pathways that are confined to distinct intracellular 
compartments, and that activation of the particulate fraction of PKA is essential 
for the  metabolic and inotropic responses of the heart to elevated cAMP 
whereas activation of the soluble pool of PKA is not involved in these 
responses (Keely, 1977) (Keely, 1979) (Hayes et al., 1979) (Hayes and Brunton, 
1982) (Hayes et al., 1980) (Byus et al., 1979) (Corbin et al., 1977) (Brunton et 
al., 1979). 
More recently, such a hypothesis has been confirmed by real-time 
experiments in living cells. Experiments in frog ventricular myocytes 
(Jurevicius and Fischmeister, 1996), in which Ca2+ transients were recorded at 
two physically distant portions of the myocyte, using a whole-cell patch-clamp 
approach, demonstrated that local application of isoproterenol caused local 
activation of ICa, whereas local application of forskolin (a non selective AC 
activator) caused activation of ICa throughout the cell, both at local and at 
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distant sites. These results support the notion that -AR-dependent cAMP 
accumulation and responsiveness are compartmentalised in at least some 
myocardial cells (Jurevicius and Fischmeister, 1996). 
At the same time, several lines of evidence indicated that PDEs may 
contribute to cAMP compartmentalisation. Pharmacological inhibition of PDEs 
showed that their activities are localised to prevent the spread of -adrenergic 
signals from particulate (membrane) locations to soluble fractions. When PDEs 
were inhibited, the otherwise local cAMP elevation elicited by a -adrenergic 
stimulus became diffused and similar to that seen with forskolin (Fischmeister 
et al., 2006) (Hohl and Li, 1991). These data suggest that β-AR-stimulated 
accumulation of cAMP occurs in defined locales in the cell so as to be 
specifically effective and may originate from a subset of cellular adenylyl 
cyclases, whereas forskolin generally stimulates most or all available tmACs. 
The above evidence suggests that there is compartmentalisation of the cAMP 
signalling pathway, and that this compartmentalisation is subordinate to four 
postulates: 1) not all cAMP can activate all PKA subsets; 2) not all PKA subsets 
can phosphorylate all possible targets; 3) not all cAMP can be degraded by all 
PDEs; 4) there is a spatial relationship between a given receptor-Gs-adenylyl 
cyclase complex and a specific intracellular compartment (Steinberg and 
Brunton, 2001). 
In the past decade a large number of studies have tried to dissect the 
crucial role played by both AKAPs and PDEs in cAMP/PKA signalling pathway 
compartmentalisation, where AKAPs account for the spatial location of the 
signalling pathway components whereas PDEs assure the shaping of restricted 
pools of cAMP. The tight cooperation of these two families of proteins provides 
the means to achieve physical and biochemical compartmentalisation of the 
cAMP signal transduction pathway. 
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1.5.1  AKAPs and the physical compartmentalisation 
of PKA pathway 
AKAPs are a structurally diverse family of functionally-related proteins 
that are defined on the basis of their ability to anchor the PKA holoenzyme 
inside the cell and to co-precipitate catalytic activity (Colledge and Scott, 1999) 
(Figure 1-9). 
 
A
K
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Figure 1-9 Schematic representation of AKAP-PKA interaction. 
The first AKAP to be isolated was the microtubule associated protein-2 
(MAP2), a protein that co-purifies with the PKA holoenzyme when isolated 
from brain extracts (Lohmann et al., 1984). Since then, a variety of gel overlay, 
interaction cloning, yeast two-hybrid and proteomic approaches have 
identified more than fifty AKAPs when splice variants with different cellular 
targeting are included (Table 2). 
Although the majority of identified AKAPs anchor PKA type II (Huang et 
al., 1997b), a number of PKA type I specific AKAPs have also been 
characterised. For instance AKAPCE (Angelo and Rubin, 1998), myosin VIIa 
(Kussel-Andermann et al., 2000a) (Kussel-Andermann et al., 2000b) and 4 
integrins (Lim et al., 2007) show higher affinity for RI than RII subunits. In 
addition, several AKAPs including D-AKAP1, D-AKAP2 (Huang et al., 1997a), 
AKAP220, Ezrin, Merlin, PAP7, show dual specificity and can therefore 
Chapter 1 Introduction 
29 
 
associate with both RI and RII subunits (Gronholm et al., 2003) (Huang et al., 
1997a) (Huang et al., 1997b) (Li et al., 2001) (Liu et al., 2006). 
Structurally, each AKAP contains at least two functional domains: a PKA 
(R subunit) binding motif and a unique subcellular targeting motif. In addition 
to these two domains, AKAPs include also regions of interaction with different 
other proteins such as phosphoprotein phosphatases (PP), PDEs and protein 
kinases (Tasken et al., 2001) (Feliciello et al., 2001). 
PKA binding motif 
The conserved PKA-binding motif consist of 14-18 amino acids arranged 
to form five turns of an amphipathic helix that exposes a hydrophobic face on 
one side and charged residues along the other side (Carr et al., 1991).  
Surface plasmon resonance experiments suggest that AKAP-RII binding 
has high affinity whereas AKAP-RI binding has low affinity and faster off-rate; 
this implies that the AKAP-RI complex is rather dynamic compared with the 
AKAP-RII complex. The differences at the N-terminus of the two regulatory 
subunits seem to account for the AKAP-binding specificity (Jarnaess et al., 
2008). 
Anchoring of PKA type II to AKAPs occurs when the hydrophobic side of 
the  helix in the AKAP lies across the four helix bundle formed by the RII 
docking domain (Newlon et al., 2001). This mechanism of interaction of RII 
with AKAPs is robust enough to favour the maintenance of the AKAP-PKA 
complex within the cells. Conversely the extreme N-terminus of RI subunit is 
believed to be helical and this additional helix collapses on the four helix 
bundle, causing a steric hindrance for high affinity anchoring to AKAPs. Dual 
specificity AKAPs have an additional binding motif, RISR (RI specific region) at 
the N-terminus of the conserved  helix, which enhances the affinity of AKAPs 
for RI by providing an additional site of contact for the AKAP-RI interaction 
and thus stabilising the formation of the anchored complex (Jarnaess et al., 
2008). 
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Other mechanisms that do not involve the amphipathic helix may be 
responsible for the anchoring of PKA. For instance pericentrin binds the D/D of 
the regulatory subunit of PKA type II through a 100 amino acid domain that is 
not predicted to form an amphipathic helix (Diviani et al., 2000), whereas 4 
integrins interact directly with the intact PKA type I holoenzyme through its 
cytoplasmatic domain (Lim et al., 2007). Interestingly, these AKAPs contain 
neither the conserved amphipathic helix nor the RISR motif (Jarnaess et al., 
2008). 
Disruption of the amphipathic helix motif by the introduction of a 
proline within the helix abolishes AKAPs binding to R subunits both in vivo and 
in vitro (Carr et al., 1991). Moreover, ectopic expression of peptides designed 
on the amphipathic helix inhibits PKA interactions with AKAPs. The Ht31 
peptide (or Rt31, the rat homologous), derived from AKAP-Lbc, was the first 
disrupter peptide to be used in competition experiments (Klussmann et al., 
2001). Bioinformatics studies allowed the generation of improved versions of 
this peptide first to a more potent dual specific anchoring disrupter peptide 
named AKAP-in silico (AKAP-IS) (Alto et al., 2003) and successively to a RII and 
a RI isoform specific anchoring disrupter peptides termed SuperAKAP-IS (Gold 
et al., 2006) and RIAD (Carlson et al., 2006). Both these peptides were 
exploited to selectively delineate functional roles of anchored PKA type I and 
PKA type II (Carlson et al., 2006) (Jarnaess et al., 2008) (Di Benedetto et al., 
2008). 
Targeting motif 
The AKAP subcellular targeting domain is a unique sequence that directs 
the AKAP-PKA complex to defined subcellular structures, membrane or 
organelles (some examples of these are plasma membrane, Golgi apparatus, 
centrosome, nucleus, mitochondria and cytosol); such a sequence is either a 
lipid modification targeting motif or a protein-protein interaction domain 
(Colledge and Scott, 1999) (Beene and Scott, 2007) (Edwards and Scott, 2000). 
This unique sequence accounts for AKAP-PKA compartmentalisation. Different 
AKAPs can also be localised to the same subcellular organelle whereas splice 
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variants of the same AKAPs can be differentially targeted. For example 
AKAP79/150 binds to the plasma membrane through interaction with 
phospholipids (Dell'Acqua et al., 1998) whereas  and β isoforms of AKAP18 
anchor to the plasma membrane via a myristoylated and palmitoylated 
sequence (Trotter et al., 1999). AKAP450 anchors to the centrosome (Witczak 
et al., 1999) whereas its short splice variant Yotiao is targeted to the post-
synaptic membranes (Westphal et al., 1999). Interestingly AKAP450 and 
pericentrin anchor both to the centrosome through the same conserved 
domain named pericentrin-AKAP450 centrosomal targeting domain (PACT) 
(Gillingham and Munro, 2000). Although these two AKAPs share the same 
targeting domain they are different otherwise, and it is therefore likely that 
they account for different PKA-mediated phosphorylation pathways.  
As for PDEs, the great number of unique AKAPs ensures a great level of 
specificity and complexity as well as accuracy to each physiological process. 
AKAPs were first classified according to their molecular weight on 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS Page). 
However this classification has been considered cumbersome since there are 
several splice variants of the same AKAP resulting in different molecular 
weight and other anchoring proteins, such as gravin, that were named before 
the discovery of their ability to bind PKA. Recently, a gene-based nomenclature 
system has been introduced (Table 2). In this thesis, I will refer to AKAPs 
according to the molecular weight based nomenclature. 
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AKAP (molecular weight-
based nomenclature)
AKAP 
(gene 
nomenclat
ure)
Tissue Subcellular 
localization
Properties and 
Interactos
S-AKAP84/D-
AKAP1/AKAP121/AKAP14
9
AKAP1 Testis, thyroid, 
heart, lung, liver, 
skeletal muscle 
and kidney
Outer mitocondrial
membrane, 
endoplasmid reticulum,
nuclear envelope, 
sperm midpiece
Dual specific
AKAP. Binds 
laminB, PP1,
PDE7A
AKAP-KL AKAP2 Kidney, lung, 
thymus and 
cerebellum
Actin cytoskeleton, 
apical membrane of 
epithelial cells
AKAP110 AKAP3 Testis Axoneme Binds G13
AKAP82/FSC1 AKAP4 Testis Fibrous sheath of 
sperm tail
Dual-specific 
AKAP
AKAP75/79/150 AKAP5 Bovine/human/rat 
orthologus
Brain
Plasma membrane, 
post synaptic density
Binds PKC, 
calcineurin
(PP2), -AR, 
SAP97 and 
PSD95
mAKAP AKAP6 Heart (mAKAP, 
shorter), skeletal 
muscle and brain 
(mAKAP, 
longer)
Nuclear membrane Binds PDE4D3, 
Epac, 
MEKK/MEK5/E
RK5 and PDK1 
(only mAKAP)
AKAP15/18     AKAP7 Brain, skeletal 
muscle, pancreas 
and heart
Basolateral () and 
apical () plasma 
membrane, cytoplasm  
(), secretory vesicles 
()
AKAP95 AKAP8 Heart, liver, 
skeletal muscle, 
kidney and 
pancreas
Nuclear matrix Binds 
Eg7/condensin
Zinc-finger 
motif, PDE7A
AKAP350/450/CG-
NAP/Yotiao/Hyperion
AKAP9 Brain, pancreas, 
kidney, heart 
skeletal muscle, 
thymus, spleen, 
placenta, lung , 
liver and testis
Post-synaptic density, 
neuromuscular 
junction, centrosome
and Golgi apparatus
Binds PDE4D3, 
PP1, PP2, PKN, 
PKC, CK1
D-AKAP2 AKAP10 Liver, lung, spleen 
and brain
Dual-specific
AKAP
AKAP220/hAKAP220 AKAP11 Testis and brain Vesicles, peroxisomes, 
centrosome
Dual-specific 
AKAP. Binds 
PP1
Gravin AKAP12 Endothelium Actin cytoskeleton and
cytoplasm
Binds PKC and 
-AR
AKAP-Lbc/Ht31/Rt31 AKAP13 Ubiquitous Cytoplasm 
MAP2B Ubiquitous Microtubules Binds tubulin
Ezrin/AKAP78 Secretory
endothelia
Actin cytoskeleton Dual-specific
AKAP
T-AKAP80 Testis Fibrous sheath of 
sperm tail
AKAP80/MAP2D Ovarian granulosa
cells
 
Chapter 1 Introduction 
33 
 
AKAP (molecular weight-
based nomenclature)
AKAP 
(gene 
nomenclat
ure)
Tissue Subcellular 
localization
Properties and 
Interactos
SSeCSK (Src-supressed C 
kinase substrate)
Testis and 
elongating 
spermatids
Actin remodelling Gravin-like
Pericentrin Ubiquitous Centrosome Binds dynein and 
-tubulin
WAVE-1/Scar Brain Actin cytoskeleton Binds Abl and 
Wrp
Myosin VIIA Ubiqitous Cytoskeleton Binds RI
PAP7 Steroid-producing 
cells (adrenal
gland and gonads)
Mitocondria Binds RI 
Neurobeachin Brain Golgi apparatus
AKAP28 Primary airway 
cells
Ciliary axonemes
Myeloid translocation gene 
(MTG) 8 and 16b
Lymphocytes Golgi apparatus Binds PDE7A
AKAP140 Granulosa cells 
and meiotic 
oocytes
Not cloned
AKAP85 Lymphocytes Golgi apparatus Not cloned
BIG2 (Brefeldin A-inhibited 
guanine nucleotide-exchange 
protein 2)
Cytosol and Golgi 
apparatus
Binds RI, RI, 
RII and RII
through three 
different  PKA 
binding domains
Rab32 Mitochondria Binds RI 
AKAPCE Caenorhabditis
elegans
DAKAP550 Drosophila Plasma membrane/ 
cytoplasm
DAKAP200 Drosophila Plasma membrane Binds F-actin and 
Ca-calmodulin
Nervy Drosophila Axons
AKAP97/radial spoke 
protein 3 (RSP3)
Chlamydomonas Flagellar axonemes
 
Table 2 Correlation between the AKAPs molecular weight-based nomenclature and the 
gene-based nomenclature. Adapted from (Pidoux and Tasken). 
Since the discovery of AKAPs, the evidence of their key role in the 
organisation of discrete PKA signalling domains has become increasingly clear. 
Firstly, it was hypothesised that selective activation of targets was due to the 
specific activation of a subset of PKA located near the intracellular targets 
themselves. The same hypothesis was consolidated by the finding that 
components of the cAMP/PKA signal transduction pathway are organised in 
three dimensional clusters where receptor, effector, targets and regulatory 
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proteins are specifically associated in macromolecular complexes to maintain 
localised pools of kinase activity (Feliciello et al., 2001). 
The first evidence of a multivalent AKAP complex was reported in 1995 
when AKAP79 was shown to be localised in the postsynaptic membrane where 
it interacts with PKA, protein kinase C (PKC) and the calcium/calmodulin-
dependent protein phosphatase (PP2B) (Coghlan et al., 1995) (Klauck et al., 
1996). Subsequent studies revealed that the role of this complex is to regulate 
the phosphorylation and activity of the associated -amino-3-hydroxi-5-
methyl-4-isoxazoleproprionic (AMPA) and N-methyl-D-aspartic acid (NMDA)-
type glutamate receptors, as well as L-type Ca2+ and M-type K+ channels. As far 
as the mechanism of regulation of AMPA receptor glutamate receptor 1 
(GluR1) is concerned, biochemical and electrophysiological studies indicate 
that this elaborate molecular architecture ensures that PKA and PP2B 
preferentially modulate the phosphorylation status of serine 845, a PKA target 
on the GluR1 subunit of the AMPA channel (Colledge et al., 2000) (Tavalin et 
al., 2002). AKAP79 holds PP2B in an active state. The functional consequence 
of this appears to be a reduced activity of the AMPA channel. Activation of PKA 
by cAMP overcomes this inhibition, leading to an enhancement of the current 
lowing through the channel (Coghlan et al., 1995). Interestingly AKAP79 
anchors and inhibits the catalytic core of PKC. Binding of the 
calcium/calmodulin complex to AKAP79 releases PKC from the anchoring 
protein, resulting in activation of the kinase (Faux et al., 1999) (Faux and Scott, 
1997). Thus, signalling that proceeds through calcium/calceneurin can lead to 
the liberation and activation of an anchored pool of PKC at postsynaptic 
densities. The complexity of this cluster was further appreciated with the 
finding that 2-AR co-precipitates with AKAP79 (Fraser et al., 2000). The 
association of the receptor with PKA to the same AKAP was shown to enhance 
the phosphorylation of the receptor in an agonist-dependent manner. This 
phosphorylation favours the switch of the receptor coupling from Gs to Gi 
which in turn results in activation of the MAP kinase cascade (Fraser et al., 
2000). Recent biochemical assays and FRET-based analysis of PKA activity 
(using the FRET based sensor for PKA activity, AKAR, see section 6.1.1) provide 
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evidence for an additional interaction between AKAP79 and AC5/6 (Bauman et 
al., 2006). Similarly to the 2-AR inhibition, direct phosphorylation of AC5 by 
PKA inhibits AC5 activity and cAMP synthesis in an agonist dependent manner 
(Bauman et al., 2006). 
Another example of such an interaction has been shown for the class C 
L-type Ca2+ channel in neurons from hippocampus. This channel assembles in a 
complex with 2-AR (Davare et al., 2001) and contains a docking domain for 
anchoring to the AKAP MAP2B, which in turn binds PKA (Davare et al., 1999). 
Hormonal stimulation of -AR receptors leads to an increase of cAMP. The 
consequent activation of the associated PKA leads to phosphorylation of the 
channel and regulation of its activity in a highly localised manner (Davare et al., 
1999). Thus, the direct physical interaction between PKA-AKAP MAP2B and 
the channel accounts for a rapid and precise transmission of the signal elicited 
by the -AR. 
The role of AKAPs in mediating the high levels of specificity and 
complexity of the cAMP/PKA signal transduction pathway has been widely 
studied. It is now clear that AKAPs have more complex functions than was 
originally thought. Beside the primary function of anchoring and targeting PKA 
in distinct subcellular compartments, AKAPs also act as multi-scaffold proteins, 
linking upstream activators with their downstream targets and allowing for 
specificity of transduction as well as for integration and linear relay of multiple 
signalling pathways (Bauman et al., 2006). AKAPs can also interact with PDEs 
and protein phosphatases and thus account for coordinated termination of the 
response. For instance, mAKAP targets PKA and PDE4D3 to the perinuclear 
region in cardiomyocytes (Dodge et al., 2001) (Kapiloff et al., 2001). This 
interaction generates a macromolecular complex within which, upon activation 
by local increases of cAMP, PKA phosphorylates and activates the associated 
PDE, which in turn reduces cAMP to generate a loop of negative feed-back 
regulation. In an elegant experiment two different fluorescent PKA activity 
reporters (AKAR) were modified in order to recruit PKA (AKAR-PKA) or PKA 
and PDE4DE3 (AKAP-PKA-PDE). By using these reporters, it was possible to 
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demonstrate that co-anchoring of PDE leads to a brief pulse of PKA activity, 
whereas in the absence of PDE anchoring, a sustained PKA activity is recorded 
under the same conditions, demonstrating that recruitment of PDE4D3 
terminates the activation of the anchored PKA via a negative feed-back loop 
mechanism (Figure 1-10) (Dodge-Kafka et al., 2006). 
 
 
Figure 1-10 Schematic representation of a negative feedback loop regulation 
mechanism involving an AKAP-anchored PDE4. 1) mAKAP anchors PKA and PDE4D3 at 
the perinuclear region of cardiomyocytes. 2) When cAMP increases, PKA is activated 
and 3) it phosphorylates the associated PDE4D3 4) which in turn degrades cAMP re-
establishing the cAMP level below the threshold of PKA activation. 
Anchoring of AC, PKA and PDE to the same AKAP may generate local 
fluctuations in cAMP and pulses of compartmentalised PKA activity (Dodge-
Kafka et al., 2006). Each substrate appears to have a selective anchored subset 
of PKA and its own local spatio-temporally organised pool of cAMP shaped by 
anchored PDEs. A rise in the intracellular cAMP level, leads to the activation of 
PKA and the consequent phosphorylation of PKA targets, including associated 
PP and PDEs. The activation of both these enzymes promotes the de-
phosphorylation of the targets and the degradation of the cAMP below the PKA 
activation threshold thereby promoting re-association of the PKA holoenzyme 
and rapidly terminating the cAMP response. 
It is also important to consider the control exerted by AKAPs on the 
cAMP/PKA signalling pathway through the dynamic reorganisation of the 
complexes. For example the binding domain for the RII subunit on Wave1, a 
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Wiskott-Aldrich syndrome scaffolding protein, overlaps with the actin binding 
region in a mutually exclusive manner. This might lead to a situation in which 
binding of PKA is favoured over Wave1 binding to the actin cytoskeleton or 
vice versa (Westphal et al., 2000). 
Phosphorylation of AKAPs represents another way to modify the 
subcellular location of an AKAP complex. For instance, phosphorylation of 
AKAP79/150 by PKC abolishes the interaction between the AKAP and the 
plasma membrane leading to the release of the complex into the soluble 
fraction of the cells. This might result in relocation of the AKAP79/150-PKA 
complex to a microdomain where the cAMP concentration is below the 
activation threshold of the anchored PKA, thereby promoting the re-
association of the holoenzyme and rapidly terminate the response (Dell'Acqua 
et al., 1998). 
Finally, recruitment of PKA type I rather then PKA type II to a specific 
compartmentalised AKAP complex could increase the sensitivity to cAMP of 
the particular physiological process regulated by the signal complex (Jarnaess 
et al., 2008) (Di Benedetto et al., 2008).  
Taken together all this observation it is clear that these multivalent 
signal transduction complexes nucleated by AKAPs represent an efficient way 
to regulate forward and backward steps of a given signalling processes; 
moreover AKAPs exert a tight control on cAMP levels, via anchored PDEs, 
thereby modulating PKA activity.  
1.5.2 PDEs and the biochemical compartmentalisation 
of cAMP  
cAMP is generally considered to be freely diffusible in the cytosol, with a 
diffusion constant of 220m2/sec (Bacskai et al., 1993). This notion is in 
contrast with the concept of compartmentalisation of the AKAP/PKA/PDE 
complex as free diffusion of cAMP would result in activation of all PKA subsets, 
whatever their specific localisation within the cell. In fact, an increasing body 
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of evidence indicates that diffusion of cAMP can be constrained to prevent the 
inappropriate activation of effectors. 
Four different hypotheses on restriction of cAMP diffusion have been 
formulated. 
First of all the presence of a “physical barrier” has been hypothesised by 
Rich et al., based on the evidence that the endoplasmic reticulum comes into 
close contact with the plasma membrane (Finch and Augustine, 1998) (Takechi 
et al., 1998) (Patterson et al., 1999) (Ma et al., 2000). These authors suggested 
that the interactions between the ER and the caveole with the cytosolic face of 
plasma membrane may limit cAMP diffusion from the site of synthesis at the 
plasma membrane to the cytosolic effectors. PKA localised in the sub-plasma 
membrane microdomain would be rapidly activated after stimulation of AC, 
whereas cytosolic pools of PKA would be activated more slowly by persistent 
stimulation of PKA. Without such restrictions on diffusion cAMP would spread 
throughout the cell (Rich et al., 2000). 
An alternative hypothesis for restricted diffusion of cAMP was proposed 
by Hall & Hell. These authors hypothesised that AC and PKA might be arranged 
in such a way that cAMP is “channelled” from the AC to PKA with a mechanism 
similar to that described for Salmonella typhimurium in which indole is 
channelled from its point of production to the site of tryptophan synthesis 
along the different subunits of tryptophan synthase 2β2 multi-enzyme 
complex (Hyde et al., 1988). Such ‘channelling’ mechanism would dramatically 
increase the likelihood that newly synthesised cAMP binds to PKA (Hall and 
Hell, 2001). 
Although the above mechanisms may be involved, at least in some 
circumstances, an increasing body of direct and indirect evidence indicates 
that the major contributors in limiting diffusion and in shaping cAMP pools are 
PDEs (Willoughby and Cooper, 2006) (Rochais et al., 2006) (Barnes et al., 
2005) (Rich et al., 2001a) (Abrahamsen et al., 2004) (Perry et al., 2002) 
(Jurevicius et al., 2003). PDEs, being dynamically recruited to defined 
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subcellular sites via protein-protein interaction and binding to AKAPs, shape 
asymmetric gradients of cAMP and generate local clouds of the cyclic 
nucleotides. Zaccolo & Pozzan, using fluorescence energy transfer-based 
imaging demonstrated that, in cardiomyocytes, stimulation with 
catecholamines causes a local increase of cAMP, providing the first direct 
visualisation of microdomains of cAMP (Zaccolo and Pozzan, 2002). When 
PDEs were inhibited with 3-isobutyl-1-methylxanthine (IBMX), cAMP was 
found to be free to diffuse and accumulate homogeneously in the cytosol with 
consequent loss of specificity in the downstream response (Zaccolo and 
Pozzan, 2002). 
A similar observation has been made in airway epithelia cells by patch-
clamp recording of chloride currents through the cystic fibrosis trans-
membrane conductance regulator (CFTR) channels. In these cells PKA is 
anchored at the apical membrane and is coupled to adenosine A2B receptors 
and AC. In addition, PDE4 has been shown to be localised in this region. 
Occupancy of A2R leads to the activation of PKA and the consequent opening of 
the CFTR chloride channel. However luminal A2B receptor activation does not 
increase total cellular cAMP levels and cAMP is confined to the apical 
microdomain that includes CFTR. Only when PDE4 is pharmacologically 
inhibited the confinement of cAMP signalling is abolished, suggesting that PDEs 
are critically involved in modulating the spread of cAMP signalling at the apical 
membrane of airway epithelia (Barnes et al., 2005). According to this model, 
PDEs create an “enzymatic barrier” to limit cAMP diffusion. Thus, when agonist 
binds to the receptor, cAMP is produced and PDEs are recruited to prevent its 
overflow and the phosphorylation of non specific targets. Because PDEs are 
positively regulated by PKA this spatial diffusion barrier is sensitive and 
proportional to the levels of local cAMP and the degree of receptor stimulation 
(Barnes et al., 2005). 
Additionally, it has been shown that PDE4D5 can be dynamically 
engaged by -arrestin. -arrestin is a cytosolic protein responsible for the 
desensitisation of G-protein coupled receptors, including 2-adrenergic 
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receptor (Luttrell and Lefkowitz, 2002). When 2-adrenergic receptor is 
activated -arrestin is dynamically recruited to the plasma membrane to 
prevent receptor coupling to Gs and promote the switching to Gi, thereby 
inhibiting further adenylyl cyclase activation and cAMP production (Luttrell 
and Lefkowitz, 2002). Interestingly, the gathering of PDE4D5 to the plasma 
membrane specifically decreases the sub-plasma membrane cAMP 
concentration in an agonist-dependent manner inhibiting the subsequent PKA-
mediated phosphorylation of the -adrenoreceptor and rapidly terminating the 
PKA signal cascade (Perry et al., 2002) (Baillie et al., 2003).  
In cardiomyocytes the compartmentalisation of each PDEs family, rather 
than the total enzyme expression level, prevails in determining their effects on 
intracellular cAMP concentrations (Mongillo et al., 2004). For example it has 
been demonstrated that the role of PDE2, which represent only 1% of the total 
amount of PDEs in cardiac cells, is crucial for the control of the cAMP response 
to -AR stimulation, as demonstrated by the observation that, in the presence 
of agonist, PDE2 inhibition releases a very large amount of second messenger 
(Mongillo et al., 2005). 
Based on the above data, a physical or an enzymatic barrier appears to 
be an adequate model to explain cAMP signalling in cardiomyocytes upon -AR 
activation, nevertheless an enzymatic barrier implies the generation of a 
gradient of cAMP with a higher concentration of the second messenger at the 
plasma membrane as compared with the bulk cytosol. This model, therefore, 
fails to explain how cAMP selectively activates a subset of PKA anchored deep 
inside the cells, far from the site of synthesis, without affecting pools of PKA 
which are closer to the AC at the plasma membrane. Our previous work in the 
model cell line HEK293 showed that the nucleus may accumulate higher cAMP 
levels as compared with the bulk cytosol, demonstrating the existence of 
multiple, contiguous domains inside the cell each with different cAMP 
concentrations, irrespective of their distance from the cAMP synthesis site. In 
those studies we demonstrated that the definition of the boundaries of these 
multiple microdomains of cAMP relies on the activity of different PDE4 
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isoforms that are differently localised within the three dimensional matrix of 
the cell. Thus, at least in the HEK293 cells, localised PDE4s appear to be the 
crucial mechanism to maintain cAMP compartmentalisation. According to the 
model we proposed, when cAMP is generated it is able to quickly diffuse into 
all cellular compartments but it can only accumulate in those compartments 
where PDE activity is low. In other compartments, in which localised PDEs act 
as a “sink” to degrade cAMP, the second messenger level is kept low to protect 
effectors from inappropriate phosphorylation, thus ensuring the specificity of 
the signal (Terrin et al., 2006). A computational model of the biochemical 
network in the HEK293 cells showed that local microdomains of cAMP do not 
require impeded diffusion, thus further supporting the notion that barriers are 
not required for compartmentalisation (Figure 1-11) (Oliveira et al., 2010). 
 
AKAPsInactive PKA
Different subsets of PDEsActive PKA
 
Figure 1-11 Schematic representation of intracellular cAMP compartmentalisation. 
cAMP is locally degraded by different compartmentalised subsets of PDEs that can act 
either as an enzymatic barrier or as a sink to prevent cAMP free diffusion and to 
generate spatially restricted pools of cAMP. In this way PDEs prevent the 
inappropriate activation of PKA. Activation of a specific GPCR generates a specific pool 
of cAMP whereas the activation of a different GPCR leads to the generation of a 
different pool of cAMP. 
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1.6 Overview on cAMP detection mechanism 
The discovery of cAMP and the consequent delineation of the “second 
messenger concept” (see section 1.1) (Robison et al., 1968) has been one of the 
major advances in the cell biology field in the past 50 years. First studies of 
cAMP pathway immediately revealed that cAMP not only elicits direct 
response, like enzyme activation, but also it controls farther physiological 
effects, such as cardiac contractility or gene transcription. We now appreciate 
that this complex mechanism of transduction of a hormonal dependent 
perturbation of the plasma membrane into a spatially and temporally specific 
response via a single second messenger relies on a precise 
compartmentalisation of all components of the pathway involved. However, 
the paradigm of compartmentalised cAMP signalling has become clear only 
recently and a pivotal role in its definition has been played by the development 
of new tools to locally monitor cAMP fluctuations in intact living cells. 
1.6.1 Classical approach 
For several years the available techniques to monitor cAMP levels were 
based on the indirect detection using either biochemical or cytochemical 
methods. The most widely employed method has been a radio-immuno assay 
(RIA), which measures the concentration of cAMP in cells lysates by using a 
specific anti-cAMP antibody (Steiner et al., 1969). 
RIA is based on the competition between intracellular cAMP and an 
exogenous radio labelled cAMP pool, used as a tracer, for the binding to the 
anti-cAMP antibody (Steiner et al., 1969). Due to its sensitivity and reliability, 
this technique, developed in 1969, is currently one of the most used to detect 
total cAMP concentration. 
Recently, new antibody-based detection methods for cAMP have been 
introduced. Like RIA, these approaches exploit a cAMP tracer as a competitor 
for endogenous cAMP and the read-out is a concentration dependent signal 
decrease. Among these more recent methods the most common are: 
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Fluorescent polarisation assay (FP) (Kariv et al., 1999), Homogeneous time 
resolved fluorescence (HTRF) (Prystay et al., 2001) and AlphaScreen 
(amplified luminescence proximity assay) (Gabriel et al., 2003). For all these 
methods the improvement compared to RIA consists in the replacement of the 
radio label with the less toxic fluorescein- and biotin-label for FP and HTRF, 
respectively. 
Additionally a novel bioluminescent-based assay has been developed 
three years ago. This technique is based on a luciferase/luciferin reaction upon 
pre-incubation of cells lysates with an exogenous PKA. Increase in cAMP 
concentration elicits the luciferin/luciferase reaction with consumption of ATP 
by cAMP-activated PKA and the consequent emission of light (Kumar et al., 
2007).  
All these methods are high throughput, simple and relatively 
inexpensive assays; moreover they do not require any sophisticated optical 
device or other specialised equipment. However, the main limitation of these 
methods is that they all involve a step in which cells are broken up to release 
endogenous cAMP. As a consequence any spatial information is completely 
lost. In addition such type of accumulation assays can only measure cAMP 
concentration at the steady state or within a time course of minutes. This 
implies that any cAMP fluctuation within a time scale of seconds will not be 
appreciated. Finally, these approaches provide information about cAMP 
dynamics that is averaged over the cell population whereas information at the 
single cell level may be more physiologically relevant. Clearly these methods 
are not suited to study the spatial and temporal aspects of cAMP signalling and 
it was only after the development of a toolkit for real-time detection of cAMP in 
single living cells that this analysis has become possible (Berrera et al., 2008).  
1.6.2  CNG-based sensors 
One approach for real-time detection of cAMP and cGMP exploits the 
over-expression of an olfactory CNG channel (Rich et al., 2000). Increase in 
cyclic nucleotides levels leads to the activation of the channels. Thus cAMP and 
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cGMP changes correlated with changes in Ca2+ influx that can be monitor by 
imaging of a fluorescent Ca2+ indicator (e.g. fura-2) or by patch clamp analysis 
of Ca2+ currents. Although the use of the wild type channel allows to monitor 
cyclic nucleotides dynamics in intact living cells, it presents several limitations: 
1) the affinity of the CNG channels is higher for cGMP than cAMP (Rich et al., 
2001b); 2) channels can be opened by nitric oxide (Broillet, 2000) and 3) they 
are negatively regulated by Ca2+-calmodulin binding via a feedback loop 
mechanism (Liu et al., 1994). To overcome this limitations, a mutated and 
deleted version of the CNG channel, 61-90/C460W/E583M, was generated 
(Rich et al., 2001a). The mutant channel is highly sensitive to cAMP and 
insensitive to calcium regulation, however it still presents some limitations. 
First, it can monitor cAMP dynamics only at the plasma membrane where it is 
localised and second, the increased calcium influx can modulate the activity of 
ACs and calcium sensitive PDEs, thereby potentially leading to a non 
physiological cAMP change. 
1.6.3  GFP and FRET: seeing is believing 
The discovery and cloning of the green fluorescent protein (GFP) from 
the bioluminescent jellyfish Aequorea Victoria in 1992 (Shimomura et al., 
1962) (Chalfie et al., 1994) (Tsien, 1992) opened a new era for the direct 
visualisation of biological processes. GFP became a tool for the in vivo study of 
proteins interactions and imaging of the flow of signalling transduction 
pathway. The combination of GFP with fluorescence resonance energy transfer 
further increased the relevance of GFP in biology. Today GFP-FRET based 
biosensors allow the quantitative study of protein-protein interactions, of 
protein activity and of small molecule signals, all with high spatial and 
temporal resolution. 
1.6.3.1 F ster resonance energy transfer 
Fluorescence resonance energy transfer (FRET), also called Fo ster 
resonance energy transfer, was first described in 1940 by Theodor Fo ster 
(Förster, 1948). 
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FRET is an electro-dynamic phenomenon that occurs between a donor 
(D) molecule in the excited state and an acceptor (A) molecule in the ground 
state. The energy transfer between D and A does not involve emission of 
photons therefore it is defined as energy of resonance. 
For FRET to occur, the following requirements must be fulfilled: 
1) the emission spectrum of the donor must show a substantial overlap 
with the absorption spectrum of the acceptor. 
2) a long range dipole-dipole interaction between the donor and the 
acceptor must be established. 
3) the distance between the donor and the acceptor must be in the 
Armstrong range. 
In addition, FRET depends on the Quantum yield of the donor (QD). 
The distance at which efficiency of FRET is 50% is called Fo ster distance 
and it is typically between 2  and 6  A . The Fo ster distance is a constant that 
depends on the overlap integral of the emission spectrum of the donor and the 
absorption spectrum of the acceptor, as well as on fluorophores orientation as 
expressed by the following function: 
 
 
where QD is the quantum yield of the donor in absence of acceptor; n is 
the refractive index of the medium and it is typically assumed to be 1.4 for bio-
molecules in aqueous solution; k2 is the factor describing the orientation in 
space of the fluorophores dipoles and usually is assumed to be equal to 2/3 for 
randomised rotation of donor and acceptor before energy transfer; J is the 
overlap integral of the spectra and it is given by: 
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where  is the wavelength (nm); FD () is the normalised fluorescence of 
the donor in the wavelength range of  to + (it is dimensionless); A () is 
the extinct coefficient of the acceptor at  and it is typically measured in M-1 
cm-1. 
Knowing the distance between donor and acceptor allows to choose the 
pair of fluorophores with maximum FRET efficiency. Vice versa, from the 
efficiency of FRET, theoretically it is possible to calculate the distance between 
the two fluorophores thereby the distance between the interacting proteins. 
The rate of energy transfer (kT(r)) from a donor to an acceptor is given 
by:  
 
 
Where D is the lifetime of the donor in absence of the acceptor; R0 is the 
Fo ster distance and r is the distance between donor and acceptor. When the 
distance donor to acceptor equals the Fo ster distance the rate of energy 
transfer equals the donor lifetime (D) and the transfer efficiency is 50%. If the 
energy transfer is faster than the decay rate, the energy transfer will be 
efficient. On the contrary if the energy transfer is slower than the decay rate 
the energy transfer will be inefficient.  
The efficiency of the energy transfer is the ratio between the photons 
adsorbed by the donor and the energy transferred to the acceptor and it is 
calculated as: 
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That can be easily rearranged to: 
 
 
It is clear that the efficiency of FRET strongly depends on the distance 
donor to acceptor accordingly to this diagram: 
 
r =R0
E=0.50
r =1/2 R0
E=0.985
r =2 R0
E=0.015
 
Figure 1-12 Schematic representation of the dependence of the energy transfer 
efficiency (E) on distance. R0 is the F ster distance. 
The efficiency of FRET increases to 100% as the donor to acceptor 
distance decrease below the R0. Conversely FRET efficiency tends to 0% if r 
doubles the R0 (Figure 1-12). 
A final factor to consider in the analysis of the energy transfer is the 
orientation of the donor and acceptor’s dipoles: k2. It is calculated as: 
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Where T is the angle between the emission transition dipole of the 
donor and the transition absorption dipole of the acceptor; D and A are the 
angles between these dipole and the vectors joining the donor and the 
acceptor. Depending on the orientation of the fluorophores this factor can 
range between 0 and 4. For head to tail parallel transition dipoles K2=4, for 
parallel dipoles K2=1 and for perpendicular dipoles K2=0, which would result is 
errors to calculate the distance between the fluorophores (Dale et al., 1979). 
1.6.3.2  FRET-based cAMP indicators 
The development of FRET-based indicators provides a toolkit to monitor 
the cAMP/PKA signal transduction pathway by allowing direct visualisation of 
localised cAMP fluctuations in intact living cell with high resolution in space 
and in time. 
Generally, a cAMP FRET-based indicator requires two essential 
components: 
1) a sensor, which may consist of two interacting protein domains or a 
protein domain undergoing a conformational change upon cAMP binding. 
2) a donor and an acceptor chromophore fused to the sensor. 
Changes in conformation or in the distance of interacting protein 
partners results in a change in the distance or in the orientation of the two 
fluorophores, affecting the efficiency of energy transfer. In turn, variation of 
energy transfer correlates with changes in the ligand concentration. 
1.6.3.2.1 PKA-based sensor 
The first FRET-based sensor that allowed the real-time imaging of cAMP 
in living cells was FlCRhR (Adams et al., 1991). This indicator was based in the 
microinjection of the fluorescein- and rhodamin-labeled PKA subunits. In the 
presence of low cAMP concentration in a resting cell, FRET occurs between the 
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two subunits of the holoenzyme, while a rise in cAMP concentration correlates 
with a decrease in FRET due to the dissociation of the PKA subunits. 
Unfortunately this sensor did not find so many applications due to some 
technical limitations such as: 1) the requirement to microinject a large amount 
of protein complex (M) (procedure not applicable to all cells type); 2) the 
aggregation and precipitation of the labelled subunits; and 3) the non-specific 
interaction of the labelled subunits with cellular structures (Goaillard et al., 
2001). 
The PKA-GFP sensor overcame these limitations (Zaccolo et al., 2000) 
(Figure 1-13). In this sensor the regulatory (RII) and the catalytic subunit 
(C) of PKA are fused to the cyan and the yellow mutants of GFP, respectively 
(Figure 1-13). Being totally genetically encoded, this sensor is introduced into 
the cells by transfection or infection of the cDNAs encoding for the two 
chimerical subunits (Warrier et al., 2005), extending the application to most 
cell types.  
 
CFPD/D IS DomainA DomainB
RII-CFP
Catalytic subunit YFP
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B)
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PKA-GFP FRET-based sensor
cAMP
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480nm
FRET
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P P
480nm
430nm
P
 
Figure 1-13 Schematic representation of PKA-GFP FRET based sensor for cAMP and its 
mechanism of activation. 
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Moreover, being the regulatory subunit of the probe the isoform type 
II, the over-expressed RII-CFP subunit binds, via its D/D domain, to 
endogenous AKAPs present in the cell, allowing detection of cAMP fluctuations 
in specific compartments within the cell. Over-expression of the PKA-GFP 
sensor in cardiomyocytes provides an example of such localisation (Figure 
1-14). 
 
 
Figure 1-14 Subcellular localisation of PKA-GFP sensor in neonatal rat ventricular 
cardiomyocytes. Bar 10µm. 
Different versions of PKA-based sensors have also been developed. In 
order to improve the dynamic range of the PKA-GFP probe a polypeptide linker 
of 20 amino acids was introduced between the R subunit and the fluorophore 
generating a cAMP indicator with doubled FRET efficiency (RII-L20-CFP) 
(Lissandron et al., 2005). In another case, the R230K mutation was introduced 
in the R subunit, thus generating a probe with a two orders of magnitude lower 
affinity for cAMP (Mongillo et al., 2004). Employment of these sensors allowed 
for the first time direct visualisation of cAMP microdomain in living 
cardiomyocytes (Zaccolo and Pozzan, 2002), and clarify the role of different 
PDEs subsets to prevent unrestrained cAMP diffusion (Mongillo et al., 2004) 
(Mongillo et al., 2006). However, the PKA-GFP sensors show some limitations: 
1) co-transfection of two different subunits does not permit to have a control 
on the stoichiometry of the R and C subunits inside the cell. This can lead to 
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experimental artefacts due to the preponderance of a fluorophore over the 
other one; 2) cAMP-dependent dissociation of R and C subunits occurs through 
a complex cooperative mechanism (Taylor et al., 2005) and the kinetics of 
FRET change may be slower than the effective kinetics of cAMP changes; 3) the 
C subunit is catalytically active and this can result in an alteration of cAMP 
dynamics as a consequence of over-activation of the cAMP/PKA pathway. 
These reasons, together with the discovery of Epac proteins (de Rooij et al., 
1998), contributed to the development of unimolecular FRET based sensors for 
cAMP. 
1.6.3.2.2 Epac-based sensors 
Upon cAMP activation Epac undergoes a conformational change and this 
mechanism of activation has been exploited to develop FRET-based sensors 
(Bos et al., 2003) (Ponsioen et al., 2004). 
In 2004, Nikolaev and co-workers developed simple sensors based on 
the fusion of individual cAMP binding domains of PKA and Epac to cyan and 
yellow GFP variants. In this way they generated sensors lacking the catalytic 
activity and the cooperative binding typical of PKA and offering faster speed of 
activation and capability of measuring cAMP in the physiological range with 
high temporal resolution (Nikolaev et al., 2004).  
Simultaneously, two other groups took advantage of the cAMP binding 
property of Epac. Using a different approach than Nikolaev, both groups 
sandwiched the full length Epac1 between the cyan fluorescent protein (CFP) 
and the yellow florescent protein (YFP) generating the ICUE sensor (DiPilato et 
al., 2004) and the CFP-Epac-YFP sensor (Ponsioen et al., 2004). Despite the 
improvement compared to the PKA-based sensors, (Adams et al., 1991) 
(Zaccolo et al., 2000) (Zaccolo and Pozzan, 2000) the CFP-Epac-YFP probe 
showed localisation to the cytosol and to membranes, in particular to the 
nuclear envelope and to perinuclear compartments. To generate a soluble 
version of the probe the DEP domain was deleted (1-148 aa). Moreover, in 
order to render the indicator catalytically dead, other mutations were 
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introduced (T781A, F782A) leading to the generation of CFP-Epac (DEP-CD)-
YFP, also called H30 (Ponsioen et al., 2004) (Terrin et al., 2006). Compared to 
the PKA sensor this probe shows faster activation kinetics, an extended 
dynamic range but a lower affinity for cAMP. The lower affinity results on one 
hand in a lower buffering of cytosolic cAMP but on the other hand represents a 
limitation of application of the probe to systems that show larger changes in 
cAMP concentration (Ponsioen et al., 2004). 
1.6.3.2.3 Compartment specific sensors 
The well established concept that cAMP concentration can fluctuate 
rapidly and non-uniformly within the cell led to the generation of a set of FRET 
based sensors for cAMP that can be targeted to different compartments within 
the cell.  
The first targetable sensors for cAMP were generated by fusing a specific 
targeting sequence to the N- or the C-terminus of ICUE. Thus ICUE was targeted 
to the plasma membrane, mitochondria and the nucleus. The simultaneous 
transfection of these probes revealed, for the first time, different spatio-
temporal cAMP dynamics at the cytosol and at the plasma membrane in 
response to the activation of -adrenoreceptors or prostanoid receptors 
(DiPilato et al., 2004). 
Two years later, in order to investigate cAMP compartmentalisation and 
to assess the role of PDEs in shaping cAMP microdomains in HEK293 cells, we 
generated the plasma membrane targeted PKA-GFP (mpPKA-GFP). To obtain 
this sensor a myristoylation/palmitoylation signal from the Lyn kinase was 
fused to the N terminus of the R subunit. Cells co-transfected with mpR-CFP 
and C-YFP (mpPKA-GFP) show a localisation of the R and C subunit to the 
plasma membrane (Figure 1-15) (Terrin et al., 2006). 
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Figure 1-15 Subcellular localisation of mpPKA-GFP sensor in HEK293 cells. Bar 10µm. 
When cAMP binds to the mpPKA-GFP sensor it causes the probe to 
dissociate and to release of the catalytic subunit away from the regulatory 
subunit partner. This may result in over-estimation of the FRET response at 
the plasma membrane. To avoid this possibility, we generated an mpH30 
sensor in which the mp sequence was fused to the N-terminus of H30. A 
further modification was the fusion of the nuclear localisation sequence (nls) 
to C-terminus of the H30 which targets the sensor to the nucleus (Terrin et al., 
2006). All these targeted sensors allowed us to study cAMP dynamics within 
discrete compartments of the HEK293 cell (membrane, cytosol and nucleus) in 
response to prostaglandin 1 stimulation, thus describing a new mechanism in 
which PDEs act as a “sink” to shape contiguous pools of cAMP with different 
concentrations, independently from their distance from the site of synthesis 
(Terrin et al., 2006). 
In cardiomyocytes, different isoforms of PKA show different subcellular 
localisation. In particular, PKA type I (containing the isoform RI) is 
predominantly localised in the cytosol whereas the PKA type II (containing the 
isoform RII) is mainly associated with the particulate fraction. In order to 
clarify if these two different isoforms of PKA can be activated by different pools 
of cAMP in response to the activation of specific receptors, we generated two 
FRET based reporters targeted to those intracellular sites where endogenous 
PKA type I and PKA type II isoforms normally localise. To achieve this we fused 
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the D/D domain of RI or RII to the N terminus of Epac1 (Nikolaev et al., 2004), 
to generate the sensor RI_epac and RII_epac, respectively (Di Benedetto et al., 
2008) (Figure 1-16).  
 
 
Figure 1-16 Subcellular localisation of RI_epac and RII_epac sensors in neonatal rat 
ventricular cardiomyocytes. Bars 10µm. 
The sensors show equal sensitivity to cAMP but display a different 
pattern distribution, with RI_epac localisation overlaying with the Z and M 
sarcomeric line and RII_epac localising to the M line. This different localisation 
of the probes is due to the binding to specific endogenous AKAPs, as 
demonstrated by the re-distribution of the sensor to the cytosol when the 
sensor was co-expressed with AKAP/PKA disruptor peptides (Di Benedetto et 
al., 2008). The different regulation of cAMP levels in the two compartments 
also points to a different association of the two PKA isoforms with specific 
PDEs subsets. Moreover, we showed that stimulation of different GPCR leads to 
the activation of specific PKA isoforms and, in turn, to specific phosphorylation 
of downstream targets (Di Benedetto et al., 2008). 
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1.7 A PKA signalling domain localised to the 
centrosome 
1.7.1 Centrosome structure  
The Centrosome of animal cells is a small organelle of ~ 1-2 m in 
diameter usually located at the centre of the cell. It is composed of two barrel-
shaped centrioles, orthogonally arranged and linked by a pericentriolar 
material (PCM), from which the microtubules are nucleated. For this reason it 
is considered as the major microtubule organising centre of the cell (MTOC).  
The PCM is a proteinaceous material containing two subsets of protein 
complexes defined as matrix and non-matrix proteins and responsible for 
nucleation, anchoring and stabilisation of the microtubule network. The matrix 
subset is composed by proteins that link together the proximal minus end of 
the centrioles pair. The most abundant protein of this group is pericentrin, a 
protein that has been shown to be involved in all the centrosomal functions 
(Bornens, 2002); however AKAP450 and ninein are also included in this group 
(Figure 1-17). These proteins are specifically localised to the centrosome but 
can also be found in the cytosol, although the size of the cytosolic pool is small. 
The second subset of the PMC proteins, the non-matrix proteins, is composed 
by proteins such as -tubulin and centrin. These two proteins are classical 
markers for the centrosome, where they a have specific localisation. However 
80-90% of the total amount of these proteins is not centrosome-associated. 
The role of -tubulin and centrine in the centrosome is to interact, in a poly-
glutamylation dependent manner, with the walls of the two centrioles to create 
a connective bridge between them (Figure 1-17) (Bornens, 2002).  
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Figure 1-17 Schematic representation of the centrosome and centrosomal proteins 
distribution according to their proximal-distal polarity. Adapted from (Bornens, 
2002). 
In order to stabilise the interactions and fully assemble the PMC, other 
proteins cross link these two protein subsets (Bornens, 2002). 
Three AKAPs have been identified at the centrosome: the human 
hAKAP220 (Reinton et al., 2000), pericentrin (Diviani et al., 2000) and 
AKAP450 (Witczak et al., 1999) (Schmidt et al., 1999) (Takahashi et al., 1999). 
1.7.1.1  hAKAP220 
Human AKAP220 (hAKAP220) is the homologous of the AKAP220 
previously isolated from rat testis extracts and localised to peroxisomes 
(Lester et al., 1996). hAKAP220, isolated from human testis and spermatocytes, 
shows high level of similarity with the C-terminal of the AKAP220 of rat 
although it contains a 727 N-terminal portion that is not present in the rat 
sequence. Immunofluorescence assays with specific antibodies revealed that 
hAKAP220 localises in the cytoplasm of premeiotic spermatocytes and to the 
centrosome of developing post-meiotic germ cells, elongating spermatocytes 
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and mature sperm. In addition, hAKAP220 seems to be a dual AKAP since it co-
precipitates with both type I and type II regulatory subunits of PKA in human 
testis lysates (Reinton et al., 2000). Binding of PKA to the centrosomal 
hAKAP220 may have a role in regulating spindle formation and microtubule 
organisation during spermatogenesis and in post-meiotic germ cells since 
microtubule stability in somatic cells is influenced by PKA (Lane and Kalderon, 
1994); (Gradin et al., 1998).  
1.7.1.2  Pericentrin 
Pericentrin is a coil-coiled protein, an integral component of the PMC 
and it is exclusively present at the centrosome (Doxsey et al., 1994). At the 
centrosome pericentrin interacts with -tubulin, centrin, dynein and other 
proteins of the PMC to assure the proper centrosomal architecture and 
microtubules nucleation during mitosis and meiosis (Doxsey et al., 1994) 
(Bornens, 2002) (Dictenberg et al., 1998) (Purohit et al., 1999). The binding of 
pericentrin to -tubulin is required for the correct organisation of microtubule 
network whereas pericentrin interaction with the motor protein dynein is 
essential for the transport of -tubulin containing complexes along the 
microtubules from the cytosol to the centrosome (Purohit et al., 1999) (Young 
et al., 2000) (Doxsey et al., 1994). 
Despite this critical role in centrosome organisation, co-
immunoprecipitation of percentrin with catalytic activity of PKA in HEK293 
cells showed that pericentrin is also an AKAP. However the interaction 
between the RII subunit of PKA and pericentrin occurs through an 
unconventional region of 100 amino acid residues characterised by leucine-
repeat sequences (see 1.5.1 section). Interestingly, this 100 amino acid 
polypeptide does not show the typical amphipathic helix motif presents in all 
the others AKAPs (Diviani et al., 2000). 
The role of centrosomal pericentrin-PKA complex seems to be 
correlated to the PKA-dependent regulation of dynein-dynactin functions. In 
fact, it has been shown that impairment of dynein functions results in spindle 
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defects, such as spindle fragmentation and disorganisation (Purohit et al., 
1999) (Diviani and Scott, 2001). 
1.7.1.3  AKAP450/350/CG-NAP  
The localisation of PKA type II  and  to the Golgi/centrosome area was 
demonstrated more than 20 years ago (De Camilli et al., 1986) (Nigg et al., 
1985) (Rios et al., 1992) (Keryer et al., 1993). First of all a family of high 
molecular weight proteins where identified as components of the 
pericentriolar matrix of human lymphoblastic KE37 cells (Gosti-Testu et al., 
1986). A few years later the same research groups, using cell fractioning, 
immunoprecipitation and immunoblotting assays, showed that both the RII 
isoforms  and  localise to the centrosome of human lymphoblasts. Moreover, 
RII overlay techniques, revealed that the high affinity binding of RII subunit 
with the centrosome is due to the interaction with a 350 kDa protein which 
could be phosphorylated by the catalytic subunit of the PKA and that was 
detectable only in centrosome extracts (Rios et al., 1992) (Keryer et al., 1993). 
This protein was named AKAP350, based on its molecular weight and the 
ability to co-precipitate with PKA catalytic activity. Subsequent analysis 
demonstrated that the previously identified high molecular weight proteins in 
the PMC of human lymphoblastic cells (Gosti-Testu et al., 1986) were splice 
variants of the larger AKAP350 protein (Keryer et al., 1993) (Schmidt et al., 
1999). 
In 1998, two different groups cloned and characterised a cDNA of 12.1 
kb (11.7 kb of open reading frame) and encoding a protein of 453 kDA capable 
of tethering PKA to the centrosome (DDBJ/EMBL/GenBank accession 
N°AJ131693) (Witczak et al., 1999) (Schmidt et al., 1999). One year later 
Takahashi and co-workers, in a yeast two hybrid screen using the N-terminal 
of PKA as bait, identified a novel coiled-coil protein of 450kDa as a PKN 
interacting protein. They also showed that this protein was localised to the 
centrosome throughout the cell cycle and to the Golgi in interphase cells so 
that they named it CG-NAP (centrosome and Golgi localised PKN-associated 
protein) (Takahashi et al., 1999). We now know that AKAP350, AKAP450 or 
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CG-NAP represent a family of differently spliced proteins encoded by a single 
gene sequence localised on the human chromosome 7q21 (Schmidt et al., 
1999). From now on I will refer to it as AKAP450 since it is closest to its 
molecular weight. 
At least two splice isoforms of AKAP450 are known: AKAP120, a widely 
expressed AKAP in rabbit gastric parietal cells (Dransfield et al., 1997) and 
Yotiao, an AKAP involved in anchoring to the cytoskeleton of NMDA receptor in 
post-synaptic densities of rat neurons (Lin et al., 1998). Despite splice variants 
may be differentially distributed among tissues and cells types, AKAP450 
contains a coiled coil domain typical of proteins involved in the framework of 
the perinuclear matrix and was mainly identified anchored to the centrosome 
(Schmidt et al., 1999) (Takahashi et al., 1999) (Witczak et al., 1999). 
The C-terminal domain of AKAP450 accounts for the binding to the 
centrosome (Gillingham and Munro, 2000). This 90-amino-acid-long domain 
shares a high degree of homology with the centrosomal targeting domain of 
pericentrin and for this reason it has been called PACT domain (pericentrin 
AKAP450 centrosomal targeting). Over-expression of the AKAP450-PACT 
domain in COS cells results in the displacement of pericentrin, indicating 
competition for a shared binding site (Gillingham and Munro, 2000). However 
Keryer and co-workers provided another evidence showing that over-
expression of the AKAP450-PACT domain in HeLa cells displaces AKAP450 but 
not pericentrin, and vice versa, indicating specificity in the targeting of both 
AKAPs (Keryer et al., 2003b). 
It is not clear if AKAP450 can bind to the Golgi apparatus. According to 
Gillingham and colleagues, AKAP450 can only localise to the centrosome and 
any Golgi apparatus staining is due to the cross reaction of the antibody used 
with one of the many coiled-coil proteins localised to these organelles 
(Gillingham and Munro, 2000). Conversely, Shanks and colleagues reported the 
presence of a Golgi targeting sequence of 48 amino acids adjacent to the PACT 
domain (Shanks et al., 2002b). 
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Further studies showed that in addition to two PKA binding sites, 
AKAP450 interacts with protein kinase N (PKN), protein phosphatases 1 (PP1) 
and protein phosphatases 2A (PP2A) (Takahashi et al., 1999), 
phosphodiesterases 4D3 (PDE4D3) (Tasken et al., 2001), protein kinases C 
epsilon (PKC) (Takahashi et al., 2000) and the isoform delta of casein kinase I 
(CKI). 
Moreover it is worth to consider that in lysates from COS1 cells 
AKAP450 co-immunoprecipitated with the catalytic dead PDE4D3 and 
PDE4C2, suggesting a possible interaction of PDE4C2 with this specific AKAP in 
this cell type (McCahill et al., 2005). 
PKN is a serine/threonine kinase that associates with and 
phosphorylates intermediate filament proteins (Mukai, 2003) (Mukai and Ono, 
1998). Thus targeting of PKN to AKAP450 may be important for cytoskeleton 
reorganisation-related events. (Mukai and Ono, 1998) (Mukai, 2003). 
Interaction between AKAP450 and the immature non phosphorylated 
form of PKC seems to be required either for the phosphorylation-dependent 
maturation of PKC or for indirectly protect unstable immature PKC species 
(Takahashi et al., 2000). Moreover, it has recently been shown a role of PKC 
for the correct abscission during cytokinesis (Saurin et al., 2008). The correct 
completion of cytokinesis seems to require the correct assembling of PKC-14-
3-3 complex during the late stages of mitosis. Absence or inhibition of this 
functional complex leads to failure of cytokinesis (Saurin et al., 2008).  
It has been suggested that the interaction of AKAP450 with PDE4D3 may 
account for a feedback loop mechanism of negative control of the cAMP/PKA 
pathway in that specific compartment (Tasken et al., 2001). It has indeed 
already been shown in other PKA signalling domains, that PDE4D3 allows for 
tight control of PKA activity by local degradation of cAMP (Dodge et al., 2001).  
Finally CKI has been shown to regulate cell cycle progression and its 
specific inhibition causes a mitotic arrest (Sillibourne et al., 2002). Recent 
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studies strongly suggest that CKI and PKA physiologically interact within the 
same compartment. Moreover, PKA mediated phosphorylation of CKI inhibits 
CKI activity and interferes with normal development of Xenopus embryos 
(Giamas et al., 2007). 
The same author identified a region (1382-1515 amino acids) in 
AKAP450, showing 47% similarity with the centrosomal protein pericentrin 
(Shanks et al., 2002a), which is responsible for targeting of the chloride 
intracellular channel (CLIC) family (Shanks et al., 2002a). Although the 
function of this family of proteins is poorly understood it is well know that all 
the CLIC isoforms contain a PKA phosphorylation site, hence their anchoring to 
AKAP450 could regulate their functions and cell distribution (Shanks et al., 
2002a).  
All these observations suggest that AKAP450 provides a point for 
integration of distinct signalling pathways that are involved with the cell cycle 
progression and/or cell proliferation. 
1.7.2 Centrosome functions 
The major function of the centrosome is the organisation of 
microtubules cytoskeleton. In interphase, the centrosome arranges the 
microtubules astral array involved in crucial cellular functions like trafficking, 
cell motility, cell adhesion and cell polarity (Azimzadeh and Bornens, 2007). 
During cell cycle progression the centrosome undergoes a maturation process, 
involving the accumulation of -tubulin and centrin, and culminating with the 
centrosome duplication at the onset of S phase. The newly synthesised 
centrosomes are essential for the assembly, organisation and orientation of a 
bipolar mitotic spindle. Moreover they regulate the fidelity of chromosome 
segregation and the late events of cytokinesis (Bornens, 2002) (Azimzadeh and 
Bornens, 2007). 
Recent studies indicate that centrosome coordinate cell cycle 
progression from G1 to S phase (G1-S), from G2 to M phase (G2-M), from 
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metaphase to anaphase (M-A) and through cytokinesis (Doxsey et al., 2005b) 
(Doxsey et al., 2005a). 
1.7.3 The cell cycle and its regulation  
The cell cycle is the process that leads a cell to its division and 
duplication in two daughter cells.  
The cell cycle can be divided into four distinct phases: G1 phase, S phase, 
G2 phase and M phase. The G1, S and G2 phases are collectively known as 
Interphase, and represent the stage of the cycle in which the cell prepares itself 
for the following division (Smith and Martin, 1973). 
G1 phase, also called growth phase, is the period from the end of mitosis 
and the beginning of DNA replication. During this phase the biosynthetic 
machinery of the cell reaches the maximum activity and all the enzymes 
required during the following S phase are synthesised. In this stage the cell 
contains one centrosome with two orthologue centrioles (Smith and Martin, 
1973). 
S phase starts with the synthesis of DNA and ends when all of the 
chromosomes have been replicated. While the content of DNA is doubled in 
this phase the RNA transcription and protein synthesis are completely 
switched off except for histones production. During this phase the two 
centrioles of the centrosome replicate (Smith and Martin, 1973). 
G2 phase starts at the end of DNA replication and lasts until the cells 
enter mitosis. In this period, components of the spindle pole body, such as 
microtubules, are synthesised. During this phase protein synthesis is again 
very high and its inhibition will results in a G2 arrest of the cycle progression. 
At the end of this phase the two pairs of centrioles start to separate and to 
become part of the spindle poles body (Smith and Martin, 1973). 
M phase or mitosis is the phase during which chromosomes separate 
and the nucleus divides. Mitosis includes five distinct sub-phases called: 
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prophase, metaphase, anaphase, telophase, and cytokinesis. During mitosis the 
chromosomes condense and align on the metaphase plate by attaching to the 
microtubules of the spindle poles body that in turn pull the sister chromatides 
to opposite sides of the cell. 
During cytokinesis then the cell completes the formation of two 
daughter cells through the division of the nuclei, cytoplasm, organelles and 
membranes (Smith and Martin, 1973). 
1.7.4  Cell and centrosome coordinating cycles 
Accurate cell division requires the coordinated completion of three 
cycles: the cell, the centrosome and the nuclear cycles. Regulation of the cell 
cycle is crucial for the survival of a cell. To this purpose the cell has several 
control mechanisms to detect genetic damage and to prevent uncontrolled cell 
division. 
Cyclins and cyclin dependent kinases (Cdks) are the two key classes of 
regulatory molecules which control cell progression through the cell-cycle. 
Cyclins and Cdks are respectively the regulatory and the catalytic subunit of a 
large family of heterodimeric serine/threonine protein kinases. In addition 
cyclins, which are synthesised and degraded during each cell cycle, have no 
catalytic activity, whereas Cdks, constitutively expressed, are not active unless 
they are bound to cyclins (Malumbres and Barbacid, 2005). 
In G1 phase, an incoming mitogenic signal induces synthesis of CyclinD 
and promotes the folding of Cdk4. The active complex Cdk4-CyclinD 
phosphorylates and inactivates the retinoblastoma (Rb) protein family. The 
function of the Rb proteins is to repress transcription by binding and 
modulating the activity of transcription factors. Cdk4-CyclinD complex-
dependent phosphorylation of Rb leads to the release of the inhibition exerted 
by Rb on the transcription factors thereby promoting the transcription of 
genes such as DNA polymerase, thymidine kinase, chromatin remodelling 
complexes and also CyclinA and CyclinE, necessary for entry into the following 
phases. The next activation of the complex Cdk2-CyclinE, during G1-S 
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transition, carries out the irreversible inactivation of the Rb proteins and 
favours the onset of DNA replication, thereby promoting the exit from G1 phase 
and leading the cell into S phase. In addition, Cdk2-CyclinE complex 
phosphorylates proteins involved in histones modification and centrosome 
maturation and duplication, as well as its own inhibitor p27, thus promoting its 
degradation. Once cells enter in S phase CyclinE is rapidly degraded in order to 
inactivate the Cdk2-CyclinE complex and avoid the re-replication of the DNA 
(Smith and Martin, 1973).  
During S phases CyclinA and B are synthesised and the consequent 
association of Cdk2-CyclinA promotes the completion and exit from S phase, by 
phosphorylating numerous substrates such as upstream regulators of CyclinA, 
transcription factors and protein involved in DNA replication. At this stage 
CyclinA associates also to Cdk1 (also named cdc2 or p34 kinase). Cdk1-CyclinA 
shares similar substrates with Cdk2-CyclinA and both promote the S-G2 
transition (Smith and Martin, 1973). 
At the beginning of G2, CyclinB is synthesised whereas CyclinA is 
degraded by an ubiquitin-mediated proteolysis process. As a consequence, 
Cdk1 binds and activates cyclinB, throughout a mechanism involving 
phosphatase cdc25, the checkpoint kinase 1 (Chk1) and Aurora A kinase 
(Kramer et al., 2004) (Dutertre et al., 2004). Cdk1-CyclinB complex is also 
called the M-phase Promoting Factor (MPF) and its activation is essential for 
the cell to enter mitosis; moreover, in prophase this complex associates with 
the centrosome and triggers it separation. The MPF regulates chromosomal 
condensation, fragmentation of the Golgi apparatus, breakdown of the nuclear 
lamina as well as degradation of the CyclinB for correct exit from mitosis. As 
for the other cyclins, CyclinB is also degraded upon ubiquitination and 
subsequent proteolysis. The ubiquitin ligase which promotes degradation of 
mitotic cyclins is the anaphase-promoting complex (APC) and its activity 
ensures the correct progression of the cell cycle through the anaphase, 
telophase and the cytokinesis (Malumbres and Barbacid, 2005). 
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Centrosome duplication is precisely coordinated with cell cycle 
progression; however how these two processes are coupled is still matter of 
study. One possible link can be the use of the same molecular complexes such 
as Cdks and the anchoring of such complexes to the centrosome. Thus 
centrosome becomes a scaffold for a network of signalling pathways involved 
in cellular division. For example, the cell cycle kinase Cdk2, in complex with 
CyclinE and A, is required to the centrosome for G1-S transition and initiation 
of centrosome duplication (Hinchcliffe et al., 1999) (Lacey et al., 1999). Also 
mitotic entry (G2-M transition) requires centrosome localisation of Cdk1 and 
its modulator checkpoint kinase 1 (Chk1) (Kramer et al., 2004). In addition, 
other kinases have been shown to be targeted to the centrosome and to 
regulate its functions. For example, polo-like kinase (Plk) and Aurora A kinase 
control centrosome maturation, centrioles duplication (Blagden and Glover, 
2003) and recruitment of Cdk1-cyclinB (MPF) to the centrosome before its 
activation (Dutertre et al., 2004). 
As a consequence, perturbations of the centrosome result in the 
aberration of one or more of these processes leading to the arrest of the cells 
cycle progression. 
1.7.4.1 G1 arrest 
It has been shown that microsurgical (Hinchcliffe et al., 2001) or laser 
ablation (Khodjakov and Rieder, 2001) of core centrosome components, such 
as centrioles, before the completion of S phase, results in cells cycle arrest in G1 
phase. Acentriolar cells form functional mitotic spindle but about 50% of them 
are not able to exit cytokinesis, generating tetraploid cells. All the population, 
both the acentriolar and the tetraploid, do not enter S-phase in the following 
cycle. In a similar manner, ablation of one of the centrioles in pro-metaphase 
cells results in a daughter cell with a functional centrosome and an acentriolar 
daughter cell that does not enter the following S-phase (Khodjakov and Rieder, 
2001). The same effect results from changes in centrosomal proteins 
expression level or localisation. An example of this was provided by the over-
expression of pericentrin-AKAP450 centrosomal targeting domain (PACT 
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domain). Displacement of both pericentrin and AKAP450 from the centrosome 
upon PACT domain over-expression is associated with impaired centrioles 
duplication and inhibition of cell cycle progression. Cells over-expressing the 
PACT domain enter mitosis but do not complete cytokinesis, showing arrest in 
G1 (Kramer et al., 2004) (Keryer et al., 2003b). Based on this evidence it 
appears that G1 arrest arises from alterations in centrosome composition 
leading to cytokinesis defects. However the pathway linking the centrosomal 
disruption to the G1 arrest is currently unknown. A model proposed for this 
arrest involves CyclinE, the recruitment of which to the centrosome has been 
shown to be essential for G1-S transition (Lacey et al., 1999). Ectopically 
expression of CyclinE in CHO cells accelerates S phase entry whereas 
displacement of the CyclinE from the centrosome results in cells population 
arrest in G1 (Matsumoto and Maller, 2004). Therefore it is possible that 
centrosome disruption may affect anchoring of CyclinE to the centrosome, 
thereby leading to the observed G1 arrest. 
1.7.4.2  G2 arrest (pre-mitotic entry) 
The role of centrosome in G2-M transition has been recently correlated 
to the Cdk1-CyclinB (MPF) activation complex. The activation of this complex, 
that is the key event for mitosis entry, occurs at the centrosome. It has been 
shown that Cdk1-CyclinB is activated in late prophase by cytoplasmatic 
phosphatase cdc25, which in turn is under temporary negative control by 
centrosome associated checkpoint kinase 1 (Chk1; Cdk1 modulator) (Kramer 
et al., 2004). With an elegant set of experiments Lukas and colleagues showed 
that Chk1, anchored to the centrosome, shields Cdk1 from activation during 
interphase. At the onset of mitosis Chk1 displaces from the centrosome and 
releases Cdk1 inhibition. Eventually Cdk1 is available for cdc25-dependent 
activation, leading the cells to enter mitosis at the right moment. To dissect this 
mechanism, a wild-type and a catalytically dead version of the ChK1 fused to 
the PACT domain have been generated. The immobilisation of the wild-type 
Chk1 to the centrosome results in a permanent inhibition of the Cdk1-
activation that leads to mitotic failure and formation of polyploid cells. On the 
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contrary, replacement of the endogenous Chk1 with a catalytically dead 
version results in a premature Cdk1 activation and a consequent premature 
mitotic entry (Kramer et al., 2004). 
A role in G2-M transition is also played by the pericentrin--tubulin 
complex. In fact, uncoupling of pericentrin--tubulin interaction or knock-
down of pericentrin and the consequent disruption of binding to -tubulin, 
induces arrest at G2-M transition. Cells arrested in G2 then undergo apoptosis. 
However it is not clear at the moment what is the mechanism responsible for 
the arrest and if disruption of pericentrin--tubulin interaction is responsible 
for the mislocalisation of other centrosomal molecules involved in the 
regulation of cell cycle progression (Zimmerman et al., 2004). 
1.7.4.3 Cytokinesis failure 
Video imaging of cells stably expressing the centrosomal protein centrin 
tagged to GFP revealed the crucial steps of cytokinesis (Piel et al., 2001). 
During cytokinesis the mother centriole transiently and quickly migrates to the 
intracellular bridge near to the midbody. The reason for this repositioning 
seems to be related to the delivery of membranes and vesicles as well as 
regulatory components for mitosis exit and cytokinesis ending. Cytokinesis 
completes with the abscission of the two daughter cells only when the mother 
centriole moves back to the centre of the cell. This mechanism shows how 
centrosome is involved also in cytokinesis. It has also been shown that ablation 
of the centrosome or manipulation of its protein content generates a 
population of cells that complete the furrow cleavage but do not undergo the 
abscission, thus remaining attached through a cytoplasmatic bridge 
(Hinchcliffe et al., 2001, Khodjakov and Rieder, 2001, Keryer et al., 2003b). 
Finally, it is worth mentioning that the correct completion of cytokinesis seems 
to require the correct assembly of PKC-14-3-3 complex during the late stage 
of mitosis. Absence or inhibition of this functional complex leads to failure of 
cytokinesis (Saurin et al., 2008). PKC binds to AKAP450 at the centrosome. 
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As described above, cytokinesis failures usually results in a G1 arrest of 
the cell population (see section 1.7.4.1). 
1.8  cAMP and PKA in cell cycle progression 
The relationship between cAMP/PKA and cell cycle progression is very 
controversial and contradictory evidence is present in the literature. cAMP and 
PKA seem to both activate and inhibit cell proliferation and, despite the 
overwhelming number of studies, it is not clear what mechanisms may trigger 
such opposite effects. This is in part due to the numerous targets of PKA so that 
activation of PKA can trigger both positive and negative signalling pathway for 
the initiation and progression of the cell cycle. In addition, most of the studies 
available have been performed on populations of cells that had been 
synchronised by chemical treatment. Cell synchronisation achieved by these 
means is known to be difficult to maintain for more than one cycle. Finally, it is 
important to consider that analysis of cAMP and PKA activity in these studies 
has always been carried out on cell lysates thereby any relevant information on 
local differences in cAMP/PKA activity could not be appreciated. Despite such 
limitations, the emerging picture is that activation of the cAMP/PKA signalling 
pathway has an anti-mitotic effect. 
Studies of the mitogenic role of cAMP and its effect on the inter-
conversion of a quiescent population into a cycling population revealed that 
cAMP alone does not stimulate cells to divide unless the population has already 
been programmed to undergo cell division (Abell and Monahan, 1973). 
Accordingly MacManus and Whitfield showed that addition of physiological 
concentrations of cAMP (between 10 nM and 1 M) to resting thymocytes and 
lymphocytes cultures stimulates cell entry into mitosis by promoting DNA 
synthesis. However, an increase in cAMP to a concentration greater than 10 M 
resulted in inhibition of cell growth (Macmanus and Whitfield, 1969). This 
finding was further confirmed by many others showing that elevation of cAMP 
concentration induces either by stimulation of AC, inhibition of PDEs or by 
addition of cAMP (cAMP or dibutyryl-cAMP), inhibits cells division in many 
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other mitogen-stimulated cells types, including HeLa cells and 3T3 mouse 
fibroblasts (Macmanus and Whitfield, 1969) (Ryan and Heidrick, 1968) 
(Sheppard, 1972). In agreement with these findings, an immediate drop in 
cAMP level is observed when cells are released from quiescence. It has been 
shown in fact that proteolytic treatment of 3T3 mouse fibroblasts, growth-
arrested for contact inhibition, results in stimulation of proliferation and in a 
drop in cAMP concentration. The proliferative effect of the protease treatment 
can be reversed by replenishment of cAMP or dibutyryl cAMP (Burger et al., 
1972) (Sheppard, 1972) (Sheppard, 1971). Similarly, the inhibitory effect 
exerted by cAMP on cell cycle progression is reversible and cell cycle 
progression can be rescued upon removal of cAMP (Ryan and Heidrick, 1968). 
Based on this evidence it was possible to conclude that agents that stimulate 
proliferation in a resting cell population decrease intracellular cAMP level; on 
the contrary, agents that inhibit cells proliferation induce an increase in 
intracellular cAMP concentration. Thus cAMP elevation appears to counteract 
cell growth (Bombik and Burger, 1973). 
The involvement of cAMP in regulating cell cycle progression was 
studied by in vitro analysis of endogenous cAMP concentration in each stage of 
the cells cycle. Synchronised HeLa and CHO cells revealed that cAMP level 
fluctuates throughout the cells cycle reaching the highest level in G1 and the 
lowest level in mitosis. In agreement with these measurements, early G1 cells 
have 50% more cAMP than cells in S phase and mitotic cells have half the 
amount of cAMP found in S phase cells. Late G1 cells contain the same amount 
of cAMP as cells in S phase (Sheppard and Prescott, 1972) (Zeilig et al., 1976).  
These reports confirm the inverse correlation between cAMP levels and 
growth rate. Thus, populations of cells actively dividing will have a higher 
proportion of cells in S, G2 and M phase and a lower proportion in G1 
corresponding to a lower amount of total cAMP (Zeilig et al., 1976). Despite the 
anti-proliferative effect of cAMP analysis of CHO and rat liver cells indicates 
that the surge of cAMP in late G1 seems to be necessary for specific PKA type II 
activation to promote the initiation of DNA synthesis, suggesting a 
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coordination between cAMP fluctuations and PKA signalling cascade (Boynton 
and Whitfield, 1980) (Costa et al., 1976a, Costa et al., 1976b) (Costa et al., 
1978). Interestingly, lymphoma cells expressing a defective PKA insensitive to 
cAMP (Daniel et al., 1973) are able to proceed normally through the cell cycle 
even in the presence of high cAMP concentration, indicating that block of cell 
cycle in G1, in presence of high level of cAMP, is PKA mediated (Coffino et al., 
1975). 
Further studies on the effects on cell cycle progression induced by 
experimental elevation of cAMP confirmed previous reports showing that an 
increase of intracellular cAMP in S phase synchronised cells inhibits cells cycle 
transition through G2/M phase, suggesting the existence of a cAMP-mediated 
checkpoint for the S-G2 progression. On the contrary, elevation of cAMP on a 
mitotic population accelerated cells progression throughout the cycle and the 
completion of cells division. Finally, inhibition of phosphodiesterases or 
activation of adenylyl cyclases in a G1 enriched population results in a 
prolonged G1 phase (Zeilig et al., 1976).  
Analysis of cell cycle progression in thyroid cells provided evidence that 
G1-S transition requires not only decrease in cAMP concentration but also 
modification of the PKA localisation. As previously shown for other cell lines 
evidence shows that the up-regulation of the cAMP/PKA pathway is necessary 
to induce cell cycle entry and DNA synthesis associated with the translocation 
of the catalytic subunit into the nucleus. Thus, cells entering in G1 phase display 
both nuclear and cytosolic PKA activity. Alteration of PKA activity affects the 
onset of S phase and shortens the G1 phase (Feliciello et al., 2000). 
Analysis of cAMP level and its effect on cell cycle progression as well as 
the effect of PKA activation or inhibition led to the conclusion that activation of 
the cAMP/PKA pathway has an anti-mitotic effect and that PKA is responsible 
for the maintenance of the highly ordered structure of chromatin during 
interphase (Lamb et al., 1991). By using rat embryonic fibroblasts it has been 
shown that inhibition of PKA by injection of PKI (a Protein Kinase A Inhibitor) 
at any stage of the cycle results in pronounced condensation of chromatin and 
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disassembling of the microtubule network. Moreover these effects can be 
rapidly reverted by microinjection of the purified catalytic subunit of PKA 
(Lamb et al., 1991), meaning that basal activity of PKA is constantly required to 
preserve interphase state. How PKA activity can account for the uncondensed 
status of chromatin is still unclear, however the idea is that PKA keeps the 
nucleosome1 in an open structural conformation whereas inhibition of PKA 
may lead to a refolding of the nucleosome (Lamb et al., 1991). Accordingly, 
reduction of cAMP levels or inhibition of PKA leads to increased chromatin 
condensation and induces cells entry into mitosis (Lamb et al., 1991). 
Interestingly, it has recently been shown that activation of cAMP signalling by 
-adrenergic, forskolin or 8-Br-cAMP stimulation, significantly reduces the 
percentage of mitotic Histone H3 phosphorylation in a PKA dependent manner 
(Wu et al., 1986) (Rodriguez-Collazo et al., 2008b). This reduction correlates 
kinetically with a pre-mitotic cell cycle arrest and with a rapid decrease of 
Cdk1-CyclinB kinase (MPF) activity (Rodriguez-Collazo et al., 2008b) 
(Rodriguez-Collazo et al., 2008a). The sensitivity of this effect to cAMP 
concentration is interesting since the increase of cAMP to induce a maximal 
loss on H3 phosphorylation is around 10 M (EC50=8.9 M) whereas 150 M 
cAMP is required to induce phosphorylation of the cAMP Response Element 
Binding Protein (CREB) (EC50=144 M) (Rodriguez-Collazo et al., 2008a). 
Many pieces of other evidence suggest that PKA plays a key role in 
several interphase processes as well as a direct function in preventing the 
initiation of mitosis. Thus PKA activity has been associated with the 
maintenance of the nuclear envelope integrity, through the phosphorylation of 
lamins A and C (Lamb et al., 1990), as well as the organisation of the 
cytoskeleton by modulating the integrity of actin filaments (Lamb et al., 1988) 
and organisation of the microtubule network. Although injection of active 
catalytic subunit in mouse embryo fibroblasts does not show any effect on the 
                                                       
1 A nucleosome is the fundamental unit of the eukaryotic chromatin. It consists on a DNA 
segment wound around an histone protein core, like a thread wrapped around a spool. 
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microtubules organisation, inhibition of PKA by PKI results in very pronounced 
disassembly of microtubules, even though this does not seem to affect spindle 
formation (Lamb et al., 1991). This evidence suggests that in living fibroblast 
the microtubule network is dependent on the presence of an active PKA. 
Interestingly, PKA localises to the microtubules through the binding with the 
microtubule-associated protein 2 (MAP2) (a family of cytoskeletal proteins 
predominantly expressed in neurons involved in the stabilisation of 
microtubules, see section 1.5.1) and AKAP450.  
Similarly, studies in oocytes indicated that cAMP and PKA are negative 
regulators of maturation. Indeed, a drop in basal cAMP levels has been 
measured during oocytes maturation of starfish, fish, amphibians and 
mammals. Maturation can also be induce by injection of phosphodiesterases, 
the enzymes that degrade cAMP thus reducing its intracellular levels, or by 
inactivation of PKA via injection of PKI and the regulatory subunit of PKA, 
thereby inhibiting the catalytic activity of PKA. Furthermore in mammalian 
oocytes PKI and PKA inhibition result in maturation whereas direct activation 
of PKA or injection of the catalytic subunit shows inhibitory effects on oocytes 
maturation. Finally, elevation of cAMP levels inhibits or significantly delays 
oocytes maturation (Lamb et al., 1991). 
Further studies of Xenopus oocytes provided evidence that maturation 
required the release of p34cdc2 (Cdk1 in mammals) from the indirect PKA 
inhibitory effect. According to this model PKA would phosphorylate cdc25 in 
interphase, generating a binding site for a 14-3-3 protein that sequesters cdc25 
within the cytoplasm. This would prevent translocation of cdc25 to the nucleus 
where it functions and would keep cdc25 inactive (Schultz, 2009). At the onset 
of mitosis a decrease in cAMP level and, consequently, PKA inactivation, would 
result in release and activation of cdc25 that in turn would de-phosphorylate 
p34cdc2 kinase promoting oocytes maturation (Grieco et al., 1994). Hence, 
inhibition of PKA during interphase prematurely activates p34cdc2 resulting in a 
premature interphase-mitosis transition. On the contrary, activation of PKA by 
8-Br-cAMP prevents p34cdc2 activation and prolongs interphase (Grieco et al., 
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1994). An interesting consequent finding is that the high level of activity of 
p34cdc2 reached at metaphase-anaphase transition is necessary to activate the 
cAMP/PKA pathway, which in turn is required for the activation of APC and the 
inactivation of p34cdc2, establishing in this way a mechanism of feed-back loop 
regulation (Grieco et al., 1996). 
All these indications suggest that fluctuations of cAMP levels are 
relevant in controlling cellular proliferation. 
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2 Aim of the thesis 
A large body of evidence highlights the importance of a functional 
centrosome for the completion of the cell cycle from one mitosis to another. 
There is also evidence indicating that cAMP is involved in regulating the 
entrance and the progression of a cell through the cell cycle. Based on the 
knowledge that the cAMP/PKA signalling network is compartmentalised and 
that a macromolecular complex containing PKA and PDE4D3 is nucleated to 
the centrosome through binding to AKAP450, it is possible to hypothesise that 
a cAMP/PKA signalling is selectively regulated. The presence of such a specific 
signalling domain at the centrosome may be required for tight control of the 
progression of the cell through the cell cycle. 
The aim of my project was to study cAMP dynamics in the centrosomal 
area, to define the role of PDE4D3 anchored to AKAP450 in shaping a 
centrosomal pool of cAMP and to investigate the functional involvement of the 
AKAP450/PKA/PDE4D3 macromolecular complex anchored to the centrosome 
in the progression of the cell cycle. 
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3 Materials and Methods 
3.1 Molecular Biology 
3.1.1  Generation of competent cells 
This protocol allows preparation of batches of bacteria that yield 5x106 
to 2x107 of transformed colonies per microgram of DNA.  
A single colony of TOP10 E.coli from a plate freshly grown overnight at 
37°C was picked and transferred to 2 ml of sterile 2xYT broth. The cells were 
grown overnight at 37°C. The next day the culture was used to inoculate 100 
ml of sterile 2xYT broth and incubated at 37°C with vigorous shaking (300 
rpm) for about 3 hours or until the OD600 was 0.3-0.4. Particular care was taken 
to avoid the number of viable cells exceeding 108 cells/ml; to this purpose the 
OD600 was measured every 20-30 minutes. 
The culture was transferred aseptically into a pre-cooled 50 ml tube and 
left to cool down for 30 minutes on ice. Bacteria were then pelleted by 
centrifuging the culture at 4000 rpm (1617 rotor type for 15/50 ml tubes, 
speed max 5000 rpm, max RCF 3875 x g) for 10 minutes at 4°C. The 
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supernatant was discarded and all traces of media were let drain away. The 
pellet was re-suspended in 10 ml of ice-cold 100 mM CaCl2 and incubated in ice 
for 30 minutes. Bacteria were collected once again by centrifugation at 4000 
rpm for 10 minutes at 4°C. The supernatant was discarded and all traces of 
media were let drain away. Each pellet was re-suspended in 2 ml of ice-cold 
100 mM CaCl2 and 10% glycerol (v/v). Cells were finally dispensed into 100 l 
aliquots and snap frozen in liquid nitrogen. Competent cells are stored at -80°C. 
3.1.2  Bacterial transformation  
Competent cells were thawed on ice. No more than 50 ng of DNA were 
added per aliquot of competent cells. The tube was swirled gently to mix 
(avoiding pipetting) and incubated on ice for 30 minutes. Cells were then heat 
shocked for not more than 1 minute at 42°C without shaking, placed on ice for 
1-2 minutes and, after addition of 400 l of sterile 2xYT media, incubated at 
37°C for 30 minutes. Finally the suspension was spread on a pre-warmed LB 
plate with the appropriate antibiotic(s) for selection (usually ampicillin or 
kanamycin) and incubated overnight at 37°C. 
3.1.3  DNA extraction and purification 
Generally plasmid DNA was extracted and purified from bacterial 
cultures using the Hispeed Plasmid Maxi kit from QIAgen (cat. n°12163, 
QIAgen), following the manufacturer’s instructions. However, in order to 
obtain large amounts of ultrapure DNA, an alkaline lysis procedure, followed 
by equilibrium ultracentrifugation in caesium chloride-ethidium bromide 
gradients was also utilised. Briefly, 400 ml of cells containing the plasmid of 
interest were grown overnight at 37°C. The next day the culture was 
centrifuged at 6000 rpm (1617 rotor type for 15/50 ml tubes, speed max 5000 
rpm, max RCF 3875 x g) for 8 minutes. The pellet was re-suspended in a 
lysozyme and glucose buffer (20 mg lysozyme per ml of glucose buffer: 50 mM 
glucose, 25 mM Tris-HCl pH 8, 1 mM EDTA) containing 20 mg/ml of RNAse A, 
incubated on ice for 10 minutes and then treated with alkaline detergent (0.2 N 
NaOH, 1% SDS). Solubilised membranes and proteins were precipitated with 
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potassium acetate solution (3 M KOAc, pH 5.5). The lysate was then cleared 
first by filtration of the precipitate through gauze and then by centrifugation at 
8000 rpm (1617 rotor type for 15/50 ml tubes, speed max 5000 rpm, max RCF 
3875 x g) for 8 minutes. The supernatant containing the DNA was precipitated 
with 3/5 volume of isopropanol, collected by centrifugation at 10000 rpm 
(1617 rotor type for 15/50 ml tubes, speed max 5000 rpm, max RCF 3875 x g) 
for 5 minutes. The pellet was re-suspended in a solution containing 1 gr/ml of 
caesium chloride and 500 g/ml of ethidium bromide in Tris-EDTA, loaded 
into a polyallomer tube and ultra-centrifuged at 57000 rpm (NVT65 rotor type 
for 13.5 ml tubes, speed max 65,000 rpm, max RCF 402,000 x g) at 
20overnight. After ultra-centrifugation the DNA band could be visualised under 
long wave UV light. Usually, if more than a band is visualised the lower band 
corresponds to the plasmid DNA whereas the upper band is genomic DNA. The 
plasmid DNA (lower band) was removed with a 5 ml syringe and dialysed 
against TE buffer for three hours. Finally the DNA was extracted with phenol-
chloroform, precipitated with NaOAc 3N pH 4.8 and cold ethanol and re-
suspended in TE 0.1X. 
3.1.4  mRNA extraction 
Cells (about 4x106) were seeded in a 10 cm tissue culture dish and 
grown for 48 hours. Total mRNA was extracted with TRIzol® Reagent (cat. 
n°15596026, Invitrogen). After a wash with D-PBS the cells were lysed with 1 
ml of TRIzol® Reagent, directly added into the dish, collected with a scraper 
and homogenised by passing several times through a 1 ml syringe and a 26 
gauge needle. Insoluble material was removed from the homogenate by 
centrifugation at 12000 rpm in a bench top centrifuge for 10 minutes at 4°C. At 
this point the pellet contains membranes and high molecular weight DNA, 
whereas the supernatant contains the RNA. The cleared supernatant was 
transferred to a new tube, 200 l of chloroform added, shaked vigorously and 
incubated for 5 minutes at room temperature. After incubation the sample was 
centrifuged at 12000 rpm for 15 minutes at 4°C. Following centrifugation, the 
mixture separated into a lower red, phenol-chloroform phase, an interphase, 
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and a colourless upper aqueous phase (about 600 l, 60% of the volume of 
TRIzol® Reagent used for homogenisation). RNA remains exclusively in the 
aqueous phase. The aqueous phase was transferred to a fresh tube, 500 l of 
isopropanol added and incubated for 10 minutes at room temperature to 
precipitate RNA. RNA was collected by centrifugation at 12000 rpm for 10 
minutes at 4°C. The RNA pellet was washed with 1 ml of 70% EtOH (v/v) in 
sterile water and centrifuged at 10000 rpm for 10 minutes at 4°C. Finally the 
RNA was briefly dried under vacuum and re-suspended in RNAse-free sterile 
water  
3.1.5  Nucleic acid quantification  
DNA and RNA concentration was determined using a PerkinElmer 
LambdaBio+ Spectrophotometer (cat. n°L7110186) and the Lambert-Beer law 
which relates the absorption of light (A) to the properties of the material 
through which the light is travelling (extinction coefficient,  [mol-1 cm-1]), the 
concentration of the absorbing species in solution (c, mol) and the light path 
length (l [1 cm]): 
 
 
The nucleic acid absorption peak is at 260 nm and the average  for 
double-stranded DNA is  . 2  (μg/ml)-1 cm-1. Thus, an optical density (or 
"OD") of 1 corresponds to a concentration of 5  μg/ml for double-stranded 
DNA. It is important to consider the dilution factor so that the formula to use 
will be: 
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Proteins are the major contaminants of DNA. Since the absorption peak 
of proteins is at 280 nm the ratio A260/A280 has been used to evaluate the purity 
of the sample. Pure DNA preparations have an A260/A280 ratio of 1.8. 
RNA quantification was performed using the same formula used for 
DNA.  for single strand RNA is 0.027 (mg/ml)-1 cm-1. Moreover pure RNA 
preparations have an A260/A280 ratio of 2. 
3.1.6  cDNA preparation  
An aliquot of total mRNA was reversed transcribed with 1 μl 
SuperScript™ II RT 2000U/l (cat. n°18064022, Invitrogen). Briefly, 1 μg 
mRNA was mixed with 0.5 g oligo (dT)12-18 primer (cat. n°18418, Invitrogen) 
to a final volume of 10 l in water and incubated at 70°C for 10 minutes. After 
incubation the tube was quickly transferred on ice for 10 minutes. A mix 
containing 1 μl RNAout™ (4  U/l, Ribonuclease Inhibitor, cat. n° 10777019, 
Invitrogen), 1 μl 1   mM dNTPs (cat. n° 1 297 18, Invitrogen) 4 μl 5x first 
strand buffer, 2 μl of  .1 mM dithiothreitol (DTT) and 1 μl SuperScript™ II was 
then prepared, added to the tube and brought to a final volume of 2  μl with 
sterile water. The tube was incubated in a thermocycler at 42°C for 45 minutes. 
A final incubation step at 70°C for 10 minutes was required to inactivate the 
reaction. 
3.1.7  PCR and DNA purification  
PCR products were precipitated with 2.5 volumes of 95% EtOH (v/v) 
and 1/10 volume of 3N NaOAc pH 4.8 for 30 minutes at -80°C and a 30 minute 
spin at 14000 rpm in a bench top centrifuge. The pellet was washed with 70% 
EtOH (v/v) and re-suspended in an appropriate volume of sterile water. 
Digested DNA was separated on an agarose gel, the bands of interest cut 
out with a sterile scalpel and purified with the QIAquick Gel Extraction kit (cat. 
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n°287 6, QIAgen) following the manufacturer’s instruction. DNA was eluted 
from the spin column by using 65°C pre-warmed sterile water to promote and 
increase DNA elution rate. 
3.1.8  De-phosphorylation reaction  
Digested vectors were incubated with Shrimp alkaline phosphatase 
(SAP) (cat. n°11758250001, Roche) for 10 minutes at 37°C, according to the 
manufacture’s instruction, in order to remove the free phosphate group from 
the 5’ end and prevent re-circularisation. 
3.1.9  Restriction enzymes and Ligation 
All restriction enzymes were purchased from New England Biolabs. 
Digestion reactions were performed by mixing from 3 to 5 µg of DNA with the 
required restriction enzymes and the specific buffer solution. The mix are then 
incubated at 37°C for at least 1h. Each restriction enzyme required a buffer 
solution that contains the unique mix of cations and other components that aid 
the enzyme in cutting as efficiently as possible. Moreover they also have 
different optimal temperatures under which they function. For this reason it is 
important to follow the manufacture’s instruction. 
For ligation reactions T4 DNA ligase (cat. n°M0202, New England 
Biolabs) or the Rapid DNA Ligation kit (cat. n°11635379001, Roche) were 
used. Insert and plasmid were quantified on an agarose gel by comparing the 
band intensity to a known DNA standard and combined at a 1 to 3 plasmid to 
insert ratio. A reaction containing all components but the insert was always 
included in the experiment as a negative control. 
3.1.10 Sub-cloning of RII-CFP in pCDNA3.1/Zeo (+) 
The CFP tagged regulatory subunit (RII) of PKA (Lissandron et al., 
2005) was sub-cloned into pCDNA3.1/Zeo (+), which contains the Zeocin™ 
resistance gene for selection in both E.coli and mammalian cells in the presence 
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of the antibiotic Zeocin™. RII-L20-CFP was inserted in the NheI and XbaI sites 
of the multiple cloning site of pCDNA3.1/Zeo (+). 
3.1.11 Sub-cloning of C-YFP in pCDNA3 
The YFP tagged catalytic subunit of PKA was inserted in the HindIII-XbaI 
sites of the multiple cloning site of pCDNA3. This plasmid contains a gene 
coding for resistance to Geneticin® (G418 Sulphate, neomycin) for mammalian 
selection. 
3.1.12 Generation of RII_epac 
The RII_epac sensor was generated by fusion of the dimerisation 
docking domain of RII (49 aa) to the N-terminus of the Epac1-camps FRET-
based sensor (Nikolaev et al., 2004). Between the docking domain and the 
Epac1-camps sensor a 26 amino-acid linker (A (EAAAK)5) has been inserted 
(Di Benedetto et al., 2008). The functional role of this linker is to prevent steric 
hindrance between the two hetero-functional domains.  
The sensor is cloned into pCDNA3 and thus contains the gene encoding 
for resistance to Geneticin® (G418 Sulphate, neomycin) for mammalian 
selection. 
3.1.13 Generation of RII-RFP 
RII-RFP (Di Benedetto et al., 2008) was constructed by substituting the 
CFP in the RII-L20-CFP construct with mRFP (monomeric red fluorescent 
protein) (Lissandron et al., 2005). 
3.1.14 Generation of SuperAKAP-IS and RIAD 
The constructs containing the cDNA for SuperAKAP-IS and RIAD (Di 
Benedetto et al., 2008) were generated in the lab by external PCR using the 
SuperAKAP-IS-GFP and the RIAD-GFP constructs as a template (kindly 
provided by Prof John D. Scott, Howard Hughes Medical Institute, Department 
of Pharmacology, University of Washington School of Medicine, Seattle, USA). 
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3.1.15 Generation of AKAP450-2 fragment and 
mutAKAP450-2 fragment 
The fragment from amino acid 933 to amino acid 1804 encoded by the 
AKAP450 cDNA (DDBJ/EMBL/GenBank accession N AJ131693) was a kind gift 
from Prof Kjetil Taskén, (The Biotechnology Centre of Oslo and Centre for 
Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo, 
Oslo, Norway). This fragment was amplified by using the primers: AKAP450-
2_NheI_frw: 5’-CTAGCTAGCATGGTTGTTGAAAAGGATACA-3’ and AKAP45 -
2_BamHI_rev: 5’-CGGGATCCTTACATATCACTTCCAGAATAA-3’ and inserted into 
the NheI-BamHI sites of the multiple cloning site of pcDNA3.1/Hygro (+).  
For the mutAKAP450-2 fragment the point mutation S1451P was 
introduced, using the QuickChange™ Site-directed Mutagenesis Kit (cat. 
n°200518, Stratagene) as described by the manufacturer with the primers: 
AKAP450-2_mut_frw: 5’-
GAAGAAGTAGCTAAGGTTATTGTGCCAATGAGTATAGCATTTGC-3’ and 
AKAP450-2_mut_rev: 5’-
CTTCTTCATCGATTCCAATAACACGGTTACTCATATCGTAAACG-3’. 
3.1.16 Generation of PKA-GFP 
The fragment from amino acid 5  to amino acid 419 of RIIβ was 
amplified by PCR and substituted for the full length RIIβ of the RII-L20-CFP 
construct (Lissandron et al., 2005). 
3.1.17 AKAP79 and AKAP149 
These plasmids were kindly provided by Prof Kjetil Taskén, (The 
Biotechnology Centre of Oslo and Centre for Molecular Medicine Norway, 
Nordic EMBL Partnership, University of Oslo, Oslo, Norway). 
3.1.18 Generation of the Rt31 fragment 
Rt31 in pGEX4T3 was a kind gift from Dr Enno Klussmann, (Leibniz 
Institute for Molecular Pharmacology, Berlin, Germany). The fragment from 
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amino acid 1 to amino acid 940 was amplified by using the following pair of 
primers: Rt31_2-19_frw: 5’-CCGGAATTCATGGCACGAGAAACAACGCGA-3’ and 
Rt31_1659-1678_rev: 5’-CGCCGCTCGAGTTACCTGTTTAACTTTGACGTCTG-3’; 
and inserted into the EcoRI-XhoI sites of the multiple cloning sites of pIRES. 
3.1.19 Generation of RII_AKAR3 and GIT1_AKAR3 
The pcDNA3-AKAR3 sensor was kindly provided by Prof Jin Zhang, 
(Department of Pharmacology and Molecular Sciences, John Hopkins 
University School of Medicine, Baltimore, USA). RII_AKAR3 was generated by 
inserting the docking domain of RII (1-49aa) in the HindIII site of the multiple 
cloning site of pcDNA3, in frame with the N-terminus of the original AKAR3.  
The fragment from amino acid 1 to amino acid 119 of GIT1 in pXJ40GST 
(kind gift from Prof Edward Manser and Dr Zhao S. Zhuoshen, GSK-IMCB 
Group, Institute of Molecular and Cell Biology, Singapore) was amplified using 
the primers: GIT1_BamHI_frw_long: 5’-CGCGGATCCATGTCCCGGAAGGGGCCG-3’ 
and GIT1_BamHI_rev_long: 5’-GCGGGATCCAAGCTTGTGCACAAACGCCAGC-3’ 
and inserted into the BamHI site of the multiple cloning site of pcDNA3, in 
frame with the N-terminus of the original AKAR3. 
3.1.20 Generation of mutRII-CFP 
The regulatory subunit of the RII-L20-CFP construct was mutated by 
introducing the mutation S114A using the QuickChange™ Site-directed 
Mutagenesis Kit (cat. n°200518, Stratagene) as described by the manufacturer 
with the primers: RII-P sense 5’-
CCGGTTCACAAGGCGTGCCGCGGTATGTGCAGAAGCTTATAATCC-3’ and RII-P 
antisense: 5’-GGATTATAAGCTTCTGCACATACCGCGGCACGCCTTGTGAACCGG-3’. 
3.1.21 Generation of dnPDE4D3mRFP 
The constructs for dnPDE4D3 was kindly provided by Prof Miles 
Houslay, (Neuroscience and Molecular Pharmacology, Wolfson Link & 
Davidson Buildings, University of Glasgow, Glasgow, UK). dnPDE4D3 contains 
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the mutation D484A that render it catalytically inactive (McCahill et al., 2005). 
The insert was amplified by PCR using the primers: PDE4D3_BstXI_frw: 5’-
CACTAGTCCAGTGTGGTGGATGATGCACGTGAATAATTTTCC-3’ and 
PDE4D3_BstXI_REV: 5’-
GCAGAATTCCACTGTGCTGGCGTGTCAGGAGAACGATCATCT-3’ and sub-cloned 
into the BstXI site of the multiple cloning site of pcDNA3.1/Hygro (+). The 
monomeric red fluorescent protein was then inserted into the XhoI-XbaI 
restriction sites of the multiple cloning sites of pcDNA3.1/Hygro (+), in frame 
with the C-terminus of dnPDE4D3.  
3.1.22 dnPDE4A4-GFP 
dnPDE4A4 in pCDNA3 was a kind gift from Prof Miles Houslay 
(Neuroscience and Molecular Pharmacology, Wolfson Link & Davidson 
Buildings, University of Glasgow, Glasgow, UK). dnPDE4A4 contains the 
mutation D591A that render it catalytically inactive (McCahill et al., 2005). 
3.2  Cell Biology 
3.2.1  Cell culture and transfection 
3.2.1.1  CHO cells 
CHO-K1 cells from Hamster Chinese ovary (Puck et al., 1958) are 
characterised by an epithelia morphology and adherent growth mode.  
Cells were grown in Ham’s F-12 medium (cat. n°21765-029, Invitrogen) 
supplemented with FBS (cat. n°10270106, Invitrogen) 10% v/v, 2 mM L-
glutamine (cat. n°25030- 24, Invitrogen), 1   U/ml penicillin and 1   μg/ml 
streptomycin (cat. n°P07081, SIGMA) at 37°C in a humidified atmosphere 
containing 5% CO2. 
3.2.1.2  SH-SY5Y cells 
SH-SY5Y cells from human neuroblastoma (Biedler et al., 1978) are 
characterised by a neuroblast morphology and adherent growth mode. 
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SH-SY5Y is a thrice cloned sub-line of the SK-S-SH line derived from 
bone marrow biopsy (Biedler et al., 1973). 
Cells were grown in Ham’s F-12:EMEM (cat. n°42430-025, Invitrogen) 
(1:1) supplemented with FBS 10% (v/v), 2 mM L-glutamine, non essential 
amino acids (cat. n°11140-035, Invitrogen) 1% (v/v), 100 U/ml penicillin and 
1   μg/ml streptomycin at 37°C in a humidified atmosphere containing 5% 
CO2. 
3.2.1.3  Thawing of cells 
Cells were thawed in a water bath at 37°C and added drop wise to 5 ml 
of pre-warmed medium, spun for 5 minutes at 1200 rpm (TTH-750 rotor type, 
speed max 4600 rpm, max RCF 4,570), re-suspended in fresh medium and 
seeded in a 75 cm2 flask containing 10 ml of the appropriate medium.  
3.2.1.4  Freezing of cells 
Cells were trypsinised (trypsin-EDTA 0.05%, cat. n°25300-054, 
Invitrogen), spun for 5 minutes at 1200 rpm (TTH-750 rotor type, speed max 
4600 rpm, max RCF 4,570), re-suspended in 3 volumes of FBS and 1 volume of 
freezing solution (DMEM, glucose 12% (w/v) and DMSO 40% (v/v)) added 
drop wise. Cells were then dispensed into 2 ml cryo vials and transferred to -
80°C for 24h. Cells were then stored in liquid nitrogen tank. 
3.2.1.5  Cell transfection 
Approximately 3x105 cells/well were plated on a 6-well plate in 
complete medium and grown for 24 hours. The transfection mix was prepared 
as follows: 6 l/well of TransIT®-LT1 Reagent (cat. n°M2300, Mirus) was 
added drop wise to 100 l/well of serum-free DMEM and incubated for 5 
minutes at room temperature. After incubation 2-4 g of DNA and/or 125 pmol 
of small interference RNA were added to the diluted TransIT®-LT1 Reagent 
and incubated for 15 minutes at room temperature. The TransIT®-LT1 
Reagent-DNA complex was finally added drop wise to the cells. Experiments 
were performed 24-48 hours after transfection. 
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3.2.2  Stable clone selection 
3.2.2.1  Antibiotics 
Zeocine™ (cat. n°450003, Invitrogen), Geneticin® (G418 Sulphate, 
neomycin) (cat. n°V7983, Promega) and Hygromycin B (cat. n°10 843 555 001, 
Roche). 
3.2.2.2  Dose-response curve 
Zeocine™  
To test the sensitivity of CHO cells to Zeocine™, a dose-response curve 
has been performed, as natural resistance to antibiotics varies among cells 
lines. Approximately 3x104 cells/well were plated and grown for 24 hours in a 
24 well plate. After 24 hours the medium was removed and replaced with 
medium containing increasing concentrations of Zeocine™ (0, 50, 100, 200, 
400, 600, 800 and 1000 g/ml). Every concentration was tested in duplicate. 
After 12 days of treatment a concentration of 300 g/ml of Zeocin™ was 
selected as the minimum amount of antibiotic required for selection of stable 
clones.  
Geneticin® (G418 Sulphate, neomycin) 
Approximately 3x104 cells/well of CHO cells stably expressing RII-CFP 
were plated in a 24 wells plate. After 24 hours of incubation medium was 
replaced with media containing increasing concentration of Geneticin® (G418 
Sulphate, neomycin) (0, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 and 
1100 g/ml). After 12 days of incubation a concentration of 800 g/ml was 
determined as the minimum amount of antibiotic necessary to select against 
untransfected cells. 
Hygromycin B 
Approximately 3x104 cells/well of CHO cells were plated in a 24 well 
plate. After 24 hours of incubation medium was replaced with medium 
containing increasing concentration of Hygromycin B (0, 100, 200, 300, 400, 
500, 600, 700, 800, 900, 1000 and 1100 g/ml). After 12 days of incubation a 
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concentration of 700 g/ml was determined as the minimum amount of 
antibiotic necessary to select against untransfected cells. 
3.2.2.3  Stable clone selection  
3.2.2.3.1  CHO stably expressing PKA-GFP 
Two 3 cm tissue culture dishes were seeded with approximately 105 
CHO cells per dish. 24 hours later one of the two dishes was transfected (see 
section 3.2.1.5) with pcDNA3.1/Zeo(+)RII-CFP subunit. The following day 
medium in both dishes was replaced with medium containing 300 g/ml of 
Zeocine™ and plates were incubated for an additional 12 days. During this 
period medium was replaced every 2 days with fresh medium. After 12 days 
non-transfected CHO cells had died whereas the transfected cells were starting 
to form foci. Colonies were then picked with a 200 l tip, limit diluted (dilution 
1 to 7 cells to well ratio), transferred into 96 well plates and grown until 
confluent. A single clone expressing high levels of RII-CFP was selected 
according to the brightness of the cells under an epifluorescence microscope 
upon excitation at 430 nm. 
Approximately 105 of CHO cells stably over-expressing RII-CFP subunit 
were plated in two 3 cm tissue culture dishes. After 24 hours one of the two 
dishes was transfected with pCDNA3 C-YFP. Selection with 800 g/ml of 
Geneticin® (G418 Sulphate, neomycin) was carried out analogous to the 
Zeocine™ selection. After limited dilution in a 96 well plate cells stably 
expressing both RII-CFP and C-YFP subunit were selected at the microscope 
upon direct excitation of CFP and YFP at 430 nm and 500 nm respectively. 
Where necessary a further limited dilution has been performed. 
3.2.2.3.2  CHO-RII_epac and SH-SY5Y-RII_epac 
As described for the selection of CHO cells stably expressing PKA-GFP, 
approximately 105 of CHO or SH-SY5Y cells were plated and transfected after 
24 hours with the RII_epac sensor. The following day medium was replaced 
with fresh medium containing 800 g/ml or 500 g/ml (Jang and Juhnn, 2001) 
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of Geneticin® (G418 Sulphate, neomycin) for CHO and SH-SY5Y cells 
respectively. A control sample of untransfected cells was included in each 
experiment. After 12 days of treatment cells were limit diluted and transferred 
to a 96 plate. Cells stably expressing the RII_epac sensor were selected at the 
microscope according to their brightness upon direct excitation of CFP and YPF 
at 430 and 500 nm, respectively. 
3.2.2.3.3  CHO-dnPDE4D3mRFP and CHO-dnPDE4A4-GFP 
Approximately 105 of CHO cells were plated and transfected after 24 
hours with dnPDE4D3mRFP or dnPDE4A4-GFP. The following day medium 
was replaced with fresh medium containing 700 g/ml of Hygromycin B or 
800 g/ml of Geneticin® (G418 Sulphate, neomycin) for cells transfected with 
the dnPDE4D3mRFP or with the dnPDE4A4-GFP respectively. A control sample 
of untransfected cells was included for each antibiotic used. After 12 days of 
treatment cells were limit diluted and transferred to a 96 plate. Cells stably 
expressing the dnPDE4D3mRFP or the dnPDE4A4-GFP were selected at the 
microscope according to their brightness upon direct excitation of RFP at 568 
nm or GFP at 500 nm.  
A further verification of the clones was carried out by retro-
transcription (see section 3.1.6) of total RNA extracted (see section 3.1.4) from 
the CHO-dnPDE4D3mRFP cells and amplification of the coding regions of 
dnPDE4D3mRFP using specific primers annealing on the D484A mutation 
(McCahill et al., 2005). Primers used are the following: PDE4D3frw911: 5’-
GGTAACCGGCCCTTGACTG-3’ and PDE4D3frw151 _wild_asp: 5’-
GGTTCTTCAGAATATGGTGCACTGTGCAGAT-3’ for the PDE4D3 wild type 
amplification; and PDE4D3frw911: 5’-GGTAACCGGCCCTTGACTG-3’ with 
PDE4D3frw151 _mut_ala: 5’-GGTTCTTCAGAATATGGTGCACTGTGCAGCA-3’ for 
dnPDE4D3 amplification. 
3.2.3  PDE4D knock-down  
Knock down of PDE4D was achieved by using a small interfering RNA 
oligonucleotide targeting the PDE4D gene (125nM final concentration) 
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(sequence: GAACUUGCCUUGAUGUACA, Thermo scientific Dharmacon) as 
previously described (Lynch et al., 2005). CHO cells were transfected using 
TransIT®-LT1 Reagent following the supplier’s instructions (see section 
3.2.1.5). Control experiments were carried out using siGLO® Red transfection 
indicator (125 nM) (cat. n°D-001630-02-20, Thermo scientific Dharmacon). 
3.3  FRET based analysis of cAMP  
Fluorescence resonance energy transfer occurs when two 
chromophores, a donor and an acceptor, with the appropriate distance, 
orientation and spectral properties are close enough for resonance energy 
transfer from the donor to the acceptor upon direct excitation of the donor 
(see section 1.6.3.2).  
Generally a FRET-based sensor for cAMP consists of a cAMP binding 
domain, which undergoes conformational changes upon cAMP binding, 
genetically fused to cyan fluorescence protein and yellow fluorescent protein. 
When cAMP concentration is low the two fluorophores are close enough for 
FRET to occur. Excitation of CFP (430 nm) results in the transfer of part of its 
excited-state energy to YFP that can in turn emit at its own emission 
wavelength (545 nm). Both CFP and YFP emission are collected. 
As far as the FRET-based sensors for cAMP used for this research are 
concerned the mechanism of activation is the following. When the intracellular 
cAMP concentration increases, the activation of the sensor and the subsequent 
conformational change will affect the distance and the orientation of the two 
fluorophores thereby decreasing the efficiency of energy transfer. In this 
situation YFP is too far to be excited and only CFP emission (480 nm) can be 
detected upon CFP excitation. Changes in FRET correlate with changes in cAMP 
concentration. 
FRET changes are measured as changes in the ratio between 480 
nm/545 nm upon excitation at 430 nm and expressed as the percentage of 
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increase of 480 nm/545 nm emission over the basal value of 480 nm/545 nm 
emission at the beginning of the experiment. 
3.3.1  Imaging set up 
A system for FRET imaging of cAMP in cultured live cells comprises of a 
wide field fluorescence microscope, a light source for excitation of CFP, a beam 
splitter or a filter wheel for simultaneous collection of CFP and YFP emission 
signals separately onto a digital camera and a computer to store the acquired 
images and to analyse the data. 
The characteristics of the FRET imaging system I used for the 
experiments presented here are as follows: 
Microscope: Olympus IX81 inverted microscope.  
In principle, both inverted and upright microscopes can be used for 
FRET imaging. Generally an inverted microscope is more flexible, since it 
allows to easily access to the sample for compound addition as well as 
insertion of manipulators or microelectrodes. 
Light source: Xenon Mercury mixed gas arc burner Intense peaks at 365, 
405, 436, 546, and 577 nm (MT-ARC/HG LG2076, Ushio). 
Generally excitation light must fall into the spectral window where CFP 
is excited selectively. The appropriate spectral range of excitation is between 
430 and 440 nm and such excitation can be obtained either with a 
monochromatic source or with a conventional mercury or xenon bulb. While 
monochromators can be tuned to the appropriate excitation wavelength, 
mercury or xenon bulbs need to be coupled to an appropriate long band-pass 
filter in excitation. Filter manufacturers (Chroma, Omega optical) provide filter 
sets with exciter, dichroic and emitter that are optimised for FRET 
measurements with CFP and YFP.  
Excitation Filters: CFP: excitation filter ET436/20x, dichroic mirror 
T455LP, (Chroma Technology). The filter ET436/20x transmits all 
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wavelengths above 436 nm to the dichroic mirror that reflects wavelength 
below 455 nm to the sample therefore exciting CFP at 430 nm. This dichroic 
also transmits wavelength longer than 455 nm to the beam splitter, thereby 
allowing emission of CFP at 480 nm and YFP at 545 nm to be separated. YFP: 
excitation filter ET500/30x, dichroic mirror T515LP (Chroma Technology). 
Emission Filters: CFP: emission filter ET480/40m; YFP: emission filter 
ET535/30m beam splitter: dichroic mirror 505DCLP, YFP emission 545 nm, 
CFP emission 480 nm (all from Chroma Technology). 
A beam splitter is an optical device that allows simultaneous collection 
of CFP and YFP emission images on the two halves of the chip of the digital 
camera. This device mounts a dichroic filter and two band-pass filters, within a 
single apparatus and is commercially available (Micro imager, Optical Insight). 
When light emitted by the samples reaches the dichroic filter it is split into two 
beams. Wavelengths shorter than 505 nm, including CFP emission at 480 nm, 
are reflected towards the CFP emission filter whereas wavelength longer than 
505 nm, including YFP emission at 545 nm, are transmitted and directed to the 
YFP filter.  
Alternatively, different solutions can be adopted to collect CFP and YFP 
emission separately. One possibility is to use a motorised, software controlled 
filter wheel that contains emission filters for CFP and YFP. In this case, each 
time point of the FRET measure is composed of two sequential pulses of 
excitation and acquisition of two sequential images, each with a different 
emission filter. Such a solution is flexible, since the same setup can mount 
several filters and can be used to image other fluorescent indicators and 
probes. On the other hand, CFP and YFP emission images will necessarily be 
collected with a delay, depending on the time required for the wheel to switch 
between the two. This problem is often negligible, but it might introduce 
artefacts in case the sample or the focal plane move during the lag time 
between the acquisition of the CFP and YFP images. Also, the total time 
required for the acquisition of each time point is doubled leading to increased 
photo-damage and hindering imaging at fast acquisition rates. 
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Albeit very expensive, another possible strategy is to equip the 
microscope with a dichroic filter to separate CFP from YFP emission channels 
that are then collected with two separate digital cameras.  
Objective: PlanApoN 60X/1.42 oil /0.17/FN26.5 
High NA optics allows to collect emission light efficiently with high 
resolution. 
Camera: ORCA AG (model C4742-80-12AG, Hamamatsu Photonics K.K., 
Made in Japan) and HAMAMATSU camera controller. 
A high sensitivity cooled charge-coupled-device (CCD) camera is usually 
preferred. 
Image acquisition and analysis: All the devices of the imaging system, 
such as the shutter on the excitation beam path, the motorised filter wheel (if 
present), and the digital camera must be software-controlled. 
Several commercial software packages are available and generally they 
allow image acquisition and offline image analysis and data processing. Image 
analysis can also be optimally performed with freely available open source 
software programmes (i.e. ImageJ, National Institutes of Health; Bethesda) 
(Evellin et al., 2004), (Mongillo et al., 2005), (Berrera et al., 2008). 
3.3.2  FRET experiment 
CHO and SH-SY5Y cells stably or transiently expressing a FRET-based 
cAMP sensor were used to monitor the basal intracellular cAMP concentration 
and changes in cAMP concentration upon addition of cAMP raising agents.  
3.3.2.1  Procedure 
A FRET experiment consists basically of three steps: 
1. Sample preparation 
2. Data acquisition 
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3. Data analysis 
3.3.2.2  Sample preparation 
48 hours before FRET analysis cells are seeded on a 24 mm cover-slip at 
30% confluence.  
24 hours later cells will reach 60% of confluence and are ready to be 
transfected with the appropriate cAMP FRET-based sensor (see section 
3.2.1.5).  
Cells were imaged 24 hours after transfection. The cover-slip is mounted 
in ring metal slide holders sealed at the bottom that allow addition of stimuli 
directly to the bath (Figure 3-1). CHO cells were maintained in D-PBS solution 
(cat. n°14190-094, Invitrogen) at room temperature (20-22°C) whereas 
experiments on SH-SY5Y cells were performed in Hank's buffered salt solution 
(HBSS: 137 mM NaCl, 5mM KCl, 0.6mM Na2HPO4, 5.5mM glucose, 20 mM 
HEPES, 1.4 mM CaCl, pH 7.4)  at room temperature (20-22°C). 
 
 
Figure 3-1 Representation of the slide holder used for live fluorescence imaging 
experiments. 
3.3.2.3  Data acquisition 
Before starting the actual time-course experiment a standard protocol 
for all series of experiments has to be designed with respect to exposure time, 
frequency of acquisition, number of acquisitions and camera binning.  
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3.3.2.3.1  Exposure Time 
This is the time during which the sample is illuminated and the camera 
acquires CFP and YFP signals. Optimal exposure time depends on the 
expression levels of fluorophores as well as the characteristics of the lamp, the 
optics and the camera. Usually the exposure time is between 50 and 300 ms 
according to the brightness of the sample to be imaged. A good rule of thumb is 
to aim at generating images with signal to noise ratio >3. Experiments in this 
thesis have been acquired with a 200 ms exposure time. 
3.3.2.3.2  Setting the Time course and Number of Acquisitions 
The frequency of acquisition corresponds to the time between two 
consecutive acquisitions. Normally it is between 2 and 60 seconds and depends 
on the sensor characteristics and the kinetics expected. Shorter intervals have 
to be used for rapid and transient responses. During this interval the shutter 
controlling the incident light has to be closed to avoid photo-damaging of cells 
and photo-bleaching of the fluorophores. For the experiments presented here 
the frequency of acquisition was 10 sec. 
3.3.2.3.3  Camera Binning 
Camera binning is the process through which a CCD (charged-coupled 
device) camera clocks multiple pixel charges into a single larger super-pixel. 
This super-pixel represents the area of all individual pixels contributing to the 
charge. A binning of 1x1 means that each individual pixel is used as such 
whereas a binning of 2x2 means that an area of 4 adjacent pixels is combined 
into one larger pixel, and so on. This process can improve the signal to noise 
ratio at the expense of spatial resolution. For example, in the case of 2x2 
binning there is a four-fold increase in signal (the four single pixel 
contributions), a two-fold loss in resolution and a two-fold improvement in 
signal-to-noise ratio. 
Experiments in this thesis have been acquired with binning 1x1. 
Chapter 3 Materials and Methods 
95 
 
At this point it is possible to run the actual experiment and record the 
time-course. 
During the experiments the chosen cell is excited at 430 nm (CFP 
excitation wavelength, donor) and the emission of CFP (480 nm) and YFP (545 
nm, acceptor) are collected by the camera on the two halves of the camera chip. 
Most packages of software allow the live display of the mean 
fluorescence intensity of each channel as well as the ratio (480 nm/545 nm) 
changes. Following these kinetics it is possible to estimate when the ratio 
signal is stable (normally after about 20 acquisitions). Once the signal is 
stabilised it is possible to add the stimulus to the cells in order to perturb the 
intracellular cAMP concentration. Further stimuli can be added to the cell 
every time a new plateau has been reached. 
3.3.2.4  Data analysis 
After data acquisition, the collected images are software-processed.  
Our set up is equipped with a beam-splitter. This means that the FRET 
experiment is stored as a stack of images combining the information for CFP 
and YFP fluorescence intensity changes.  
The first step of the analysis is to split and align CFP and YFP images, in 
order to obtain two distinct and super-imposable movies (one each intensity 
channel).  
The second step is to draw regions of interest (ROIs) on the background 
and in the cells (different cell compartments can be analysed by drawing 
different ROIs) (Figure 3-2). Figure 3-2 shows how cytosol and centrosome 
within the same cell have been analysed for FRET changes in the experiments 
presented in this thesis. 
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Figure 3-2 CHO cell stably expressing the PKA-GFP sensors. Black line represents a 
typical region of interest (ROI) drawn on the cytosol;grey line represents a typical 
region of interest (ROI) drawn around the centrosome. Bar 10 µm. 
At this point mean intensities values are calculated for each ROI from 
both stacks (CFP and YFP). Numerical values, exported in excel, are processed 
in this way: 
1. The background noise is subtracted (mean intensity value of the ROI 
drawn on the background) from each mean intensity value of the ROIs drawn 
inside the cell, both for CFP and YFP intensity. This operation serves to remove 
the out-of-the-cell fluorescence and the intrinsic electronic noise of the camera, 
reducing artefacts and increasing the dynamic range of the measurement. 
2. The ratio (R) between CFP and YFP mean intensity values is calculated 
for each frame. The value of each pixel in the ratio movie corresponds to the 
CFP/YFP ratio in the corresponding pixels of the raw images. Such a ratio-
metric movie is normally displayed in pseudo-colour, according to a user-
defined lookup table that assigns a different colour to each ratio value. 
3. The kinetic of the ratio is plotted and the FRET change is calculated as 
follows: 
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Where R(t0) corresponds to the basal FRET level and mathematically is 
the average of all ratio values before the addition of the stimulus; whereas R(t1) 
is the average of the five data points after the plateau is reached for the 
corresponding stimulus. 
Ratio-metric calculation helps to correct for focus changes and for 
unequal distribution of the probe, as well as for bleaching of the fluorophores 
occurring during the time course experiment. However, FRET changes can be 
considered reliable only when donor and acceptor emission kinetics are 
divergent, i.e. an increase in CFP emission must be accompanied by a decrease 
in YFP emission. 
A fundamental problem of wide-field fluorescent microscopy is the 
partial overlapping of excitation and emission spectra. As a consequence the 
FRET signal will always be affected by direct excitation of the YFP acceptor at 
the donor CFP excitation wavelength and by CFP emission into the YFP 
channel.  
When static FRET (i.e. basal FRET ratio) instead of dynamic FRET 
changes have to be assessed it is possible to generate a correction curve to 
clean up the signal and increase the differences. Direct excitation of YFP at the 
CFP excitation wavelength can be quantified by the ratio between emission at 
545 nm upon excitation at 430 nm and 500 nm of cells over-expressing YFP 
only. The “bleed-through” of CFP emission into the YFP channel instead can be 
estimated as the ratio between YFP and CFP emission channel intensity in cells 
expressing CFP only, on excitation of CFP. In our system about 50% of CFP 
emission bleeds through into the YFP channel. 
In this thesis numerical values of the basal FRET ratio measured in the 
cytosol (R0cyt) and at the centrosome (R0centr), and presented in chapter 4, were 
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expressed as normalised as respect to the cytosol basal FRET ratio value 
(R0cyt). Thus the plotted values are: 
 
 
3.3.2.5  Statistics 
Data are presented as mean  standard error (SEM). Two tailed paired 
and un-paired Student’s t-tests were used to determine significance between 
groups. One-way ANOVA test was used to compare means from multiple 
samples. Number of replicates and the type of Student’s t-test used are 
indicated in the text. Asterisks are used to indicate levels of significance based 
on p-values:  p<0.05;  0.05<p<0.01;  p<0.001. 
3.3.3  Stimuli and reagent 
Forskolin (cat. n°F6886), Rolipram (cat. n°R6526), Cilostamide (cat. 
n°C7971), EHNA (cat. n°E114), H-89 (cat. n°B1427) were purchased from 
SIGMA. Caliculyn A (cat. n 1336) was purchased from TOCRIS. 
3.4 Biochemistry 
3.4.1  Western Blotting 
3.4.1.1  SDS-PAGE (sodium dodecyl sulphate 
Polyacrylamide gel electrophoresis) 
3.4.1.1.1  Sample preparation  
CHO cells or PKA-GFP stable clones were seeded on 10 cm tissue culture 
dishes, treated as indicated and washed twice with ice cold D-PBS before cell 
lyses. 
Cell lysates were prepared in lysis buffer containing 25 mM Hepes, pH 
7.5, 2.5 mM EDTA, 50 mM NaCl, 30 mM sodium pyrophosphate, 10% (v/v) 
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glycerol and 1% (v/v) Triton X-100 (cat. n°1 6K 177, SIGMA) and Complete™ 
EDTA-free protease inhibitor cocktail tablets (cat. n°11836170001, Roche). 
Protein concentration was quantified using the Bradford Protein Assay (cat. 
n 500-0006, Biorad) (Nguewa et al., 2011). Equal amounts of protein were 
mixed with lithium dodecyl sulphate sample buffer (LDS, NuPAGE LDS cat. 
n°NP00084, Invitrogen) and 1, 4-Diothiothreitol (DTT, 100mM) and boiled at 
75°C for 10 minutes. 
3.4.1.1.2  Gel electrophoresis and immuno-blotting 
Proteins were separated by gradient gel electrophoresis on NuPAGE 
Novex 4-12% Bis-Tris gels, 1 mm thickness (cat. n°NP0321BOX, Invitrogen), 
and transferred to Polyvinylidene fluoride (PVDF) membranes (Millipore). 
Membranes were then blocked either with Protein-Free T20 (TBS) 
Blocking Buffer (cat. n°37571, Thermo Scientific) or 5% (w/v) skimmed milk 
in TBS-T for 1 hour at room temperature. 
3.4.1.1.3  Primary Antibodies 
The following antibodies were used to probe the membranes: Purified 
Mouse Anti-PKARII (cat. n°610625, BD Transduction Laboratories™), Purified 
Mouse Anti-PKARII (pS114) (cat. n°612550, BD Transduction Laboratories™), 
goat pan-PDE4D (kind gift from Prof Miles Houslay, Neuroscience and 
Molecular Pharmacology, Wolfson Link & Davidson Buildings, University of 
Glasgow, Glasgow, UK) and goat Anti -tubulin (C-20) (cat. n°sc-7396, Santa 
Cruz). Primary antibodies were diluted to the appropriate concentration either 
in TBS-Tween (cat. n°P7949, SIGMA) or in 1% skimmed milk (w/v) in TBS-T 
and incubated overnight at 4°C. 
3.4.1.1.4  Secondary Antibodies 
The species specific secondary antibodies were HRP conjugated. 
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Secondary antibodies were diluted to the appropriate concentration 
either in TBS-Tween or in 1% skimmed milk (w/v) in TBS-T and incubated for 
1 hour at room temperature. 
3.4.1.2  Detection and quantification 
Western blots were detected on X-ray film following enhanced 
chemiluminescent (ECL) reaction (cat. n°P34080, Pierce Protein Research 
Products). After image scanning, intensity quantification of the bands was 
performed using ImageJ software (National Institutes of Health, Bethesda). 
Results, representing the mean of at least three independent experiments, 
were normalised to the amount of the structure protein -tubulin. This practice 
ensures correction for the amount of total protein on the membrane in case of 
loading errors or incomplete protein transfers. 
3.4.2  Immunostaining and Confocal Imaging 
CHO cells stably expressing PKA-GFP sensor was washed three times 
with ice cold D-PBS. The centrosome was exposed by treatment with PHEM 
solution (45 mM Pipes, 45 mM HEPES, 10 mM EGTA, 5 mM MgCl2, 1 mM PMSF 
and 0.1% (v/v) Triton X-100, pH 6.9) for 30 seconds at room temperature. 
Cells were then fixed with ice cold methanol for 5 minutes at -20°C, washed 
twice in PBS and saturated in 3% BSA for 30 minutes at room temperature. 
Primary antibodies were diluted in 3% BSA and incubated over night in a wet 
chamber. CTR453 (a kind gift from Dr Guy Keryer Institut Curie, Orsay F-
91405, France), a centrosome specific monoclonal antibody raised in mouse 
was used at a 1:5 dilution, rabbit anti-PDE4D3 (kind gift from Prof Miles 
Houslay, Neuroscience and Molecular Pharmacology, Wolfson Link & Davidson 
Buildings, University of Glasgow, Glasgow, UK) was used at a 1:500 dilution 
and goat anti -tubulin (C-20) (cat. n°sc-7396, Santa Cruz) was used at 1:2000. 
Goat anti-mouse AlexaFluor® 568 (cat. n°A11004, Invitrogen), goat anti-rabbit 
AlexaFluor® 568 (cat. n°A11011, Invitrogen) and donkey anti-goat 
AlexaFluor® 488 (cat. n°A11055, Invitrogen) were used as secondary 
antibodies. Control cells were stained for the secondary antibody only. 
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Confocal images were acquired with a Nikon Eclipse TE300 inverted 
microscope equipped with a spinning disk confocal system (Ultraview LCI; 
PerkinElmer), a 60×1.4 NA PlanApo objective (Nikon) and an Orca ER 12-bit 
CCD camera (Hamamatsu Photonics, Hamamatsu City, Japan). Cells were 
excited using the 568 nm laser line of a 643 series Argon-Krypton-Laser Melles 
Griot (643-Ryb-A02; Melles Griot) for imaging of the AlexaFluor568 
fluorophore and the 405 nm line of a diode laser (iFlex2000; Point Source) for 
imaging CFP. The emission filters were 607/45 for the red emission and 
480/30 for the cyan emission, respectively. 
3.5  Flow cytometry scan analysis of cell cycle 
distribution of a cell population using 
Propidium Iodide 
This assay exploits the properties of Propidium iodide (PI), a water 
soluble DNA intercalator, to bind and dye DNA after cell permeabilisation. After 
staining, cells are analysed on a flow cytometer. The amount of dye correlates 
with the amount of DNA inside the cell and the relative content of DNA 
indicates the distribution of a cell population throughout the cell cycle. The 
content of nuclear DNA changes throughout the cell cycle. Cells in the G0/G1 
phases of the cell cycle are diploid and have a DNA content of 2n. Cells within 
the G2/M phases have a DNA content of 4n, while S-phase cells have DNA 
content greater than 2n and less than 4n. Accordingly, cells in G2/M will have 
twice the fluorescence intensity of cells in G1 and cells in S will have 
fluorescence values between the G1 and G2/M population. The resulting 
histogram will show two Gaussian curves, for the G1 and G2/M population 
respectively, overlapped and connected by the area representing the S-phase 
population.  
Approximately 106 of cells were grown with or without 5 M forskolin in 
a T75 flask for 48 hours. After 48 hours exponentially growing cells were 
trypsinised, washed twice with D-PBS, and re-suspended in 300 l of D-PBS. 
700 l of ice-cold 70% (v/v) EtOH/PBS was added drop-wise and the samples 
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were incubated at 4°C for 1 hour. After incubation cells were spun down (TTH-
750 rotor type, speed max 4600 rpm, max RCF 4,570), washed with 1 ml of D-
PBS and then re-suspended in 250 l of D-PBS containing 5 l of 10 mg/ml 
RNAaseA (Ribonuclease A cat. n°R6513, SIGMA) and incubated for 1 hours at 
37°C. Finally samples were stained with 5 l of 1 mg/ml of PI (Propidium 
iodide cat. n°P4864) and kept in the dark at 4°C until analysis. 
Flow cytometry scan analysis (FACS) has been done by using a 
FACSCalibur flow cytometer (Becton Dickinson). 104 cells in the FCS/SSC gate 
were scanned for each sample. No more than 400 events per seconds were 
collected. The plot of the width versus the area of the pulse (FL2-A versus FL2-
W dot plot) was used to discriminate the single cell population from aggregate 
and debris subpopulations. Single cells will have a similar pulse width whereas 
doublets will show a larger width of the pulse and thus can be easily 
distinguished from the single cell region. 
Data collected have been analysed with FlowJo software and compute 
with "Dean-Jett-Fox” model.  
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4 The centrosome is a subcellular 
domain characterised by low basal cAMP 
levels 
Background: 
3’,5 cyclic adenosine monophosphate (cAMP) is a ubiquitous cyclic 
nucleotide that has been described as the first second messenger (Rall and 
Sutherland, 1958), (Ashman et al., 1963). cAMP is responsible for a large 
number of cellular effects and regulates multiple biological functions including, 
among others, learning and memory, immune response, insulin secretion, 
cardiac frequency and strength of contraction, ion channel conductivity, 
synaptic release of neurotransmitters, cell growth, cell differentiation and gene 
transcription (Friedman, 1976), (Abel and Nguyen, 2008) (Colledge et al., 
2000) (Serezani et al., 2008) (Rall and Sutherland, 1959). The intracellular 
level of cAMP depends on the activities of two families of enzymes: adenylyl 
cyclases (ACs), the only enzymes that generate cAMP and phosphodiesterases 
(PDEs), proteins capable of degrading cAMP into 5’-AMP. The principal effector 
of cAMP is the cAMP-dependent protein kinase (PKA), which can 
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phosphorylate hundreds of cellular targets. Such targets may be localised at 
the plasma membrane or other internal membranes, may be soluble in the 
cytosol or localised in the nucleus and the PKA-mediated phosphorylation of 
these diverse targets is responsible for an array of different cellular functions. 
In other words, an enormous amount of information is encoded into the 
changes of one single intracellular signal, cAMP. This scenario has raised the 
question of how specificity is achieved in the cAMP/PKA signalling pathway. A 
simple concentration gradient of the second messenger does not appear to be 
adequate to account for the specificity and diversity of the intracellular 
transduction events that depend on cAMP. Recent studies have uncovered a 
sophisticated array of regulatory mechanisms that allow for a tight control of 
signalling both in time and space and the notion of spatio-temporal 
compartmentalisation of cAMP is now well accepted (Steinberg and Brunton, 
2001). 
A critical role in the spatial control of the cAMP/PKA signal transduction 
events is played by A-Kinase Anchoring Proteins (AKAPs), which, by anchoring 
PKA, PDEs and other specific signalling enzymes in distinct subcellular 
domains, nucleate macromolecular signalling complexes that may generate 
spatially restricted pools of cAMP. For example it has been shown that in 
cardiomyocytes mAKAP anchors PDE4D3 and PKA in the perinuclear region. 
This organisation results in a negative feed-back loop mechanism in which an 
increase in cAMP activates the mAKAP-anchored PKA; in turn, active PKA 
phosphorylates and activates the mAKAP-anchored PDE4D3 which then 
degrades cAMP more efficiently. Such a feedback loop has profound effects on 
the local functions of PKA as it generates local fluctuations in cAMP and pulses 
of compartmentalised PKA activity (Dodge-Kafka et al., 2005). 
The centrosome is a small non-membranous organelle whose primary 
role is to nucleate and organise the microtubules network (Doxsey, 1998), 
(Abal et al., 2002), (Bornens, 2002). Three AKAPs have been identified at the 
centrosome: hAKAP220 (Michel and Scott, 2002), pericentrin (Diviani et al., 
2000), and AKAP450 (Witczak et al., 1999). The existence of multiple AKAPs 
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that anchor PKA to the centrosome suggests that the cAMP/PKA signals may 
have an important role in the regulation of centrosomal functions and that 
specific, local control of such signal may be critical for correct activity. In 
addition, the apparent redundancy of PKA anchoring to the centrosome may 
reflect the necessity to achieve a high level of compartmentalisation of PKA 
activity at this site (Diviani and Scott, 2001). 
Pericentrin is a component of the pericentriolar matrix and forms a 
centrosomal macromolecular complex with -tubulin (Dictenberg et al., 1998) 
and dynein (Purohit et al., 1999). Pericentrin and AKAP450 share a high degree 
of homology and a common centrosomal-targeting region, named PACT 
domain (Gillingham and Munro, 2000). Interestingly two opposite evidence 
have been shown upon over-expression of the AKAP450-PACT domain. In one 
case over-expression of AKAP450-PACT domain displaces pericentrin 
indicating competition between pericentrin and AKAP450 for a shared binding 
site (Gillingham and Munro, 2000), in another case over-expression of specific 
AKAP450-PACT domain displaces AKAP450 but not pericentrin, indicating a 
specificity in the targeting of both AKAPs (Keryer et al., 2003b).  
While the role of pericentrin has been correlated to the correct 
microtubule nucleation in interphase and spindle formation in mitosis (Purohit 
et al., 1999) (Young et al., 2000) (Doxsey et al., 1994), the role of AKAP450 at 
the centrosome is largely unknown and no information is available on the 
dynamics of cAMP in this subcellular compartment, on the mechanisms that 
regulate activation of the PKA subsets anchored to AKAP450 and/or on the 
role of PDE4D3 localised at this site. 
Hypothesis: 
The leading hypothesis of my research project is that the centrosomal 
subcellular compartment represents a domain where cAMP dynamics are 
uniquely regulated. Based on this hypothesis the first aim of my work was the 
analysis of cAMP levels in the centrosomal area in intact, unstimulated cells.  
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Experimental procedure: 
1) Generation of two different stable clones expressing the 
genetically encoded FRET based sensors PKA-GFP (Zaccolo 
and Pozzan, 2000) or RII_epac (Di Benedetto et al., 2008). 
2) Validation of the localisation of the sensors PKA-GFP and RII_epac 
to endogenous centrosomal AKAPs. 
3) Analysis of cAMP levels in the centrosomal region and 
comparison with cAMP levels in the bulk cytosol using FRET-
based imaging. 
4) Analysis of the role of centrosomal PDE4D3 in determining basal 
cAMP levels in the centrosomal area. 
4.1  Results 
4.1.1  Generation of a CHO clone stably expressing a 
FRET sensor based on PKA (PKA-GFP)  
Chinese hamster Ovary (CHO) cells (see section 3.2.1.1) were selected as 
the experimental model due to their morphology that allows to easily inspect 
the centrosome at the epifluorescence microscope. In order to analyse cAMP 
levels in the centrosomal region of intact and non-synchronised cells I 
performed real-time imaging of cAMP using a FRET biosensor based on PKA 
(Zaccolo and Pozzan, 2000). The sensor was stably expressed in CHO cells. One 
of the most important advantages of FRET-based real-time imaging of cAMP is 
that it allows to monitor local cAMP signals in intact living cells. Recently a 
large number of FRET based sensors for cAMP have been developed that are 
either cytosolic or targeted to specific subcellular compartments, providing a 
varied toolkit for real-time study of cAMP dynamics (see section 1.6.3.2). The 
choice to use the PKA-GFP sensor was based on two considerations. First of all 
this reporter can naturally anchor to endogenous AKAPs, allowing the direct 
visualisation of cAMP levels in the microenvironment surrounding AKAPs; 
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second, the PKA-GFP sensor is catalytically active and thereby offers the 
possibility to further investigate specific mechanism related to PKA activation 
at the centrosome.  
The PKA-GFP probe comprises the regulatory (RII) and the catalytic (C) 
subunits of PKA genetically fused to the cyan (CFP) and the yellow mutants 
(YFP) of the green fluorescent protein (GFP), respectively (see section 
1.6.3.2.1). When the intracellular concentration of cAMP is low the two 
subunits in the inactive PKA holoenzyme are close enough for FRET to occur. 
When the cAMP concentration rises, two cAMP molecules bind to each 
regulatory subunit promoting the release of the catalytic subunits and a 
concomitant decrease in FRET. FRET changes therefore correlate with changes 
in intracellular cAMP concentration (see section 1.6.3.2.1) (Zaccolo and 
Pozzan, 2000). 
In order to generate a stable clone expressing both the regulatory 
subunit and the catalytic subunit of PKA-GFP the RII-CFP subunit (Lissandron 
et al., 2005) was sub-cloned into the vector pCDNA3.1/Zeo (+), that allows 
stable expression in mammalian cells using Zeocine™ as a selective antibiotic 
(Drocourt et al., 1990), (Mulsant et al., 1988). As natural resistance to 
antibiotics varies among cells lines it was necessary to test the sensitivity of 
CHO cells to Zeocine™. To this end I determined a dose-response curve for 
Zeocine™ from which the concentration of 300 g/ml of Zeocin™ resulted to be 
the lowest concentration required for untransfected CHO cells to die. Using the 
pcDNA3.1/Zeo(+)RII-CFP subunit and the Zeocine™ concentration determined 
by the dose-response curve, a stable clone in CHO cells was established (see 
section 3.2.2.2). I further used these cells for the selection of a stable clone 
over-expressing also the C-YFP subunit. The C-YFP subunit was inserted in the 
pCDNA3 vector, which contains the gene coding for resistance to Geneticin® 
(G418 Sulphate, neomycin). As described in the material and methods (see 
section 3.2.2.2), I performed a dose-response curve by using cells stably 
expressing RII-CFP. After treating the cells for 12 days with media containing 
increasing concentration of Geneticin® the concentration of 800 g/ml was 
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determined as the minimum amount of antibiotic necessary to select against 
cells not expressing the C-YFP protein. The resultant clone stably express both 
subunits of the PKA-GFP sensor (Figure 4-1)(Vaasa et al., 2010). 
 
 
Figure 4-1 CHO stably expressing the PKA-GFP sensor. The two panels show the signal 
generated by the RII-CFP (left panel) and C-YFP (right panel) subunit in interphase 
cells A) and mitotic cells B). The arrows point to the centrosome A) and centrioles B). 
The region of the cell in which the fluorescent signal of the probe is excluded is the 
nucleus in interphase cells A) and the metaphasic plate in mitotic cells B). Bars 10m. 
4.1.2  The PKA-GFP FRET sensor localises to the 
centrosome in CHO cells via binding to 
endogenous AKAPs 
Fluorescence microscopy analysis revealed that interphase CHO cells 
stably expressing the PKA-GFP sensor exhibited a clear localisation of the 
probe in proximity to the nucleus, suggestive of localisation to the centrosome. 
In a number of cells it was possible to clearly recognise two orthogonally 
arranged structures that could represent the two centrioles (Figure 4-2 ). 
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Figure 4-2 Detail of a CHO cell stably expressing the PKA-GFP sensor (left panel) and 
imaged at the confocal microscope. The cell shows a clear localisation of the sensor in 
correspondence of a perinuclear structure in which it is possible to recognise two 
elements organised orthogonally to each other. Bar 10m; and schematic 
representation of a centrosome (right panel). 
In mitotic cells, the sensor clearly localises in two separate spots 
positioned on the opposite sides of the metaphasic plate, recognisable as a 
central area in which the fluorescent signal of the probe is excluded due to the 
presence of the condensed and aligned chromosomes (Figure 4-1, B). 
To assess if the localisation of the sensor corresponds to the 
centrosomal area I performed an immunostaining using an antibody for -
tubulin as a centrosome-specific marker. In the same cells the localisation of 
AKAP450 was assessed by using CTR453, an antibody that specifically 
recognised AKAP450 (Keryer et al., 2003a), (Bailly et al., 1989). As shown in 
Figure 4-3, PKA-GFP clearly co-localises with both -tubulin and AKAP450 
(Figure 4-3). 
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Figure 4-3 Immunostaining of CHO cells stably expressing the PKA-GFP FRET sensor. 
Images show co-localisation of RII-CFP with CTR453 (antibody specific for AKAP450), 
top panel; and with -tubulin (specific marker for centrosome) middle panel. 
Secondary antibody (nc) control in the bottom panel. The signal from the C-YFP 
component of the sensor is not shown. Bars 10m. 
Next, I set out to establish if the observed localisation of the PKA-GFP 
sensor to the centrosome was due to anchoring of the GFP-tagged PKA to the 
endogenous centrosomal AKAPs. To this end “green fluorescent protein”-
tagged versions of the AKAP-competing peptides RIAD (Carlson et al., 2006) 
and SuperAKAP-IS (Gold et al., 2006) were used. These peptides have been 
shown to compete selectively with the binding to endogenous AKAPs of 
regulatory subunit type I (RI) and type II (RII), respectively. In particular, the 
RIAD peptide was shown to have more than 1000-fold selectivity for RI over 
RII (Carlson et al., 2006) whereas the peptide SuperAKAP-IS was shown to be 
10000-fold more selective for the RII isoform relative to RI (Gold et al., 2006). 
Due to the spectral overlap between GFP signal from the tagged competing 
peptides and the signal from the tagged sensor subunits this experiment was 
performed using a red fluorescent protein (RFP)-tagged version of the RII 
subunit that had been previously generated in our laboratory (see section 
3.1.13) (Di Benedetto et al., 2008). RII-RFP was co-expressed in CHO cells in 
combination with either SuperAKAP-IS-GFP or RIAD-GFP. As shown in Figure 
4-4, cells over-expressing both SuperAKAP-IS and RII-RFP, show no 
localisation of RII-RFP to the centrosome (Figure 4-4, top panel, cell in the left 
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end side), whereas a cell in the same field expressing only RII-RFP and not 
SuperAKAP-IS-GFP clearly shows a centrosomal localisation of RII-RFP (Figure 
4-4, top panel, cell on the right). On the contrary over-expression of RIAD did 
not affect the localisation of RII-RFP to the centrosome (Figure 4-4, bottom 
panels). 
 
 
Figure 4-4 CHO cells over-expressing RII-RFP (upper and lower panel on the left) in 
combination with SuperAKAP-IS-GFP (right upper panel) or RIAD-GFP (right lower 
panel). The arrows point to the centrosome. Bars 10m. 
These findings indicate that the specific localisation of the PKA-GFP 
sensor is due to the binding of the RII subunit to the endogenous AKAPs, as 
previously shown in cardiomyocytes (Zaccolo and Pozzan, 2002). The fact that 
SuperAKAP-IS, and not RIAD, compete for the binding of the sensor to the 
centrosome confirms that the localisation is specific and possibly mediated by 
centrosomal AKAPs. Interestingly both AKAP450 and pericentrin have been 
described as RII-specific AKAPs.  
4.1.3  A microdomain with low cAMP concentration at 
the centrosome 
Expression of the PKA-GFP FRET indicator in CHO cells offers the 
possibility to examine the relative level of cAMP in the centrosomal area 
compared to the bulk cytosol. As explained in detail in the Material and 
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Methods (see section 3.3), the FRET signal is expressed as the ratio of the CFP 
emission intensity over the YFP emission intensity (CFP/YFP) upon excitation 
of the cell at 430 nm. A pseudo-colour image of the cell expressing the FRET 
reporter can be generated by calculating, pixel by pixel, the value of the 
CFP/YFP emission intensity and by assigning to each pixel a colour according 
to a pre-defined colour scale. In the example below and throughout my thesis, 
red indicates high cAMP and green/blue indicates low cAMP. Figure 4-5 shows 
a representative example of a pseudo-colour image of a resting CHO cell stably 
expressing the PKA-GFP reporter. As evident from the differences in colour, the 
cAMP level at the centrosome is lower than the average cAMP level in the bulk 
cytosol (blue/green colour in the area corresponding to the centrosome 
compared to the yellow/red colour in the area corresponding to the cytosol, 
see section 3.3.2.4 and Figure 3-2 for details of how the analysis was 
performed). 
 
 
Figure 4-5 RII-CFP signal and pseudo-colour image of a CHO cell stably expressing the 
PKA-GFP sensor. The signal generated by the C-YFP component of the PKA-GFP sensor 
is not shown. On the left, a higher magnification of the cell area delimited by the white 
box is shown. Bar 10m. 
Statistical analysis of all the observed cells revealed a difference in basal 
ratio (CFP/YFP emission) between cytosol and centrosome of about 2.04%, 
with a centrosomal ratio expressed as normalised value with respect to the 
cytosol of R0/R0cyt=0.980±0.004 (mean±SEM; n=34) (see section 3.3.2.4 for 
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analysis details) (Figure 4-6). Paired T-test analysis shows that the difference 
in the ratio values detected in the two subcellular compartments is statistically 
significant (p<0.001).  
 
.  
Figure 4-6 Summary of the CFP/YFP ratio values recorder in the bulk cytosol and in the 
centrosome of cells stably expressing the PKA-GFP sensor. Data are normalised to the 
ratio value in the cytosol. (Error bar represents SEM. Two tailed; paired t-test, *** 
p<0.001). 
4.1.4  Generation and characterisation of a stable 
clone expressing the RII_epac cAMP sensor. 
The C-YFP component of the PKA-GFP sensor is catalytically active 
hence there is a possibility that over-expression of this sensor may lead to an 
increased phosphorylation of PKA targets, including PDEs responsible for 
cAMP degradation, thereby affecting the cAMP dynamics under investigation. 
To exclude the possibility that the lower cAMP level detected at the 
centrosome of resting CHO cells may be an artefact due to the over-expression 
of the catalytically active PKA-GFP sensor and not to a physiological condition 
of the cell I set out to monitor centrosomal cAMP levels using the sensor 
RII_epac (Figure 4-7) (Di Benedetto et al., 2008). RII_epac is a FRET-based 
unimolecular sensor for cAMP based on Epac1-camps (Nikolaev et al., 2004) 
which has been modified in our laboratory by fusing the dimerisation/docking 
domain (D/D) of the RII subunit of PKA to the N-terminus (see section 
3.1.12). This sensor is therefore capable of anchoring to endogenous AKAPs, 
similarly to the RII-CFP subunit, but is devoid of any catalytic activity (Figure 
4-7) (Di Benedetto et al., 2008). 
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Figure 4-7 Schematic representation of RII_epac sensor. D/D=PKA-RIIβ dimerization 
docking domain; CFP=cyan variant of the green fluorescent protein (GFP); cAMP 
BD=cAMP binding domain of Epac1; YFP=yellow variant of the green fluorescent 
protein. 
In order to select cells stably expressing RII_epac, the sensor was cloned 
into pcDNA3 vector containing the gene coding for Geneticin® (G418 Sulphate, 
neomycin) resistance. CHO cells were transfected with RII_epac and cultured in 
medium containing the amount of antibiotic established by the antibiotic dose-
response curve for Geneticin® (see section 3.2.2.2 and 3.2.2.3.2). As expected, 
upon inspection at the fluorescence microscope, these cells showed a clear 
localisation of the probe to the centrosome of interphase cells (Figure 4-8). 
 
 
Figure 4-8 CHO stably expressing the RII_epac sensor. The two panels show the signal 
generated by the CFP (left panel) and YFP (right panel) emission. The arrows point to 
the centrosome. Bar 10m. 
Next, I used this stable cell line to monitor cAMP levels in the cytosol and 
at the centrosome within the same cell. Similar to what I found with the PKA-
GFP sensor, FRET analysis of CHO cells stably expressing the RII_epac sensor 
showed a lower CFP/YFP ratio value at the centrosome compared with the 
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cytosol. The centrosomal ratio expressed as normalised value with respect to 
the cytosol was R0/R0cyt=0.961±0.006, corresponding to a 4.17% difference 
between the two compartments (n=31; p<0.001) (Figure 4-9). 
 
 
Figure 4-9 Summary of the differences of basal CFP/YFP ratio between the cytosol and 
the centrosome of CHO cells stably expressing RII_epac sensor. Data are normalised to 
the ratio value in the cytosol. (Error bar represents SEM. Two tailed; paired t-test, *** 
p<0.001). 
These data confirmed that the centrosome of CHO cells is a microdomain 
with low cAMP level compared with the bulk cytosol. 
4.1.5  Low cAMP centrosomal microdomain in SH-SY5Y 
In order to establish whether a microdomain with low cAMP is a feature 
exclusively found in CHO cells or rather it is present at the centrosome of other 
cell lines, the neuroblastoma cell line SH-SY5Y (see section 3.2.1.2) was 
employed.  
As a first step I established a SH-SY5Y stable clone over-expressing the 
RII_epac sensor (see section 3.2.2.3.2). In order to select cells stably expressing 
the cAMP indicator, SH-SY5Y cells were transfected with RII_epac and grown in 
EMEM/F-12 supplemented with 500 g/ml of Geneticin® (G418 Sulphate, 
neomycin). When SH-SY5Y cells stably expressing the sensor were inspected at 
the fluorescence microscope, they showed, similarly to CHO cells, a 
centrosomal sub-localisation of the RII_epac sensor, confirming anchoring of 
the sensor to endogenous AKAPs (Figure 4-10). 
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Figure 4-10 SH-SY5Y stably expressing the RII_epac sensor. The two panels show the 
signal generated by the CFP (left panel) and YFP (right panel) emission. The arrows 
point to the centrosome. Bar 10m. 
As shown in Figure 4-11, FRET based analysis of SH-SY5Y cells stably 
expressing the RII_epac sensor revealed the presence of a microdomain with 
lower cAMP concentration at the centrosome as compared with the cytosol. 
The difference in basal ratio (CFP/YFP emission) between the two 
compartments resulted to be highly significant (6.10%, p<0.001; n=12), with a 
centrosomal ratio expressed as normalised value with respect to the cytosol of 
R0/R0cyt=0.9420.013.  
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Figure 4-11 Top panel: CFP signal and pseudo-colour image of SH-SY5Y cells stably 
expressing RII_epac. The box shows the magnification of the centrosome region. Bar 
10m. Bottom panel: summary of the differences of basal CFP/YFP ratio values in the 
cytosol and in the centrosome of SH-SY5Y cells stably expressing RII_epac sensor. Data 
are normalised to the CFP/YFP value in the cytosol. (Error bar represents SEM. Two 
tailed; paired t-test, *** p<0.001).  
4.1.6  Role of PDE4D3 in the regulation of cAMP levels 
at the centrosome 
4.1.6.1  PDE4D3 localises to the centrosome in CHO cells 
It had been previously shown that PDE4D3 localises to the centrosome 
via binding to AKAP450 (Tasken et al., 2001). I therefore hypothesised that 
PDE4D3 may be responsible for maintaining the observed low basal level of 
cAMP at this site. To test this hypothesis, I sought to confirm by 
immunocytochemistry that PDE4D3 localises to the centrosome in CHO cells. 
As shown in Figure 4-12, an antibody specific for PDE4D3 decorates the 
centrosome and co-localises with -tubulin, a specific marker for this organelle. 
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Figure 4-12 Subcellular localisation of PDE4D3 in CHO cells. Images show co-
localisation of PDE4D3, top left panel, with -tubulin (specific antibody for 
centrosome) middle panel. Secondary antibody control in the bottom panels. Bars 
10m. 
4.1.6.2  Selective inhibition of PDE4 abolishes the 
microdomain with low cAMP at the centrosome 
To further test PDE4D3 involvement in maintaining a centrosomal 
microdomain with low cAMP, I selectively inhibited all PDE4 isoforms with 10 
M rolipram in CHO cells lines stably expressing either the PKA-GFP sensor or 
the RII_epac sensor (Figure 4-13). In both cases I found that inhibition of PDE4, 
while increasing the cAMP concentration in both compartments (see Fig 4-18), 
completely abolishes the observed difference in FRET signal between 
centrosome and cytosol (centrosomal ratio expressed as normalised value with 
respect to the cytosol was R0/R0cyt=0.997±0.005 [n=44]; p=0.661 when 
probing with the PKA-GFP sensor and R0/R0cyt=0.990±0.005 [n=13]; p=0.078 
when probing with RII_epac sensor). 
 
  Chapter 4 Results 
119 
 
 
Figure 4-13 Top panel: RII-CFP signal and pseudo-colour image of a CHO cell stably 
expressing PKA-GFP and treated with 10 M rolipram. The box shows the 
magnification of the centrosome region. Bar 10m. Bottom panel: summary of the 
basal CFP/YFP ratio values in the cytosol and in the centrosome of cells stably 
expressing either PKA-GFP or RII_epac sensor, as indicated, and treated with rolipram. 
Data are normalised to the CFP/YFP value in the cytosol (Error bars represent SEM. 
Two tailed; paired t-test). 
As a control, cells stably expressing the PKA-GFP sensor were treated 
with the selective PDE2 inhibitor EHNA (erythro-9-(2-hydroxy-3-nonyl) 
adenine), and with the selective PDE3 inhibitor cilostamide. 10 M EHNA and 
10 M cilostamide did not affect the cAMP gradient between cytosol and 
centrosome and the difference in the CFP/YFP emission ratio value between 
the two compartments was maintained at 1.95% upon PDE2 inhibition and at 
1.64% upon PDE3 inhibition. Specifically, centrosomal ratio expressed as 
normalised value with respect to the cytosol was R0/R0cyt=0.981±0.004 [n=46] 
p<0.001 in the presence of EHNA and R0/R0cyt=0.984±0.004 [n=39], p<0.001 in 
the presence of cilostamide (Figure 4-14). 
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Figure 4-14 Top panel: RII-CFP signal and pseudo-colour image of a CHO cell stably 
expressing PKA-GFP and treated with 10 M EHNA. The box shows the magnification of 
the centrosome region. Bar 10m. Bottom panel: summary of the differences of basal 
CFP/YFP ratio value in the cytosol and at the centrosome of cells stably expressing 
PKA-GFP and treated, as indicated, with EHNA 10 M or cilostamide (cilo) 10 M. Data 
are normalised to the CFP/YFP value in the cytosol (Error bars represent SEM. Two 
tailed; paired t-test, *** p<0.001). 
4.1.6.3  PDE4D selective knock-down abolishes the 
difference in cAMP between cytosol and centrosome 
To further confirm the involvement of PDE4D3 in shaping a centrosomal 
microdomain with low cAMP I performed a knock-down experiment in which 
PDE4D was genetically ablated by over-expression of a small interfering RNA 
oligonucleotide (siRNA). CHO cells were co-transfected with the PKA-GFP 
sensor and either a siRNA oligonucleotide for PDE4D (Lynch et al., 2005) or the 
control siRNA oligonucleotide, siGLO®. 
The efficiency of endogenous PDE4D knock-down was determined by 
western blot analysis. Lysates from cells over-expressing either the siRNA for 
PDE4D or the control siGLO® were separated by SDS-PAGE and probed with a 
specific antibody against PDE4D, as illustrated in Figure 4-15. PDE4D sub-
family-specific siRNA-mediated knock-down results in a very significant 
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reduction in the level of PDE4D expression, whereas no effect on PDE4D 
expression level was detected in cells treated with the control siGLO® (Figure 
4-15). 
 
 
Figure 4-15 Western blot of PDE4D and -tubulin obtained from cells treated as 
follows: untreated CHO (CTRL), CHO over-expressing the control siGLO® (siGLO) and 
CHO over-expressing the small RNA interference of PDE4D (siRNAPDE4D).  
Pseudo-colour images of CHO cells over-expressing siRNA for PDE4D 
show that the selective knock-down of the PDE4D completely abolishes the 
differences in the basal CFP/YFP ratio between cytosol and centrosome 
(R0/R0cyt=0.994±0.005 [n=40] at the centrosome; p=0.219). On the contrary, in 
cells transfected with siGLO®, such a difference is maintained with a basal 
ratio in the cytosol 1.43% higher than at the centrosome 
(R0/R0cyt=0.986±0.003 [n=40] at the centrosome; p<0.001) (Figure 4-16). 
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Figure 4-16 Top panel: RII-CFP signal and pseudo-colour image of a CHO cell co-
expressing PKA-GFP and siRNA for PDE4D. The box shows the magnification of the 
centrosome region. Bar 10m. Bottom panel: summary of the differences of basal 
CFP/YFP ratio value in the cytosol and at the centrosome of cells expressing either 
siRNA for PDE4D or the control siGLO®, as indicated. Data are normalised to the 
CFP/YFP value in the cytosol. (Error bars represent SEM. Two tailed; paired t-test, *** 
p<0.001 with siGLO®). 
4.1.6.4  PDE4D3 displacement abolishes the low cAMP 
compartment at the centrosome 
To further confirm that anchoring of PDE4D3 to the centrosome is 
necessary to maintain a low local concentration of cAMP, the effect of 
displacing PDE4D3 from its intracellular anchor sites, by over-expressing a 
dominant negative variant of PDE4D3 (dnPDE4D3) (McCahill et al., 2005), was 
tested. In this context, a dominant negative PDE is an enzyme containing a 
point mutation in the catalytic site that abolishes the enzymatic activity (Baillie 
et al., 2003). The over-expression of such a protein results in the displacement 
of the cognate, endogenous, active counterpart and in its replacement with the 
catalytically dead version of the same enzymes. The consequence of this is to 
abolish any effect due to the specific localisation of the enzyme. Co-transfection 
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of the PKA-GFP sensor in combination with the dnPDE4D3, in CHO cells, 
completely abolished the difference in cAMP concentration between the 
cytosol and the centrosome, with R0/R0cyt=0.993±0.006 [n=31], p=0.270. As a 
control, over-expression of a catalytically inactive PDE4A4 (dnPDE4A4) did not 
affect the difference in ratio between the cytosol and the centrosome with a 
ratio value in the cytosol 1.63% higher than at the centrosome 
(R0/R0cyt=0.984±0.006 [n=21]; p<0.012) (Figure 4-17). 
 
 
 
Figure 4-17 Top panel: RII-CFP signal and pseudo-colour image of a CHO cell co-
expressing PKA-GFP and dnPDE4D3. The box shows the magnification of the 
centrosome region. Bar 10m. Bottom panel: summary of the differences of basal 
CFP/YFP ratio values in the cytosol and at the centrosome of cells expressing either 
dnPDE4D3 or the control dnPDE4A4, as indicated. Data are normalised to the CFP/YFP 
value in the cytosol. (Error bars represent SEM. Two tailed; paired t-test, * p<0.5). 
Collectively, the above evidence strongly indicates that PDE4D3 is 
responsible for maintaining at the centrosome a level of cAMP that is lower 
than in the bulk cytosol (Figure 4-18). 
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Figure 4-18 Comparison between the effect of rolipram, siRNA for PDE4D and 
dnPDE4D3 on cytosolic (cyt) and centrosomal (centr) ratio increase compared to 
untreated control. (Error bars represent SEM. Two tailed; un-paired t-test; *** p<0.001, 
* p<0.05) 
4.2  Discussion 
The centrosome is an organelle which contains all the machinery 
required for cAMP signal transduction. Hence it is very interesting to study if a 
localised pool of cAMP could be uniquely regulated at this site and what are the 
mechanisms that may selectively control the cAMP/PKA pathway in this 
compartment. 
In order to study cAMP dynamics in intact and non-synchronised cells I 
generated stable clones over-expressing the FRET based sensors and 
performed real-time imaging of cAMP using PKA-GFP (Zaccolo and Pozzan, 
2000) (Figure 4-1) and RII_epac (Di Benedetto et al., 2008) (Figure 4-8). Using 
these stable clones I was able to show that the PKA holoenzyme is anchored to 
the centrosome through specific binding to endogenous RII-specific AKAPs 
(Figure 4-3), as this specific anchoring could be abolished by over-expression 
of the competing peptide SuperAKAP-IS (Figure 4-4). 
Subsequent FRET-based analysis of these cells revealed that the 
centrosome is a domain with a low cAMP concentration compared with the 
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cytosol (Figure 4-5 and Figure 4-6). Moreover, this special subcellular domain 
is not a peculiarity of CHO cells but it can be found in different cellular models, 
as for example in human neuroblastoma cells (Figure 4-10).  
It has been shown that AKAP450 nucleates a cAMP/PKA signalling 
complex to the centrosome by simultaneously anchoring PKA and PDE4D3 
(Tasken et al., 2001). Thus, I investigated the role of PDE4D3 bound to the 
centrosomal AKAP450 in regulating the local concentration of cAMP at the 
centrosome. Indeed, selective inhibition of PDE4 with rolipram completely 
dissipates the gradient of cAMP between centrosome and cytosol (Figure 
4-13). On the contrary, selective inhibition of different PDE families, such as 
PDE2 or PDE3, does not affect the centrosomal low cAMP microdomain, 
suggesting that these two subfamilies of PDEs are not involved in the 
centrosomal cAMP compartmentalisation (Figure 4-14). Further evidence that 
PDE4D is responsible for the lower cAMP concentration at the centrosomal 
subcellular compartment is provided by experiments in which PDE4D was 
selective knocked-down, which also showed abolishment of the difference in 
cAMP concentration between the two compartments (Figure 4-16). Finally, 
displacement of PDE4D3 confirmed that the localisation of this specific isoform 
to the centrosome is required to shape the centrosomal pool of cAMP (Figure 
4-17). It has been previously shown in our laboratory and by other groups that 
anchored PDEs act as a “sink” draining cAMP and contributing to shape 
asymmetric gradients of cAMP (Terrin et al., 2006). Based on the data 
presented in this chapter, it can be hypothesised that PDE4D3 is active at 
resting levels of cAMP and its activity may prevent the inappropriate activation 
of PKA. In addition it is important to note that this mechanism is not cell 
specific but can be extended to other cell lines, indicating that a specific cAMP-
dependent regulatory mechanism is taking place at the centrosome and this 
warrants further investigation. 
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5 Anchoring of PKA to AKAP450 
lowers PKA activation threshold 
Background: 
In the first chapter I demonstrated that the centrosome is a subcellular 
compartment in which, in resting and unstimulated cells, the level of cAMP is 
lower than the level of cAMP in the bulk cytosol. In addition, I provided 
evidence that the centrosomal PDE4D3 is necessary to maintain such a 
gradient of cAMP. The presence at the centrosome of PKA and PDE4D3 
anchored to AKAP450, together with evidence for a low cAMP microdomain in 
this compartment, suggest that the centrosome may represent a signalling 
domain in which cAMP dynamics in response to extracellular inputs are 
uniquely regulated. 
Hypothesis: 
Based on these observations the guiding hypothesis of this chapter is 
that cAMP raising agents generate a cAMP response at the centrosome that is 
different from the cAMP response in the bulk cytosol. 
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Experimental procedure: 
1) FRET-based analysis of cAMP levels in CHO clones stably 
expressing either the PKA-GFP or the RII_epac sensor and 
treated with forskolin.  
2) Comparison of FRET changes in the cytosol and at the centrosome 
upon forskolin stimulation. 
3) Study of the role of AKAP450 in the activation of centrosomal 
PKA. 
5.1  Results  
5.1.1  Upon forskolin stimulation the PKA-GFP sensor 
responds with a larger FRET change at the 
centrosome than in the cytosol  
To investigate the cAMP response at the centrosome, CHO cells stably 
expressing PKA-GFP were treated with 25 M forskolin, a direct activator of 
adenylyl cyclases, and FRET changes at the centrosome and in the cytosol were 
monitored by time-lapse fluorescence microscopy. As shown in Figure 5-1, the 
FRET change recorded at the centrosome resulted to be significantly higher 
(p<0.001) than the FRET change detected in the bulk cytosol of the same cell, 
with R/R0=12.198±0.662% and R/R0=14.334±0.910% in the cytosol and at 
the centrosome, respectively ([n=35]). Figure 5-1 shows the plots of the 
normalised average kinetics of FRET changes recorded in the two 
compartments for the entire set of analysed cells (see section 3.3.2.4 and 
Figure 3-2 for analysis details). 
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Figure 5-1 Normalised average kinetics of FRET change detected in response to 25 µM 
forskolin (frsk) and recorded in the cytosol (cyt; black circles) and at the centrosome 
(centr; grey circles) in CHO cells stably expressing PKA-GFP. (Error bar represents 
SEM. Two tailed; un-paired t-test, *** p<0.001). 
One possible explanation for these results is that the higher FRET 
increase detected at the centrosome may be due to a higher cAMP increase in 
this region compared to the cAMP increase in the bulk cytosol. The so-called 
‘soluble’ AC (sAC), has been described as being associated to the centrosome 
(see section 1.3.1) (Zippin et al., 2003). However, it should be noted that sAC is 
the only AC isoform that is not directly activated by forskolin (Zippin et al., 
2003). To verify that the larger FRET change detected by PKA-GFP at the 
centrosome upon forskolin stimulation was due to a larger cAMP signal 
generated in this compartment, I took advantage of a different FRET reporter, 
the unimolecular sensor RII_epac. CHO cells stably expressing RII_epac were 
challenged with forskolin and FRET changes were recorded at the centrosome 
and in the bulk cytosol. Interestingly, 25 M forskolin generated an equal FRET 
change in the two compartments, with R/R0=10.605±0.475% and 
R/R0=10.622±0.728% in the cytosol and at the centrosome, respectively 
([n=31]; p=0.97), as indicated by the normalised average kinetic for the entire 
set of analysed cells (Figure 5-2). 
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Figure 5-2 Normalised average kinetics of FRET change induced by 25 µM forskolin 
(frsk) in CHO cells stably expressing RII_epac and recorded in the cytosol (cyt; black 
circles) and at the centrosome (centr; grey circles). (Error bar represents SEM. Two 
tailed; un-paired t-test). 
These data indicate that treatment with forskolin leads to a comparable 
increase in cAMP at the centrosome and in the cytosol. Consequently, the 
higher FRET change observed at the centrosome with the PKA-GFP sensor 
must be explained by another phenomenon. 
5.1.2  PKA anchored to AKAP450 shows increased 
sensitivity to cAMP 
An alternative explanation for the observed larger FRET change 
detected at the centrosome by the PKA-GFP sensor upon forskolin stimulation 
is that anchoring of PKA to the centrosomal AKAPs modifies the sensitivity of 
PKA to cAMP. To investigate this possibility, a fragment of AKAP450 (933-
1804aa) (see section 3.1.15) (Witczak et al., 1999) designated AKAP450-2 and 
including the amphipathic helix (amino acidic sequence: 
LEEEVAKVIVSMSIAFA) responsible for PKA anchoring, was sub-cloned into 
pcDNA3.1/Hygro (Figure 5-3).  
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AKAP450
1aa 933aa 1804aa 3908aa
 
Figure 5-3 Schematic representation of AKAP450 and AKAP450-2 fragment. 
This fragment lacks the C-terminal domain responsible for targeting of 
AKAP450 to the centrosome (PACT domain: pericentrin-AKAP450 centrosomal 
targeting domain). As a consequence, the AKAP450-2 fragment, when 
expressed in cells, shows a cytosolic distribution (Figure 5-3). CHO cells were 
co-transfected with PKA-GFP and the AKAP450-2 fragment and FRET changes 
upon forskolin stimulation were recorded by time-lapse fluorescence 
microscopy. The rationale for this experiment was that the AKAP450-2 
fragment and the PKA-GFP sensor would interact in the cytosol, in the same 
way as endogenous PKA and AKAP450 interact at the centrosome (Figure 5-4, 
A)). As shown in Figure 5-4, B), CHO cells co-expressing the AKAP450-2 
fragment and the PKA-GFP reporter showed a significantly higher (p<0.05) 
FRET increase upon stimulation with 25 M forskolin (R/R0=11.115±0.975% 
[n=22] compared with CHO cells expressing the PKA-GFP sensor alone 
(R/R0=14.077±0.898% [n=20]). 
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Figure 5-4 Effect of PKA-GFP binding to AKAP450-2 fragment. A) Schematic 
representation of PKA-GFP and AKAP450-2 fragment interaction; B) Summary of FRET 
changes induced by 25 M forskolin in the presence or absence of the AKAP450-2 
fragment. (Error bar represents SEM. Two tailed; un-paired t-test, * p<0.05). 
Next, CHO cells over-expressing PKA-GFP, in the presence or absence of 
AKAP450-2, were challenged with increasing concentrations of forskolin 
(Figure 5-5 and Figure 5-6). From the analysis of this experiment it emerges 
that over-expression of AKAP450-2 fragment increases the number of cells 
responding to low concentrations of forskolin. Specifically, the percentage of 
cells co-expressing PKA-GFP and AKAP450-2 and showing a response to 
concentrations of forskolin between 0.2-1 M was almost double than the 
percentage of cells expressing PKA-GFP alone and responding to this range of 
forskolin concentration (Figure 5-5). 
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Figure 5-5 Percentage of cells responding to increasing concentration of forskolin. 
Open and full bars represent CHO cells expressing PKA-GFP in the presence or absence 
of the AKAP450-2 fragment, respectively. [n<10]. 
These experiments also clearly showed that in the presence of the 
AKAP450-2 fragment the dose-response curve to forskolin is shifted to the left, 
indicating an increased sensitivity of the PKA-GFP sensor to cAMP. Analysis of 
the curve fitted to the experimental points allowed to determine a reduction of 
the EC50 value by a factor of 2 (EC50=2.23 and 1.03 in the absence and in the 
presence of AKAP450-2, respectively) (Figure 5-6). These findings indicate that 
a lower concentration of cAMP is sufficient to dissociate the PKA holoenzyme 
when PKA is bound to AKAP450. 
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Figure 5-6 Dose-response curve. FRET change induced by increasing concentration of 
forskolin in CHO cells expressing PKA-GFP in the presence of absence of AKAP450-2 
[n<10]. (Error bars represent SEM. Two tailed; un-paired t-test, * p<0.05, ** 
0.01<p<0.001, *** p<0.001). 
To further confirm that the increased sensitivity of PKA-GFP to cAMP 
was the consequence of the interaction of the sensor with AKAP450, the 
amplitude of FRET change detected by PKA-GFP sensor was measured in the 
presence of SuperAKAP-IS (see section 3.1.14), a disrupting peptide that 
selectively competes for the binding of PKA type II to AKAPs (see section 4.1.2) 
(Gold et al., 2006). Upon challenge with 25 M forskolin, CHO cells over-
expressing the PKA-GFP sensor in combination with the AKAP450-2 fragment 
and SuperAKAP-IS showed a FRET change equal to the FRET change measured 
in CHO cells expressing the PKA-GFP sensor alone (R/R0=13.422±0.774% 
[n=18] with PKA-GFP, R/R0=15.563±0.561% [n=24] with PKA-GFP plus 
AKAP450-2 fragment; and R/R0=13.074±0.709% [n=24] with PKA-GFP plus 
AKAP450-2 plus SuperAKAP-IS; PKA-GFP versus PKA-GFP plus AKAP450-2 
p<0.05; PKA-GFP plus AKAP450-2 versus PKA-GFP plus AKAP450-2 plus 
SuperIS 0.01<p<0.001, Figure 5-7). 
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Figure 5-7 Effect of disrupting PKA-GFP/AKAP450-2 interaction with SuperAKAP-IS 
(SuperIS). A) Schematic representation of PKA-GFP, AKAP450-2 and SuperAKAP-IS 
interaction (SuperIS, red helix); B) Summary of FRET change induced by 25 M 
forskolin in the presence or absence of AKAP450-2 fragment and SuperAKAP-IS. (Error 
bars represent SEM. Two tailed; un-paired t-test, * p<0.05, ** 0.01<p<0.001). 
Similarly, AKAP450-2 had no effect on the FRET change detected by a 
deletion mutant of the PKA-GFP sensor, PKA-GFP, in which the regulatory 
subunit, RII-CFP, lacks the dimerisation/docking domain (see section 3.1.16) 
(Zaccolo, 2002) and therefore cannot bind to AKAPs. As shown in Figure 5-8 
cells expressing either PKA-GFP alone or PKA-GFP in combination with the 
AKAP450-2 fragment showed the same amplitude of response to forskolin 
stimulation (R/R0=13.605±0.607% [n=25] with PKA-GFP and 
R/R0=13.927±0.768% [n=23] with PKA-GFP plus AKAP450-2 fragment; 
p=0.74; Figure 5-8). 
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Figure 5-8 Effect of AKAP450-2 on PKA-GFP. A) Schematic representation of 
AKAP450-2 fragment and PKA-GFP; B) Summary of FRET change induced by 25 M 
forskolin in the presence or absence of AKAP450-2 fragment on PKA-GFP. (Error bar 
represents SEM. Two tailed un-paired t-test). 
A comparable result was obtained when, together with PKA-GFP, a 
mutant of AKAP450-2 fragment (mutAKAP450-2 fragment, see section 3.1.15) 
was co-expressed in which the point mutation S1451P was introduced in the 
amphipathic helix responsible for the interaction of the regulatory subunit of 
PKA (mutated amino acidic sequence: LEEEVAKVIVPMSIAFA). The 
introduction of a proline residue in this sequence results in the disruption of 
the helix and, as a consequence, abolishes the ability of the AKAP fragment to 
bind to PKA (Carr et al., 1991) (Feliciello et al., 2001), (Alto et al., 2003). In 
agreement with the previous findings, over-expression of mutAKAP450-2 in 
CHO cells did not affect the FRET change detected by the PKA-GFP sensor upon 
forskolin stimulation compared with cells that did not over-express the mutant 
fragment (R/R0=12.726±1.450% [n=14] with PKA-GFP, 
R/R0=16.518±0.969% [n=26] with PKA-GFP plus AKAP450-2 fragment; and 
R/R0=12.938±1.310% [n=19] with PKA-GFP plus mutAKAP450-2 fragment; 
PKA-GFP versus PKA-GFP plus AKAP450-2 and PKA-GFP plus AKAP450-2 
versus PKA-GFP plus mutAKAP450-2; p<0.05; Figure 5-9). 
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Figure 5-9 Effect of PKA-GFP binding to mutAKAP450-2 fragment compared to the 
binding to the AKAP450-2 (wild type). A) Schematic representation of PKA-GFP and 
mutAKAP450 2; B) Summary of FRET change induced by 25 M forskolin in the 
presence or absence of the AKAP450-2 and mutAKAP450-2 fragments. (Error bars 
represent SEM. Two tailed; un-paired t-test, * p<0.05). 
As a further control, the AKAP450-2 fragment was over-expressed in 
cells over-expressing the RII_Epac sensor. As shown Figure 5-10, CHO cells 
transiently expressing RII_epac alone and challenged with forskolin showed 
the same FRET increase as cells expressing RII_epac plus the AKAP450-2 
fragment (R/R0=9.684±0.467% [n=34] for RII_epac and 
R/R0=10.346±0.483% [n=41] for RII_epac plus AKAP450-2 fragment; p=0.33; 
Figure 5-10). 
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Figure 5-10 Effect of RII_epac binding to AKAP450-2 fragment. A) Schematic 
representation of RII_epac/AKAP450-2 fragment interaction; B) Summary of FRET 
change induced by 25 M forskolin in the presence or absence of the AKAP450-2 
fragment. (Error bar represents SEM. Two tailed un-paired t-test). 
These data indicate that the larger FRET change detected by the PKA-
GFP sensor in the presence of AKAP450-2 is specific for the PKA-based probe. 
Taken together these data indicate that binding of PKA to AKAP450 
lowers the activation constant of PKA for cAMP and strongly indicate that the 
larger FRET change detected at the centrosome compared to the bulk cytosol is 
the consequence of PKA being anchored to AKAP450 in this locale. 
5.1.3  The increased sensitivity to cAMP of AKAP-
anchored PKA is specific for the PKA/AKAP450 
interaction 
The next question I asked was whether the observed increased 
sensitivity to cAMP displayed by the PKA-GFP sensor anchored to AKAP450 
was specifically due to the binding to AKAP450 or if it was also occurring when 
PKA was bound to other AKAPs. To answer this question I investigated the 
effect on cAMP sensitivity of three other AKAP fragments containing the 
amphipathic helix responsible for the anchoring of PKA (see section 3.1.17 and 
3.1.19). Specifically, CHO cells expressing PKA-GFP were co-transfected with 
either the soluble AKAP Rt31 (see section 3.1.18) (Klussmann et al., 2001) or 
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with two membrane targeted AKAPs: AKAP79 (Herberg et al., 2000) and 
AKAP149 (see section 3.1.17) (Carlson et al., 2003). In all cases FRET changes 
elicited by application of 25 M forskolin were recorded by time-lapse 
fluorescence microscopy. 
 
 
Figure 5-11 Effect of PKA-GFP interaction with AKAP79, AKAP149 and Rt31 fragments 
on the sensitivity of PKA-GFP to cAMP. A) Schematic representation of PKA-GFP 
anchored to AKAP79 fragment (top) and summary of FRET change induced by 25 M 
forskolin in the presence or in the absence of the AKAP79 fragment (bottom); B) 
Schematic representation of PKA-GFP anchored to AKAP149 fragment (top) and 
summary of FRET change induced by 25 M forskolin in the presence or absence of the 
AKAP149 fragment (bottom); C) Schematic representation of PKA-GFP anchored to 
Rt31 fragment (top) and summary of FRET change induced by 25 M forskolin in the 
presence or absence of the Rt31 fragments (bottom). (Error bars represent SEM. Two 
tailed; un-paired t-test). 
As shown in Figure 5-11, none of these AKAP fragments had an effect on 
the FRET change detected by the PKA-GFP sensor upon forskolin stimulation 
(R/R0=14.222±0.913% [n=17] with PKA-GFP and R/R0=13.506±0.832% 
[n=27] with PKA-GFP plus Rt31 fragment; p=0.57; R/R0=15.583±1.073% 
[n=24] with PKA-GFP and R/R0=15.778±0.785% [n=38] with PKA-GFP plus 
AKAP79 fragment; p=0.88; R/R0=15.583±1.073% [n=24] with PKA-GFP and 
R/R0=15.740±0.924% [n=43] with PKA-GFP plus AKAP149 fragment; p=0.91; 
Figure 5-11). 
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Taken together these results show that anchoring of PKA to AKAP450 
results in a higher sensitivity of PKA to cAMP. This effect seems to be 
dependent on and specific for the binding of PKA to AKAP450. The increased 
sensitivity of PKA to cAMP can be estimated to be about two-fold (Figure 5-6) 
and points to a specific function of the centrosomal AKAP450 to lower the 
activation threshold of PKA in this area.  
5.2  Discussion 
The main result of this chapter is that, upon forskolin stimulation, CHO 
cells stably expressing a PKA-GFP sensor show a higher FRET change at the 
centrosome than in the cytosol (Figure 5-1). Since FRET changes correlate with 
cAMP increase these data suggest that forskolin leads to a higher cAMP level in 
the centrosomal region compared with the cytosol. A possible explanation for 
these findings is that a source of cAMP is present at the centrosome. Although 
it has been shown that a soluble isoform of AC (sAC) can be present at the 
centrosome, it is unlikely that sACs could be responsible for the enhanced 
activation of the centrosomal PKA-GFP. In fact, only bicarbonate is able to elicit 
a cAMP increase in nuclear extracts containing sAC, whereas forskolin does not 
produce any significant change in the same extracts (Zippin et al., 2003). 
However, to completely exclude the hypothesis of a higher cAMP increase at 
the centrosome than in the cytosol following forskolin stimulation, I monitored 
FRET changes at the centrosome and in the cytosol in cells stably expressing 
the unimolecular sensor for cAMP: RII_epac. The idea was that if the cAMP 
increase is different between the two compartments I should detect such a 
difference independently from the molecular structure of the sensor used. 
Interestingly, upon forskolin stimulation the RII_epac sensor detected equal 
FRET changes in the two compartments. This finding allows to exclude that 
forskolin induces a higher cAMP level at the centrosome (Figure 5-2).  
To explain the higher FRET change detected at the centrosome upon 
forskolin stimulation when probed with the PKA-GFP sensor, I hypothesised 
that the interaction between AKAP450 and PKA could modify the sensitivity of 
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the anchored PKA to cAMP (Figure 5-4). Supporting this hypothesis, I provided 
evidence that binding of PKA to AKAP450 in CHO cells lowers the activation 
threshold of PKA upon forskolin stimulation (Figure 5-4 and Figure 5-6). Not 
only did cells over-expressing AKAP450 show a larger response to the same 
concentration of forskolin (Figure 5-4 and Figure 5-6), but also the number of 
cells responding to low concentrations of forskolin increased when PKA was 
co-expressed with this specific AKAP (Figure 5-5). Suppression of PKA-AKAP 
interaction through the over-expression of a SuperAKAP-IS disrupting peptide 
or deletion of the PKA dimerisation/docking domain (Figure 5-7 and Figure 
5-8), as well as disruption of the AKAP450-amphipathic helix, abolished the 
increased sensitivity of PKA to cAMP, re-establishing the same activation 
threshold of soluble PKA (Figure 5-9). These finding strongly indicate that it is 
indeed the binding of PKA to AKAP450-2 that is responsible for increasing the 
sensitivity of the enzyme to cAMP. The fact that AKAP450-2 does not show any 
effect on the RII_epac sensitivity to cAMP indicates that AKAP450-2 fragment 
affects specifically PKA (Figure 5-10). Finally, over-expression of three 
different AKAPs fragments (Rt31, AKAP79, AKAP149) revealed that none of 
those modified PKA-GFP FRET change upon forskolin stimulation, 
demonstrating that this effect is specific for the binding of PKA to AKAP450 
(Figure 5-11). 
It should be noted that the results presented here also allow to exclude 
the possibility that the higher FRET changes observed at the centrosome are 
due to an artefact related to the biochemical nature of the PKA-GFP sensor. 
When measuring FRET changes in response to a specific stimulus a region of 
interest (ROI) is selected and the FRET change is calculated as the ratio 
between CFP and YFP emission in that area. Since the PKA-GFP sensor is 
bimolecular and the activation of the sensor results in the release of the 
catalytic subunit from the regulatory subunit, one needs to consider the 
possibility that the higher FRET change detected at the centrosome may be due 
to a decreasing amount of C-YFP within the ROI that is being analysed. This 
problem relates only to the analysis of small compartments such as the 
centrosome, as when analysing the entire cell the signal from all R-CFP and all 
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C-YFP subunits present in the cell is averaged to calculate the CFP/YFP change. 
Based on the observation that over-expression of PKA together with the 
AKAP450-2 fragment showed in the cytosol FRET changes comparable to FRET 
changes detected at the centrosome of CHO stably expressing PKA-GFP (Figure 
5-1 and Figure 5-4), I can exclude that the results obtained with the 
bimolecular PKA-GFP-based sensor are due to such an artefact. 
The role of AKAPs in mediating the high levels of specificity and 
complexity of the cAMP/PKA signal transduction pathway has been widely 
studied (Beene and Scott, 2007) (Pidoux and Tasken). Beside the most 
important function of scaffolding protein, there is evidence that AKAPs can 
indirectly affect cAMP signalling pathway in several other ways (Wong and 
Scott, 2004) (Tasken and Aandahl, 2004). For instance, by recruiting PKA type 
I rather then PKA type II to a specific subcellular compartment, AKAPs can 
increase the sensitivity to cAMP of a particular process, as PKA type I can more 
easily be dissociated by cAMP than PKA type II (Jarnaess et al., 2008). 
Moreover, upon specific phosphorylation, AKAPs can associate or dissociate 
from different subcellular compartments (Westphal et al., 2000) (Dell'Acqua et 
al., 1998), as well as recruit or release components to and from the complex 
they nucleates. For instance, surface plasmon resonance spectroscopy showed 
that auto-phosphorylation of PKA type II modifies PKA affinity for Ht31, 
mAKAP and AKAP15/18 (Zakhary et al., 2000a) (Zakhary et al., 2000b). In 
another example, cAMP elevation and PKA mediated phosphorylation of 
PDE4D3 increases the affinity of PDE4D3 for mAKAP, suggesting that 
activation of mAKAP-anchored PKA enhances the recruitment of PDE4D3 and 
allow for a quicker signal termination (Carlisle Michel et al., 2004). This 
evidence supports a role for AKAPs in the modulation of the cAMP/PKA signal 
transduction pathway by moving the complex where cAMP concentration is 
below the PKA-activation threshold or by favouring cAMP degradation, rapidly 
terminating the response and promoting the re-association of the PKA 
holoenzyme (see section 1.5.1). However a direct modulation of PKA 
sensitivity to cAMP as a consequence of PKA interaction with an AKAP had 
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never been shown before, and represent therefore a novel mechanism through 
which cAMP/PKA signalling can be modulated. 
In summary, the data presented here indicate that PKA anchored to 
AKAP450 can be activated by concentrations of cAMP that do not affect soluble 
PKA or other subsets of PKA anchored to different AKAPs. These data show, for 
the first time, that anchoring of PKA to an AKAP can locally modify the 
sensitivity of PKA to cAMP. This is a completely new mechanism of local 
regulation of the cAMP/PKA pathway that is achieved by lowering the 
activation threshold of the effectors without affecting the concentration level of 
the second messenger itself. The ability to modify PKA activation through 
binding to PKA also constitutes a completely new function for AKAPs. 
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6 Study of PKA activity at the 
centrosome 
Background: 
In the previous chapters I investigated the role of the centrosomal 
AKAP450 and PDE4D3 in modulating cAMP signalling at the centrosome. By 
using a FRET based approach I could demonstrate that PDE4D3 activity is 
required to maintain cAMP at low concentration at the centrosome. In addition, 
I showed that binding of PKA to the centrosomal AKAP450 modulates PKA 
sensitivity to cAMP by lowering PKA activation threshold.  
Hypothesis: 
Based on the previous results, the guiding hypothesis of this chapter is 
that, at a given cAMP concentration, the activity of the PKA subset anchored to 
AKAP450 is higher than the activity of cytosolic PKA. 
Experimental procedure: 
1) FRET based analysis of PKA activity by using an A-Kinase activity 
reporter (AKAR3) (Allen and Zhang, 2006). 
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2) FRET based analysis of PKA activity upon binding to AKAP450.  
3) Comparison of PKA activity in the cytosol and at the centrosome 
within the same cell by using different centrosome-targeted 
versions of the AKAR3 sensor. 
6.1  Results 
6.1.1  AKAR3 as a sensor to measure PKA activity 
AKAR3 is a FRET-based sensor that allows to monitor PKA activity in 
real-time with high resolution in space and time (Allen and Zhang, 2006) 
(Zhang et al., 2005) (Herbst et al., 2009). It is based on a substrate sequence for 
PKA (LRRATLVD) and the phosphothreonine binding domain forkhead-
associated domain 1 (FHA1) sandwiched between CFP and a circular 
permutant of the YFP variant named Venus (cpV). When the PKA activity is low 
the two fluorophores are too far for FRET to occur. Activated PKA 
phosphorylates the PKA substrate sequence in AKAR3 resulting in binding of 
the FHA1 domain to phosphothreonine. The consequent conformational 
change results in a reduction of the distance between the donor and the 
acceptor fluorophores leading to a FRET increase (Figure 6-1). Therefore, 
FRET changes correlate with changes in PKA activity. 
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Figure 6-1 Schematic representation of AKAR3 reporter and its mechanism of function. 
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In order to validate AKAR3 as a reporter of PKA activity I first 
challenged CHO cells over-expressing AKAR3 with 25 M forskolin. As shown 
in Figure 6-2 forskolin generated a FRET change of ~10%, indicating that the 
sensor can monitor activity of endogenous PKA (R/R0=10.0934±0.672% 
[n=56]). 
 
Figure 6-2 Representative kinetics of FRET change induced by 25 M forskolin (frsk) in 
CHO cells expressing AKAR3 reporter. 
Next, I tested the specificity of the sensor for PKA activity by incubating 
AKAR3 expressing CHO cells with the PKA inhibitor H-89 (N-[2-[[3-(4-
Bromophenyl)-2-propenyl] amino] ethyl]-5-isoquinolinesulfonamide 
dihydrate dihydrochloride, 10 M). As shown in Figure 6-3 pre-treatment with 
H-89 almost completely abolished the FRET change detected by AKAR3 to 
forskolin treatment, further confirming that the sensor measures PKA-
dependent activity. 
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Figure 6-3 Representative kinetics of FRET change induced by 25 M forskolin (frsk) in 
CHO cells expressing AKAR3 and pre-treated with 10 M H-89. 
6.1.2  Binding of PKA to AKAP450-2 increases PKA 
activity 
The next step was to assess whether binding of PKA to AKAP450, by 
affecting PKA sensitivity to cAMP, would also increase PKA activity in response 
to a given concentration of second messenger. In the experiments described 
below the PKA-activity reporter was co-expressed with AKAP450-2 and FRET 
changes were monitored upon forskolin stimulation. The rationale here is that 
anchoring of endogenous PKA to the over-expressed cytosolic AKAP450-2 
fragment should increase PKA sensitivity to cAMP leading to an increase in the 
PKA activity detected by AKAR3. CHO cells over-expressing AKAR3 and the 
AKAP450-2 fragment were challenged with 25 M forskolin and the FRET 
change recorded was compared with the FRET change detected in cells over-
expressing AKAR3 alone. As shown in Figure 6-4, over-expression of AKAP450-
2 resulted in a significantly higher FRET response (0.01<p<0.001) compared 
with control cells not expressing the AKAP450-2. The FRET change detected 
was R/R0=10.093±0.672%, [n=56] for AKAR3 and R/R0=13.577±1.059%, 
[n=53] for AKAR3 plus AKAP450-2 fragment. 
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Figure 6-4 Effect of over-expression of AKAP450-2 on endogenous PKA activity. Error 
bar represents SEM. Two tailed; un-paired t-test, ** 0.01<p<0.001). 
On the contrary, no difference in PKA activity was recorded in CHO cells 
over-expressing AKAR3 in combination with a fragment of AKAP79 (see 
section 3.1.17) (R/R0=15.811±1.860%, [n=16] with AKAR3 and 
R/R0=14.773±2.043%, [n=14] with AKAR3 plus AKAP79 fragment; p=0.69) 
(Figure 6-5). 
 
 
Figure 6-5 Effect of over-expression of AKAP79 on endogenous PKA activity. (Error bar 
represents SEM. Two tailed; un-paired t-test). 
These results confirm that anchoring of PKA to AKAP450 increases the 
sensitivity of PKA to cAMP resulting in increased PKA activity at a given cAMP 
level. 
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6.1.3  Generation of targeted AKAR3 sensors to 
monitor centrosomal PKA activity 
The purpose of the following experiment was to directly monitor the 
local activity in response to a given cAMP level of a PKA subset anchored to 
AKAP450 at the centrosome. To this end I generated two centrosome-targeted 
variants of the AKAR3 reporter (Figure 6-6). For one of these constructs, the 
RII_AKAR3 sensor (Stangherlin et al., 2011), I genetically fused the D/D of the 
RIIβ subunit (aa 1-49) to the N-terminus of AKAR3 in order to target the probe 
to endogenous AKAPs, including AKAP450 (see section 3.1.19). For the second 
construct, I fused the GIT1 sequence (aa 1-119) to the N-terminus of the 
AKAR3 reporter. GIT1 is a G-protein coupled receptor kinase interacting 
protein and a GTPase-activating protein (GAP) for the ADP ribosylation factor 
(ArfGAP protein) (see section 3.1.19) (Premont et al., 1998). It has previously 
been shown that GTI1 is concentrated at the centrosome during all stages of 
the cell cycle and the N-terminus domain of this protein (aa 1-119) has been 
shown to be responsible for centrosomal targeting (Zhao et al., 2005). 
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Figure 6-6 Schematic representations of centrosome-targeted AKAR3 reporters: A) 
RII_AKAR3 and B) GIT1_AKAR3. 
As illustrated in Figure 6-7 both these sensors showed a clear 
localisation to the centrosome in CHO cells. 
 
Chapter 6 Results 
149 
 
 
Figure 6-7 Subcellular localisation of RII_AKAR3 and GIT1_AKAR3 in CHO cells. The 
arrows point to the centrosome. Bars 10m. 
CHO cells transfected either with RII_AKAR3 or with GIT1_AKAR3 and 
challenged with 25 M forskolin generated a FRET change (averaged over the 
entire cell) of 19.5700.798% (n=50) and 15.3061.692% (n=22) respectively, 
both at the centrosome and in the cytosol, indicating that the engineering of 
the sensors did not affect their capability do generate a FRET change in 
response to PKA-mediated phosphorylation (Figure 6-8). 
 
 
Figure 6-8 Representative kinetics of FRET change generated by 25 M forskolin (frsk) 
in CHO cells expressing A) RII_AKAR sensor or B) GIT1_AKAR3 sensor. 
Subsequently, I compared the FRET changes elicited by 25 M forskolin 
at the centrosome and in the cytosol of CHO cells over-expressing either 
RII_AKAR3 or GIT1_AKAR3 (Figure 6-9).  
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Figure 6-9 Effect of 25 M forskolin on endogenous cytosolic and centrosomal PKA 
activity. Summary of FRET changes recorded in the cytosol (cyt) and at the centrosome 
(centr) of CHO cells expressing A) RII_AKAR3 or B) GIT1_AKAR3 sensor. (Error bars 
represent SEM. Two tailed; paired t-test, *** p<0.001). 
Surprisingly, both sensors showed a significantly higher FRET response 
in the cytosol compared to the centrosome (R/R0=19.570±0.798%, in the 
cytosol and R/R0=15.550±0.727% at the centrosome with RII_AKAR3, [n=50]; 
p<0.001 and R/R0=15.306±1.609%, in the cytosol and 
R/R0=11.586±1.404% at the centrosome with GIT1_AKAR3, [n=22]; p<0.001; 
Figure 6-9). These data do not seem to support the hypothesis of an increased 
PKA activity at the centrosome as a consequence of PKA binding to AKAP450. 
Moreover they are contradictory to the previous results obtained upon the 
binding of the endogenous PKA to the AKAP450-2 fragment in the cytosol. 
In Takahashi et al. it was shown that AKAP450 targets two 
phosphatases, proteins phosphatase 1 (PP1) and protein phosphatase 2A 
(PP2A) to the centrosome (Takahashi et al., 1999). A possible explanation for 
the above results could be that the centrosome-targeted sensors, RII_AKAR3 
and GIT1_AKAR3, are rapidly de-phosphorylated by these two phosphatases 
thus masking the hypothesised higher PKA activity at the centrosome. Based 
on this consideration, CHO cells over-expressing AKAR3, RII_AKAR3 or the 
GIT1_AKAR3 were pre-treated with 20 nM calyculin A, a potent and selective 
cell-permeable inhibitor of PP1 and PP2A. Figure 6-10 shows that calyculin A is 
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effective in inhibiting phosphatase activity in the cell as shown by the 
significantly higher FRET change detected by AKAR3 in the presence of the 
inhibitor (R/R0=11.745±0.696%, and R/R0=18.709±1.460% in the presence 
or absence of calyculin A, [n>24]; p<0.001, values are averages over the entire 
cell). 
 
 
Figure 6-10 Effect of 25 M forskolin on endogenous PKA activity in the presence of the 
PP1 and PP2A inhibitor calyculin A. Summary of FRET changes induced by 25 M 
forskolin in CHO cells expressing AKAR3 and in the absence or in the presence of 20 
nM calyculin A (CLA). (Error bar represents SEM. Two tailed; un-paired t-test, *** 
p<0.001). 
However, the comparison between centrosome and cytosol in the 
presence of calyculin A revealed that PKA activity was still significantly lower 
at the centrosome than in the cytosol, either when FRET changes were 
detected with RII_AKAR3 or GIT1_AKAR3 (R/R0=22.661±2.917%, in the 
cytosol and R/R0=188.19±2.088% at the centrosome with RII_AKAR3, [n=15]; 
p<0.05 and R/R0=19.705±2.234%, in the cytosol and R/R0=16.561±2.315% 
at the centrosome with GIT1_AKAR3, [n=14]; 0.01<p<0.00; Figure 6-11).  
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Figure 6-11 Effect of 25 M forskolin on endogenous cytosolic and centrosomal PKA 
activity after inhibition of PP1 and PP2A. Summary of FRET changes recorded in the 
cytosol (cyt) and at the centrosome (centr) of CHO cells expressing A) RII_AKAR3 or B) 
GIT1_AKAR3 sensor and pre-treated with 20 nM calyculin A (CLA). (Error bars 
represent SEM. Two tailed; paired t-test, * p<0.01, ** 0.01<p<0.001). 
One possible explanation for these results is that application of 20 nM 
calyculin A and 25 M of forskolin results in the saturation of the centrosomal 
anchored sensors. If this were the case, every difference in PKA activity 
between the two compartments would be masked. In an attempt to overcome 
this problem I stimulated CHO cells expressing the centrosome-targeted PKA 
activity reporter with 100 nM forskolin in the presence or in absence of the 
phosphatase inhibitor calyculin A (Figure 6-12). 
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Figure 6-12 Effect of 100 nM forskolin on endogenous cytosolic and centrosomal PKA 
activity with or without inhibition of PP1 and PP2A. Summary of FRET changes 
recorded in the cytosol (cyt) and at the centrosome (centr) of CHO cells expressing A) 
RII_AKAR3 or B) GIT1_AKAR3 sensor and pre-treated with or without 20 nM calyculin 
A (CLA). (Error bars represent SEM. Two tailed; paired t-test, * p<0.05). 
Results obtained are shown in Figure 6-12. When I probed with 
RII_AKAR3 (Figure 6-12; A), left panel), in the absence of calyculin A, the FRET 
change is significantly higher (p<0.05) at the centrosome than in the cytosol, in 
response to 100 nM of forskolin (R/R0=6.005±1.399%, in the cytosol and 
R/R0=7.303±1.727% at the centrosome for RII_AKAR3, [n=12]); however 
these data were not confirmed by the inhibition of the phosphatases. Pre-
treatment with calyculin A did not affect centrosomal-PKA activity and 
resulted in a trend towards a lower PKA activity at the centrosome than in the 
cytosol (R/R0=18.000±1.246%, in the cytosol and R/R0=16.544±1.034% at 
the centrosome for RII_AKAR plus calyculin A, [n=18]; p=0.16). 
When I probed PKA activity with GIT1_AKAR3 (Figure 6-12; B), right 
panel), in the absence of calyculin A, FRET response did not show any 
significant difference between the two compartments (R/R0=7.732±1.555%, 
in the cytosol and R/R0=7.896±1.917% at the centrosome for GIT1_AKAR3, 
[n=5]; p=0.89). However, pre-treatment with calyculin A resulted in a trend 
toward lower PKA activity at the centrosome than in the cytosol (not 
significant) (R/R0=17.675±2.280%, in the cytosol and R/R0=15.822±2.399% 
at the centrosome for GIT1_AKAR3 plus calyculin A, [n=14]; p=0.09). 
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6.2  Discussion 
In this chapter I set out to study the activity of the centrosomal, 
AKAP450-anchored, PKA by using the FRET based sensor AKAR3 (Figure 6-1). 
As a first step, the cellular responses of AKAR3 were shown to be specific for 
PKA since in the presence of H-89 (a specific PKA inhibitor) the sensor did not 
show any response upon forskolin stimulation (Figure 6-2 and Figure 6-3). 
Then, I provided evidence that endogenous PKA, upon binding to the 
AKAP450-2 fragment in the cytosol, shows increased activity (Figure 6-4), 
whereas the binding of endogenous PKA to a different AKAP fragment does not 
affect PKA activity (Figure 6-5). These data suggest, once again, that AKAP450 
is not only a scaffolding protein which anchors PKA to the centrosome, but also 
acts as a modulator of the cAMP/PKA pathway enhancing PKA sensitivity to 
cAMP. It is possible that anchoring of PKA to AKAP450 raises PKA sensitivity 
and activity in a location in which would be difficult to selectively increase 
cAMP concentration. It has been shown that ERK can inhibit PDE4D3 upon 
phosphorylation (MacKenzie et al., 2000). Thus a possible scenario would be 
that the constitutively active PDE4D3 anchored to the centrosome is 
inactivated by ERK phosphorylation, allowing centrosomal cAMP levels to rise 
independently from adenylyl cyclases activation.  
An important advantage of genetically encoded FRET reporters is that 
they can be targeted to different locations via various localisation signals. This 
approach provides a tool to monitor PKA activity in distinct subcellular 
compartments within the same cell and can reveal differences in PKA 
signalling between the site of cAMP synthesis at the plasma membrane and 
other regions where the signal is propagating to. This has been previously 
demonstrated by a study using AKAR3 sensors specifically targeted to the 
plasma membrane (pm-AKAR3, pm= palmitoylated and myristoylated 
sequence), to the cytosol (AKAR3-NES, NES=nuclear export sequence) and to 
the nucleus (AKAR3-NLS NLS=nuclear localisation sequence) (Allen and Zhang, 
2006). Based on this studies, I generated two different centrosome-targeted 
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sensors by fusing the D/D of the RIIβ subunit (1-49aa) or the N-terminus of 
GIT1 (1-119aa) to AKAR3 (Figure 6-6 and Figure 6-7). Targeting of AKAR3 to 
the centrosome, however, did not detect the expected higher PKA activity upon 
forskolin stimulation (Figure 6-9). One possible explanation for these results is 
that phosphatases anchored to the centrosome could be responsible for a rapid 
de-phosphorylation of the sensor thereby masking a higher AKAR3 activation 
at the centrosome. Although pre-treatment of cells with calyculin A did 
increase the FRET change monitored by the AKAR3 reporter (Figure 6-10), it 
failed to invert the difference in PKA activity between the two compartments 
(Figure 6-11 and Figure 6-12). 
Another possible explanation for these findings is that targeting of 
AKAR3 to the centrosome is affecting the PKA signalling complex in such a 
small compartment. In fact, the over-expression of RII_AKAR3 and its 
anchoring to the endogenous AKAPs might lead to the displacement of the 
endogenous PKA subsets from their original anchoring site. If the endogenous 
PKA anchored to AKAP450 is displaced by the over-expressed RII_AKAR3 there 
would be reduced endogenous PKA at this site and therefore I would not be 
able to monitor a higher activity of the AKAP450-anchored PKA.  
As far as the anchoring of the over-expressed GIT1_AKAR3 is concerned, 
this may occur on other centrosomal location and may not involve 
AKAP450/PKA/PDE4D3 molecular complex. This may explain why no higher 
activity of centrosomal PKA is detected in this case.  
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7 Anchoring of PKA to AKAP450 
favours auto-phosphorylation of the PKA 
regulatory subunit 
Background 
So far I have provided evidence that AKAP450, by anchoring PKA and 
PDE4D3, nucleates a multi-protein complex at the centrosome within which 
cAMP/PKA signalling is tightly regulated. On the one hand, PDE4D3 maintains 
cAMP at a lower concentration in the centrosome as compared to the bulk 
cytosol; on the other hand, anchoring of PKA to AKAP450 appears to increase 
the sensitivity of PKA to cAMP. 
In this chapter I aim at elucidating the mechanism responsible for the 
higher sensitivity to cAMP of the PKA subset bound to AKAP450. 
It is well established that the RIIβ subunit of PKA can undergo auto-
phosphorylation at Ser114. Phosphorylation at this site reduces the affinity of 
the regulatory subunit for the catalytic subunit by almost one order of 
magnitude thereby lowering the activation constant of PKA (Rangel-Aldao and 
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Rosen, 1977). Moreover, auto-phosphorylation of PKA occurs as an intra-
molecular event and does not require PKA dissociation (Rangel-Aldao and 
Rosen, 1976b).  
Hypothesis: 
The guiding hypothesis of the studies presented in this chapter is that 
anchoring of PKA to AKAP450 favours auto-phosphorylation of the RII subunit 
at S114, thus decreasing the activation threshold of PKA. 
Experimental procedure: 
1) Analysis of the phosphorylation level at S114 in the RIIβ subunit 
using western blot analysis in the presence or in the absence of 
the AKAP450-2 fragment.  
2) Analysis of FRET changes detected using a PKA-GFP sensor 
including a non-phosphorylatable R subunit (mutRII-CFP, 
containing the mutation S114A). 
3) Generation of a CHO cell line stably expressing the mutPKA-GFP 
sensor and comparison of the FRET signal in the cytosol and at 
the centrosome upon forskolin stimulation. 
7.1  Results 
7.1.1  Anchoring of PKA to AKAP450 enhances auto-
phosphorylation of the RII subunit 
To assess if auto-phosphorylation of the RIIβ subunit is involved in the 
observed increased sensitivity to cAMP of AKAP450-bound PKA, the level of 
phosphorylation at S114 of the RII-CFP component of the PKA-GFP sensor was 
determined by SDS-PAGE analysis. Lysates from CHO cells over-expressing the 
PKA-GFP sensor, in the presence or in the absence of the AKAP450-2 fragment, 
were probed with a RII antibody and with a phospho S114-specific antibody. 
Western blot analysis revealed a band at ~80kDa, corresponding to the 
molecular weight of the recombinant RII subunit tagged with CFP. A band at 
~53kDa, corresponding to the endogenous RII subunit, was also detected. 
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Clearly, over-expression of AKAP450 led to an increase of the phosphorylation 
level of both the endogenous and the over-expressed RII-CFP subunits. A 
quantitative analysis of the bands intensities confirmed that the auto-
phosphorylation level of RII subunits is indeed significantly increased (~50% 
increase) when PKA is co-expressed with AKAP450-2. These data indicate that 
anchoring of PKA-GFP to AKAP450-2 fragment promotes the auto-
phosphorylation of PKA RII subunit (Figure 7-1). 
 
 
Figure 7-1 Effect of over-expression of AKAP450-2 on endogenous PKA RIIβ-subunit 
auto-phosphorylation. A) Representative western blot of total RIIβ and phospho-RIIβ. 
B) Western Blot quantification (mean of 5 separate experiments). (Error bar 
represents SEM. Two tailed; paired t-test, * p<0.05). 
7.1.2  Generation of a non-phosphorylatable mutant of 
the PKA-GFP sensor (mutPKA-GFP) 
To further assess if the auto-phosphorylation site of the RIIβ subunit is 
involved in the mechanism that increases the cAMP-sensitivity of AKAP450-
bound PKA, I generated a non-phosphorylatable mutant of the regulatory 
subunit (mutRII-CFP) by introducing the point mutation S114A, (see section 
1.4.1, 3.1.20) (Figure 7-2) (Rodriguez-Vilarrupla et al., 2005), (Wehrens et al., 
2006), (Taylor et al., 1990).  
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Figure 7-2 Schematic representation of A) RII-CFP and B) mutRII-CFP subunit with the 
substitution S114A. D/D=PKA-RIIβ dimerisation docking/domain; IS=inhibitory site 
(or auto-phosphorylation site); DomainA=cAMP binding domain A; DomainB=cAMP 
binding domain B; CFP=cyan variant of the green fluorescent protein (GFP).  
First of all I wanted to confirm that the mutant sensor (mutRII-CFP+C-
YFP) could not be auto-phosphorylated. CHO lysates from cells expressing 
mutPKA-GFP were probed with the phospho-S114 specific antibody and 
compared with lysates from cells expressing the PKA-GFP (wild type) sensor 
(Figure 7-3). 
 
 
Figure 7-3 Western blot showing auto-phosphorylation of PKA-GFP and mutPKA-GFP. 
The PKARIIβ (pS114) antibody recognised only the auto-phosphorylation of the 
endogenous PKA in lysates from CHO cells over-expressing the mutPKA-CFP.  
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Western blot analysis, using the anti-phospho S114 antibody, revealed 
in both cell lysates a band at ~53kDa corresponding to the endogenous 
phospho-RIIβ subunit, whereas only cells over-expressing the PKA-GFP (wild 
type) also showed a band at ~80kDa, corresponding to the molecular weight of 
the RII-CFP (Figure 7-3); thereby confirming that the point mutation 
completely abolishes auto-phosphorylation of the RII subunit. 
Next, I tested the ability of mutPKA-GFP to detect FRET changes upon 
forskolin stimulation. CHO cells over-expressing mutPKA-GFP or PKA-GFP 
(wild type) were challenged with 25 µM forskolin. The mutPKA-GFP showed a 
significantly lower FRET change than PKA-GFP (R/R0=12.401±0.834% [n=38] 
with PKA-GFP and R/R0=9.746±0.643% [n=46] with mutPKA-GFP; p<0.05, 
Figure 7-4) (Rangel-Aldao and Rosen, 1976a). 
 
 
Figure 7-4 Comparison between PKA-GFP (wild type) and mutPKA-GFP FRET sensors. 
Summary of FRET changes induced by 25 M forskolin in CHO cells over-expressing 
PKA-GFP or mutPKA-GFP. (Error bar represents SEM. Two tailed; unpaired t-test, * 
p<0.05) 
7.1.3  mutPKA-GFP anchored to AKAP450-2 does not 
show increased sensitivity to cAMP 
In order to test whether anchoring to AKAP450 might affect auto-
phosphorylation of PKA thus lowering its activation threshold, I looked at the 
effect of over-expressing AKAP450-2 fragment on the FRET changes detected 
by the mutPKA-GFP sensor. When FRET changes were measured in the bulk 
cytosol of CHO cells over-expressing mutPKA-GFP in combination with 
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AKAP450-2, the response to 25 M forskolin stimulation detected was of the 
same amplitude as in cells that did not express the AKAP450-2 fragment 
(R/R0=9.745±0.643% [n=46] and R/R0=10.715±0.720% [n=28] in the 
presence or absence of the AKAP450-2 fragment, respectively; p=0.33; Figure 
7-5). 
 
 
Figure 7-5 Effect of AKAP450-2 on the FRET change detected by PKA-GFP and mutPKA-
GFP. Summary of FRET changes induced by 25 M forskolin and detected by PKA-GFP 
(wild type) and mutPKA-GFP in the presence (white columns) or absence (black 
columns) of the AKAP450-2 fragment. (Error bars represent SEM. Two tailed; un-
paired t-test, * p<0.05). 
These results differ from those obtained when over-expressing PKA-GFP 
in combination with AKAP450-2 (R/R0=11.115±0.975% [n=22] and 
R/R0=14.077±0.890% [n=20] in the presence or absence of AKAP450-2 
fragment, respectively; p<0.05; Figure 7-5) and indicate that the S114A 
mutation abolishes the ability of the AKAP450-2 fragment to affect the 
activation threshold of PKA. 
7.1.4  Generation of a stable clone over-expressing 
mutPKA-GFP 
To further address the role of the auto-phosphorylation site in the PKA 
regulatory subunit in determining increased PKA sensitivity to cAMP of 
centrosomal PKA, I established a CHO clone stably expressing the mutPKA-GFP 
Chapter 7 Results 
162 
 
sensor. The mutRII-CFP contains an intact docking domain and therefore the 
mutant sensor can, and does, anchor to the centrosome (Figure 7-6). 
 
 
Figure 7-6 Subcellular localisation of mutPKA-GFP in CHO cells. The centrosome is 
indicated by the arrow. Bar 10 µm. 
Cells stably expressing mutPKA-GFP were challenged with forskolin and 
the FRET changes were monitored both in the cytosol and at the centrosome. 
As shown in Figure 7-7 there was no significant difference in the FRET change 
detected by the mutPKA-GFP sensor at the centrosome and in cytosol (Figure 
7-7, white bars). Thus, introduction of the S114A mutation completely 
abolished the difference in cAMP sensitivity recorded in two compartments by 
the PKA-GFP sensor (Figure 7-7, black bars), confirming that auto-
phosphorylation of RIIβ at S114 is required to increase the sensitivity to cAMP 
of the AKAP450-anchored PKA subset at the centrosome (PKA-GFP (black 
columns): R/R0=12.198±0.662% and R/R0= 14.334±0.910% [n=35] in the 
cytosol and at the centrosome, respectively; p<0.001, mutPKA-GFP (white 
columns): R/R0=10.196±1.036% [n=16] and R/R0=10.662±1.358% [n=16] 
in the cytosol and at the centrosome, respectively; p=0.61; Figure 7-7). 
 
Chapter 7 Results 
163 
 
 
Figure 7-7 Effect of 25 M forskolin on the FRET change detected in the cytosol (cyt) 
and at the centrosome (centr) by mutPKA-GFP and PKA-GFP. (Error bars represent 
SEM. Two tailed; paired t-test, *** p<0.001). 
7.2  Discussion 
In this set of experiments I set out to investigate if the auto-
phosphorylation site in the PKA regulatory subunit may be involved in the 
mechanism responsible for the higher sensitivity to cAMP shown by the 
AKAP450-bound PKA subset. By western blot analysis I provided evidence that 
anchoring of PKA to AKAP450 results in increased auto-phosphorylation of the 
PKA regulatory subunit (Figure 7-1). Mutation of the auto-phosphorylation site 
in the RIIβ subunit by introducing an alanine residue in position 114 (S114A 
mutation) prevented AKAP450 from affecting the PKA activation threshold 
(Figure 7-5), although it did not interfere with the ability of the sensor to 
generate a FRET change upon forskolin stimulation (Figure 7-4). In addition, 
FRET-based analysis of CHO cells stably expressing mutPKA-GFP revealed a 
comparable FRET change generated by sensor at the centrosome and in the 
cytosol (Figure 7-7). These results strongly support the hypothesis that the 
auto-phosphorylation site in the PKA regulatory subunit is involved in the 
mechanism that leads to lowering of the PKA activation threshold. How the 
binding of PKA to AKAP450 can promote auto-phosphorylation of the RII 
subunit is still unclear and requires further investigation.  
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8 Displacement of centrosomal 
PDE4D3 from AKAP450 results in altered 
cell cycle progression 
Background: 
The centrosome is a small non-membranous organelle representing the 
major microtubules-organising centre of the cell. It consists of a pair of 
centrioles surrounded by a pericentriolar matrix composed of pericentrin and 
-tubulin, from which microtubules are nucleated (Doxsey, 1998) (Bornens, 
2002). The primary function of the centrosome is the nucleation and 
organisation of microtubules. In interphase cells the centrosome has a key role 
in establishing the cytoplasmic microtubules network for motor protein based 
transport and positioning of organelles and vesicles. During the progression of 
the cell cycle the centrosome undergoes duplication and at this stage it is 
essential for the formation and orientation of a bipolar mitotic spindle, for the 
fidelity of chromosome segregation and correct exit from mitosis (Bornens, 
2002) (Azimzadeh and Bornens, 2007). 
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A large body of evidence suggests that the centrosome is essential for 
the regulation of the cell cycle progression by acting as a scaffold protein for a 
network of signalling pathways which in turn trigger cellular division (see 
section 1.7.4) (Hinchcliffe et al., 1999) (Lacey et al., 1999) (Kramer et al., 
2004). Thus manipulation of the centrosome has often been shown to results 
in cell cycle aberrations or cell cycle arrest. For example, centrosomal ablation 
as well as silencing of centrosomal components results in impairment of 
cytokinesis with consequent arrest of the cell population in G1 phase (Kramer 
et al., 2004). Interestingly, it has been shown that displacement of endogenous 
AKAP450, by over-expression of the PACT domain (pericentrin-AKAP450 
centrosomal targeting), results in impaired centrioles duplication. As a 
consequence of this, cells enter mitosis but do not complete cytokinesis 
(Keryer et al., 2003b). Similarly, manipulation of other subsets of centrosomal 
proteins, such as Chk1 or pericentrin, results in an arrest of the cell cycle in G2 
phase (Kramer et al., 2004) (Zimmerman et al., 2004). 
It has also been shown that cAMP and cellular growth rate are inversely 
correlated and that the cAMP/PKA signal transduction pathway acts as a 
negative regulator of cell entrance in mitosis (Zeilig et al., 1976) (Lamb et al., 
1991). Total cAMP levels and PKA activity fluctuate throughout cell cycle 
progression reaching the highest level in G1 and the lowest level in mitotic 
phase (see section 1.8) (Sheppard and Prescott, 1972) (Zeilig et al., 1976). 
Accordingly, experimental manipulation of cAMP level or PKA activity results 
in the arrest of the cell cycle. Thus, elevation of cAMP results in arrest of the 
cell population in G1 whereas inhibition of PKA results in a rapid chromatin 
condensation and cells entry in mitosis (Zeilig et al., 1976) (Lamb et al., 1991).  
In the previous chapters I have shown the importance of the 
AKAP450/PKA/PDE4D3 complex anchored to the centrosome for fine 
regulation of centrosomal cAMP levels. While PDE4D3 ensures a cAMP basal 
concentration at the centrosome lower than in the cytosol, AKAP450 increases 
PKA sensitivity to cAMP by lowering its activation threshold via a mechanism 
involving the auto-phosphorylation site of PKA. 
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Based on these findings it is possible to envisage that the local 
centrosomal modulation of the cAMP/PKA pathway activity is critical for the 
correct regulation of cell cycle progression. 
Hypothesis: 
The guiding hypothesis of the experiment described in this result 
chapter is that the centrosomal AKAP450/PKA/PDE4D3 complex plays a role 
in the control of cell cycle progression.  
Experimental procedure: 
1) Generation of a CHO cell line stably expressing the dominant 
negative variant of PDE4D3 (McCahill et al., 2005) genetically 
fused to the red fluorescent protein (dnPDE4D3mRFP). 
2) Generation of a CHO cell line stably expressing the dominant 
negative variant of PDE4A4 (McCahill et al., 2005) genetically 
fused to the green fluorescent protein (dnPDE4A4-GFP). 
3) Assessment, by flow cytometry scan analysis, of cell cycle 
progression of non-synchronised cells lines stably expressing 
the dnPDE4D3mRFP compared with control CHO cells and CHO 
cells stably expressing the dnPDE4A4-GFP, before and after 
forskolin treatment. 
8.1  Results 
8.1.1  Generation of a CHO cell line stably expressing 
the dominant negative variant of PDE4D3 
In order to investigate the functional relevance of the centrosomal 
AKAP450/PKA/PDE4D3 complex, within which PKA activation and cAMP level 
are tightly and uniquely regulated, I set up to study how manipulation of this 
complex may affect cell cycle progression. As a first step for such investigation, 
the catalytically dead PDE4D3 variant (dnPDE4D3) (McCahill et al., 2005) was 
genetically fused to the monomeric red fluorescent protein (mRFP) and this 
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construct was used to establish a CHO cell line stably over-expressing the 
transgene dnPDE4D3mRFP (see section 3.1.21 and 3.2.2.3.3).  
Establishing the dnPDE4D3mRFP stable clone proved difficult when 
compared with the generation and maintenance of all the other stable clones 
developed for this project (see section 4.1.1, 4.1.4, 4.1.5 and 7.1.4). After a 
month of culture with medium containing the proper amount of antibiotic 
(700g of Higromycyn B, see section 3.2.2.2) western blot analysis of lysates 
from dnPDE4D3mRFP expressing cells probed with a specific antibody against 
PDE4D did not show any band corresponding to the molecular weight of 
PDE4D3mRFP (about 120 kDa) (Figure 8-1, “Old clone dn4D3”). This finding 
indicates that the selected cells had lost the transgene after this period in 
culture. A newly established CHO cells line over-expressing the 
dnPDE4D3mRFP was analysed for transgene expression after 15 days in 
selection medium. Western blot analysis showed in Figure 8-1, confirms that 
the “New clone dn4D3” expresses the dnPDE4D3mRFP.  
 
 
Figure 8-1 Western blot of cell lysates from CHO cells, CHO lines (“Old clone dn4D3” 
and “New clone dnPDE4D3mRFP”) stably expressing the dnPDE4D3 tagged to mRFP 
and CHO cells transiently transfected with the dnPDE4D3mRFP (CHO+dn4D3) probed 
with an antibody directed to PDE4D. “Old clone dn4D3”is the first clone selected, in 
which it is not possible to detect the dnPDE4D3mRFP; “New clone dnPDE4D3mRFP” is 
the newly selected clone in which it is possible to detect the PDE4D3, the PDE4D5 and 
the PDE4D3mRFP as well as these PDEs isoforms appear in lysate from CHO cells 
transiently transfected with dnPDE4D3mRFP. Lysates from CHO cells and from the 
“Old clone dn4D3” show only the bands for the endogenous PDE4D3 and PDE4D5. 
To further confirm the presence of the dnPDE4D3mRFP in the newly 
selected CHO clone, total mRNA was extracted and retro-transcribed (see 
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section 3.1.4, 3.1.6 and 3.2.2.3.3), and specific oligonucleotides annealing on 
the nucleotide sequence encoding for the mutation (D484A) were used to 
amplify a 650 bp band from the cDNA of the dnPDE4D3mRFP (Figure 8-2). As 
shown in Figure 8-2, the entire set of samples analysed show an amplification 
band corresponding to the wild type isoform of PDE4D3. Conversely only cDNA 
from “New clone dn4D3” and from CHO cells transiently expressing the 
dnPDE4D3mRFP yield a band when primers annealing on D484A mutation 
were used, confirming that only these two samples over-express the dominant 
negative variant of the PDE4D3. 
 
 
Figure 8-2 RT-PCR analysis of PDE4D3 wild type and dominant negative variant in CHO 
cells, CHO lines stably expressing the dnPDE4D3 tagged to mRFP, “Old clone dn4D3” 
and “New clone dn4D3” respectively, and CHO cells transiently transfected with the 
dnPDE4D3mRFP. The 650 bp band expected from the wild type isoform of the PDE4D3 
is detectable in the entire set of samples analysed (left panel), whereas only the “New 
clone dn4D3” and CHO cells transiently expressing the dnPDE4D3mRFP show 
amplification of the dominant negative variant of PDE4D3. 
Next, to test whether the dominant negative variant of the PDE4D3 
localises within the cell in the specific subcellular locales where the wild type is 
normally anchored I performed a fluorescence microscopy analysis of the 
dnPDE4D3mRFP stably expressing cells. Figure 8-3 shows an example of a 
“New clone dn4D3” cell in which it is possible to recognise the localisation of 
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the recombinant protein in proximity of the nucleus, typical of a localisation to 
the centrosome (Figure 8-3). 
 
 
Figure 8-3 Fluorescence microscopy image of a “New clone dn4D3” cell. Image show 
the subcellular localisation of the recombinant protein. Arrow points to the 
centrosome. Bar 10m. 
In order to confirm the centrosomal localisation of the catalytic inactive 
PDE4D3 isoform I used RII-CFP as a centrosomal marker. To this end, I 
transfected CHO cells stably expressing the dnPDE4D3 (“New clone dn4D3”) 
with a plasmid carrying the coding sequence for RII-CFP. Image of the co-
localisation of dnPDE4D3mRFP and RII-CFP is shown in Figure 8-4. 
 
  
Figure 8-4 Subcellular localisation of dnPDE4D3mRFP in CHO cells. Images show co-
localisation of dnPDE4D3mRFP (left panel) with RII-CFP (middle panel); arrows point 
to the centrosome. Bar 10m. 
As shown in Figure 8-4 the dominant negative variant of the PDE4D3 co-
localises with the RII-CFP at the centrosome, as previously shown for the 
endogenous PDE4D3 (Figure 4-12). This specific localisation suggests that the 
mutant dnPDE4D3 is displacing the endogenous active PDE4D3.  
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8.1.2  Generation of a CHO cell line stably expressing 
the dominant negative variant of PDE4A4 
As a control, I generated a CHO line stably expressing the dominant 
negative variant of the PDE4A4 (see section 3.1.22 and 3.2.2.3.3) (McCahill et 
al., 2005).  
As shown in Figure 8-5 fluorescent microscopy analysis of cells stably 
expressing dnPDE4A4-GFP shows a clear cytosolic distribution and no specific 
centrosomal localisation in CHO cells. 
 
  
Figure 8-5 CHO stably expressing the dnPDE4A4-GFP. Bar 10m. 
8.1.3  Flow cytometry scan analysis of cell cycle 
progression 
In order to investigate whether PDE4D3 anchored to the centrosome 
plays a role in the control of cell cycle progression I took advantage of the CHO 
cell clone stably expressing the dnPDE4D3mRFP and I analysed, at the flow 
cytometer, the distribution of the cell population among the different phases of 
the cell cycle. Non-synchronised control CHO cells, CHO cells stably expressing 
dnPDE4D3mRFP (“New clone dn4D3”) or dnPDE4A4-GFP were seeded at low 
density and let to grow for 48 hours. After two days in culture cells were 
harvested, fixed with EtOH 70% (v/v) stained with propidium iodide (PI) and 
analysed (see section 3.5). 
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As shown in Figure 8-6 CHO cells stably expressing dnPDE4D3mRFP 
showed a significant higher proportion of cells in G2/M, whereas CHO cells 
stably expressing dnPDE4A4-GFP showed a significant higher proportion of 
cells arrested in G1 as compared with control CHO cells (CHO: 
G1=36.374±2.321%, S=45.334±2.759% ,G2/M=19.293±0.785%; CHO-
dnPDE4A4-GFP: G1=42.470±1.136%, S=35.876±1.390%, 
G2/M=21.655±1.350%; CHO-dnPDE4D3mRFP: G1=34.106±1.331%, 
S=40.790±1.645%, G2/M=25.104±0.589% [n=6]; ***p<0.001; Figure 8-6). 
 
 
Figure 8-6 Quantification of flow cytometry scan analysis (mean of 6 independent 
experiments) for CHO, CHO-dnPDE4D3mRFP (dnPDE4D3mRFP) and CHO-dnPDE4A4-
GFP (dnPDE4A4-GFP). Histograms indicate the mean percentages of cells in various 
phases of the cell cycle. (Error bars represent SEM. One-way ANOVA test, ***p<0.001). 
It has been shown that experimental elevation of cAMP concentration 
induced either by stimulation of AC, inhibition of PDEs or by addition of cAMP 
(cAMP or dibutyryl-cAMP), inhibits cells division in many cell line models, 
exerting a counteracting effect on cell proliferation (see section 1.8) 
(Macmanus and Whitfield, 1969) (Ryan and Heidrick, 1968) (Sheppard, 1972). 
To test the effect of total cAMP elevation in CHO, CHO-dnPDE4D3mRFP and 
CHO-dnPDE4A4-GFP cells, flow cytometry scan analysis was performed after 
treatment with 5 M forskolin for 48 hours. As shown in Figure 8-7 upon 
forskolin stimulation, and in agreement with published evidence, CHO cells and 
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CHO-dnPDE4D3mRFP population show a significant higher fraction of cells in 
G1 phase and a significant lower fraction in S phase (white bars) as compared 
to untreated cells, suggestive of an arrest of the cell cycle progression (Figure 
8-7, A); CHO black bars: G1=36.374±2.321%, S=45.334±2.759% 
,G2/M=19.293±0.785%; CHO+FRSK white bars: G1=50.103±2.051%, 
S=30.221±1.757% ,G2/M=19.676±1.872% [n<3]; and B) CHO-dnPDE4D3mRFP 
dark grey bars: G1=34.106±1.331%, S=40.790±1.645%, G2/M=25.104±0.589%; 
CHO-dnPDE4D3mRFP+FRSK white bars: G1=40.074±0.818%, 
S=32.995±1.195%, G2/M=21.931±1.697% [n<3]). Conversely forskolin seems 
do not have any effect on CHO-dnPDE4A4 population (Figure 8-7, C) CHO-
dnPDE4A4-GFP light gray bars: G1=42.470±1.136%, S=35.876±1.390%, 
G2/M=21.655±1.350%; CHO-dnPDE4A4-GFP+FRSK white bars: 
G1=39.709±1.819%, S=42.202±4.326%, G2/M=18.090±2.584% [n<3]). 
 
 
Figure 8-7 FACS analysis quantification (mean of 6 independent experiments) for CHO, 
CHO-dnPDE4D3mRFP (dnPDE4D3mRFP) and CHO-dnPDE4A4-GFP (dnPDE4A4-GFP) 
upon treatment with forskolin 5 M. The histogram indicates the average percentages 
of cells in various phases of the cell cycle. (Error bars represent SEM. One-way ANOVA 
test, * p<0.05, ** 0.01<p<0.001, *** p<0.001). 
Interestingly, a direct comparison of CHO cells, CHO plus forskolin, CHO-
dnPDE4D3mRFP and CHO-dnPDE4A4-GFP confirmed that CHO-dnPDE4A4-
GFP cells progress through the cell cycle with a similar trend as CHO cells 
treated with forskolin (Figure 8-8). This indicates that displacement of PDE4A4 
affect the cell cycle progression in a similar manner as total cAMP elevation, 
resulting in an arrest of the cell cycle progression in G1 and a significant lower 
amount of cells entering the S phase.  
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On the contrary, the G2/M arrest detected in CHO-dnPDE4D3mRFP cells 
indicates that tight regulation of centrosomal level of cAMP is essential for the 
correct progression through G2/M and completion of the cell cycle (Figure 8-8). 
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Figure 8-8 Top panel: representative (1 out of 6) experiment showing cellular DNA 
content in untreated CHO cells, CHO cells treated with forskolin, CHO-dnPDE4D3mRFP 
(dnPDE4D3mRFP) and CHO-dnPDE4A4-GFP (dnPDE4A4-GFP). Gaussian curve around 
200 fluorescence emission value corresponds to the 2n content of DNA (G1), Gaussian 
curve around 400 fluorescence emission value corresponds to 4n content of DNA 
(G2/M), values between 200 and 400 correspond to the intermediate content of DNA 
(S). Bottom panel: quantification of flow cytometry scan analysis (mean of 6 
independent experiments). Values indicate the mean percentages of cells in each 
phases of the cell cycle, as indicated. (Error bars represent SEM. One-way ANOVA test, 
***p<0.001). 
8.2  Discussion 
The aim of this chapter was to study the functional role of the 
AKAP450/PKA/PDE4D3 macromolecular complex present at the centrosome 
in the regulation of cell cycle progression. To this purpose, I generated a CHO 
cell line stably expressing the catalytically dead variant of PDE4D3. Fluorescent 
microscopy analysis of this cell line confirmed that dnPDE4D3 binds to the 
same anchor sites where the endogenous active counterpart PDE4D3 is 
normally localised (Figure 4-12 and Figure 8-4). Moreover, co-localisation with 
RII-CFP to the centrosome indicates that dnPDE4D3 binds to AKAP450, as 
previously shown for PDE4D3 (Figure 8-4). As shown in section 4.1.6.4 and 
Figure 4-17, displacement of the centrosomal wild-type PDE4D3 results in the 
increase of the basal cAMP level at the centrosome and in the abolishment of 
the difference in cAMP concentration between centrosome and cytosol. Based 
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on these findings, I asked if local elevation of centrosomal cAMP concentration 
secondary to displacement of centrosomal PDE4D3 may have an effect on cell 
cycle progression. Flow cytometry scan analysis of CHO stably expressing the 
dnPDE4D3 showed a higher percentage of cells in G2/M as compared with 
control CHO cells. As a control, I tested the effect of displacement of a PDE that 
does not show any centrosomal localisation and that does not modified the low 
level of cAMP at the centrosome, when its catalytically dead variant is over-
expressed in CHO cells (see section 4.1.6.4 and Figure 4-7). To this end, I 
generated a CHO cell line stably expressing the catalytically dead variant of 
PDE4A4. In this case, flow cytometry scan analysis of CHO-dnPDE4A4-GFP 
showed a higher proportion of cells in G1 as compared with CHO cells; however 
arrest of cell cycle progression in G1 has already been well documented 
following experimental elevation of total intracellular cAMP or PKA activity 
(Macmanus and Whitfield, 1969) (Ryan and Heidrick, 1968) (Sheppard, 1972) 
(Lamb et al., 1991). Pre-treatment of CHO-dnPDE4D3mRFP, CHO-dnPDE4A4-
GFP and CHO control cells with forskolin results, indeed, in a cell cycle arrest in 
G1 at the expenses of S phase both for CHO and CHO-dnPDE4D3mRFP cells; 
whereas forskolin does not have any effect on cell cycle progression of CHO-
dnPDE4A4-GFP population. This data suggests that displacement of PDE4A4 
induces an increase in cAMP which exerts an effect on the cell cycle 
progression similar to that induced by forskolin treatment. On the contrary, 
cell cycle arrest in G2/M shown by CHO-dnPDE4D3mRFP population may 
result from the specific cAMP elevation at the centrosome. 
Arrest of cell cycle in G2/M phase has previously been shown to be 
associated with manipulation of the centrosome. Activation of Cdk1-CyclinB 
(MPF) occurs at the centrosome at the onset of mitosis. During interphase 
Cdk1 is kept inactive by the action of its modulator Chk1. At the beginning of 
mitosis, Chk1 dissociates from the centrosome releasing Cdk1 available for 
activation. Interestingly, fusion of the PACT domain (pericentrin AKAP450 
centrosome targeting domain) to Chk1, leads to the immobilisation of the wild 
type Chk1 to the centrosome and to a permanent inhibition of Cdk1 activation. 
As a consequence, asynchronous cell populations undergo mitotic failure and 
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formation of polyploidy cells (Kramer et al., 2004). In a similar way, it has been 
shown that over-expression of a GFP tagged-PACT domain results in a higher 
percentage of cells showing a DNA content of 4n upon flow cytometry scan 
analysis. Further investigation revealed that the G2 sub-cellular fraction is 
characterised by polyploidy cells, suggesting a defect of cytokinesis (Keryer et 
al., 2003b). Interestingly, in both studies, the approach used was over-
expression of the PACT domain which results in the displacement of the 
AKAP450/PKA/PDE4D3 complex from the centrosome. The fact that I observe 
the same functional outcome (arrest in G2/M) when displacing PDE4D3 alone, 
as described in experiments in which the entire AKAP450/PKA/PDE4D3 
complex was removed from the centrosome, suggests that PDE4D3 may be the 
key regulator for the control of these mitotic events.  
“Mitotic catastrophe” is the primary mechanism of cells death in a 
number of tumour cell lines, following treatment with chemotherapeutic 
agents, and its major function is to eliminate damaged cells from the cell 
population. It is characterised by delay of mitosis, chromosome segregation 
and cytokinesis failure and leads to the accumulation of polynucleated and 
large non-viable cells (Roninson et al., 2001). Eventually cells die. “Mitotic 
catastrophe” has been linked to G2/M arrest and centrosome disruption 
(Roninson et al., 2001). Therefore it is possible that the difficulties I found in 
maintaining the CHO-dnPDE4D3mRFP stably expressing cells may be caused 
by a counteractive selection imposed by the G2/M arrest and the consequent 
“mitotic catastrophe” response. It would be of interest to follow up these 
studies by investigating the G2/M arrested subcellular fraction in the CHO-
dnPDE4D3mRFP stable clone to define what specific mechanism is 
misregulated by over-activation of the centrosomal AKAP450-anchored PKA 
upon displacement of PDE4D3. If the consequence of PDE4D3 displacement is 
‘mitotic catastrophe’ I expect that the sub-fraction of cells arrested in G2/M is 
represented predominantly by polynucleated cells. Moreover I expect a 
progressive loss of expression of the catalytically dead PDE4D3mRFP tagged in 
the “New clone dn4D3” clone, as previously happened for the first CHO-
dnPDE4D3 clone selected (Old clone dn4D3). 
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9  Conclusion and future perspectives 
In this thesis I investigated cAMP signalling at the centrosome using 
real-time FRET-based imaging in living, non-synchronised CHO cells. 
In the first part of my project I focused on the analysis of centrosomal 
cAMP in cells in resting conditions. The major finding of this part of my work is 
that the centrosome is a subcellular domain characterised by a cAMP 
concentration that is lower than the average cAMP concentration in the bulk 
cytosol. My studies revealed that the AKAP450-associated PDE4D3 plays a key 
role in regulating the cAMP level within the centrosomal microdomain. This is 
compatible with a mechanism whereby PDE4D3 protects AKAP450-anchored 
PKA from inappropriate activation. Moreover, this specific microdomain of low 
cAMP seems to be present not only at the centrosome of CHO cells but also at 
the centrosome of other cell lines, suggesting that this may be a general feature 
of cAMP compartmentalisation, possibly playing a specific role in the control of 
centrosomal associated events.  
In the second part of my project I focused on centrosomal cAMP 
dynamics following treatment of cells with the cAMP raising agent forskolin. 
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The major finding of this part of my work is that specific anchoring of PKA to 
AKAP450 increases the sensitivity of PKA to cAMP. As a consequence, 
AKAP450-anchored PKA shows a lower activation threshold than soluble PKA 
or other subsets of PKA bound to different AKAPs. This conclusion is 
strengthened by the observation that anchoring of endogenous PKA subsets to 
a cytosolic fragment of AKAP450, which includes the PKA binding site, results 
in increased PKA activity. 
Given the co-localisation of PKA and PDE4D3 to the centrosome and the 
ability of PKA to phosphorylate and increase PDE4D3 activity (Sette and Conti, 
1996), it is possible that a negative feedback loop mechanism is present at the 
centrosome. A low level of cAMP selectively activates the PKA subset anchored 
to AKAP450. PKA, in turn, phosphorylates and activates PDE4D3 anchored to 
the same complex and this maintains a lower level of cAMP in this 
compartment. A way to further investigate if this mechanism is in place would 
be to generate a CHO cell line stably expressing a PDE4D3 mutated in the PKA 
phosphorylation site, such that PDE4D3 activity cannot be regulated by PKA-
mediated phosphorylation. If a feedback loop mechanism is indeed present in 
this compartment, the centrosomal low cAMP micro-compartment would be 
abolished in the presence of such a mutant. 
The data presented here show, for the first time, that anchoring of PKA 
type II to an AKAP can locally modify the sensitivity of a specific event to cAMP. 
This represents a completely new mechanism of PKA regulation that is effected 
by lowering the kinase activation threshold rather than by increasing the level 
of the second messenger itself. This novel mechanism introduces a further 
level of complexity to the already sophisticated regulation of the cAMP/PKA 
pathway and it defines a novel function for AKAPs. Although my results show 
that this mechanism does not apply for the interaction of PKA with Ht31, 
AKAP79 and AKAP149, I cannot exclude that a similar mechanism may 
function for other AKAP/PKA complexes. It would be interesting to explore if 
anchoring of a PKA to an AKAP can increase the activation threshold of the 
anchored PKA, thereby lowering its sensitivity to cAMP.  
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I subsequently investigated the mechanism responsible for the 
increased sensitivity to cAMP of AKAP450-bound PKA. My results strongly 
indicate that the auto-phosphorylation site of the PKA RII subunit is involved 
in this mechanism. It has been previously shown that auto-phosphorylation of 
PKA, which occurs as an intra-molecular event, promotes PKA dissociation by 
lowering its activation constant. It is possible that anchoring of PKA to 
AKAP450 promotes a conformation of the PKA regulatory subunit which 
favours the auto-phosphorylation of the holoenzyme.  
To summarise the results of my work, I propose here a model in which 
PDE4D3 acts to maintain a low level of cAMP at the centrosome and inhibits 
the inappropriate activation of the PKA subset anchored to AKAP450. This 
specific subset of PKA, characterised by a lower activation constant, can be 
activate by an amount of cAMP that cannot affect other subsets of PKA 
anchored in different subcellular compartments. Given the fact that it has been 
shown that ERK can phosphorylate and inactivated PDE4D3 (see section 1.3.2 
and 1.3.2.1) (Hoffmann et al., 1999) (MacKenzie et al., 2000), an interesting 
possibility is that in a specific phase of the cell cycle the centrosomal PDE4D3 
is inactivated by ERK phosphorylation. The consequent local increase of cAMP 
level may then be sufficient to activate the AKAP450-anchored PKA but not 
sufficient to activate other subsets of PKA. Interestingly, this mechanism would 
not require adenylyl cyclase activation and new synthesis of cAMP. Activation 
of centrosomal PKA may then regulate critical events involved in the 
progression of the cell cycle. Eventually PKA would phosphorylate and activate 
the associated PDE4D3, thereby relieving it from ERK inhibition and re-
establishing a cAMP level that is below the activation threshold of the 
AKAP450-tethered PKA. This mechanism would provide a time-specific 
feedback regulatory mechanism whereby ERK inhibition of PDE4D3 would 
allow centrosomal cAMP level to rise at the right moment of the cell cycle 
progression. In this scenario PDE4D3 would act as a “gate” for PKA activation.  
To further investigate if ERK dependent phosphorylation of PDE4D3 is a 
mechanism responsible for activation of PKA anchored to AKAP450 one 
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possibility would be to perform FRET-based analysis of CHO cells stably 
expressing the PKA-GFP sensor upon treatment with an ERK specific activator, 
such as the epidermal growth factor (EGF). If the hypothesis illustrated above 
is true ERK phosphorylation would inhibit PDE4D3, leading to a local rise of 
cAMP level. As a consequence the difference in cAMP concentration between 
centrosome and cytosol would be expected to be abolished. 
In the last part of my project I investigated the role of the 
AKAP450/PKA/PDE4D3 complex in the control of cell cycle progression. My 
findings show that displacement of endogenous PDE4D3 from the centrosome 
abolishes the difference in cAMP concentration between centrosome and 
cytosol, previously detected in cells in resting condition, and this is 
concomitant with an arrest of the cell cycle progression in G2/M. Interestingly, 
these results are in agreement with previous reports in which the 
AKAP450/PKA/PDE4D3 complex was displaced by over-expression of the 
PACT domain of AKAP450 (Keryer et al., 2003b, Kramer et al., 2004) 
suggesting that not only the AKAP450/PKA/PDE4D3 complex is essential for 
correct cell cycle progression, but also strongly indicating that PDE4D3 may be 
the complex component playing a key role in this.  
Various alterations leading to activation or inactivation of key 
components of the cAMP signalling pathway are observed in tumorigenesis. It 
has been shown that cells from different tumour models, such as chronic 
lymphocytic leukaemia and carcinoma, show an over-expression of PDEs and a 
consequent decrease of cAMP level (Marko et al., 1998, Zhang et al., 2008). 
Interestingly, treatment with chemotherapeutic agents, including PDEs 
inhibitors (i.e. caffeine and pentoxifylline), leads to a phenomenon defined as 
“mitotic catastrophe” that is characterised by aberrant mitosis, G2/M arrest, 
formation of polynucleated cells and, ultimately, cell death (Roninson et al., 
2001). Therefore it would be of particular interest to investigate whether the 
G2/M arrest induced by displacement of the PDE4D3 isoform is due to a 
“mitotic catastrophe”, as it may be suggested by the observation that cells over-
expressing the recombinant catalytically dead PDE4D3 mRFP tagged appear to 
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lose expression of the transgene (see section 8.1.1). An experiment that could 
help investigating this would be to estimate the percentage of polynucleated 
cells in the G2/M sub-fraction of cells expressing the catalytically dead version 
of PDE4D3. If this number results significantly increased compared to control 
cells, then the centrosomal PDE4D3 would become a potentially interesting 
target for anticancer therapy. In this context, it is worth considering that the 
development of specific PDEs inhibitors, allowing the activation of PKA subsets 
with specific and restricted outcomes, has recently gained crucial importance 
as anticancer therapy (Savai et al., 2010).  
Elucidation of the mechanisms responsible for cAMP 
compartmentalisation in the microenvironment surrounding specific 
macromolecular complexes and the physiological role of PDEs in this is 
essential to understand whether molecular aberrations disrupting these 
complexes can be linked to disease states. The studies presented here reveal an 
additional level of regulation in the cAMP/PKA signalling pathway in which 
anchoring of PKA to an AKAP increases the enzyme sensitivity to its activator. 
These findings may be relevant for the development of new therapeutics. 
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